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ABSTRACT 
 
Background: South Africa is in the midst of a health transition that is characterized by a 
high burden of both infectious diseases and non-communicable diseases. One of the 
drivers of non-communicable diseases in South Africa is the current epidemic of obesity. 
Vitamin D deficiency, which is defined by 25(OH)D levels in blood, has been reported to 
be a risk factor for cardiovascular disease and shares a number of risk factors with those 
traditionally linked to non-communicable diseases. Osteoporosis is another non-
communicable disease that is reportedly increasing in prevalence worldwide and may be 
linked to vitamin D levels and to body fat. There is limited data on 25(OH)D levels in South 
Africa and its association with cardiovascular risk factors. There is also limited data on 
body composition including bone mineral density. 
Aims: The aims of this thesis were to describe 25(OH)D levels in healthy Black African 
and Indian subjects recruited from the greater Johannesburg metropolis and to determine 
if differences in 25(OH)D levels contributed to differences in cardiovascular risk. A further 
aim was to describe body composition in both ethnic groups and to see if differences in 
body composition contribute to differences in 25(OH)D levels or to differences in bone 
mineral density and to determine if differences in bone mineral density are mediated by 
differences in 25(OH)D. 
Methods: This was a cross sectional study carried out from July 2011 to March 2012 on 
714 male and female subjects (male: female=340:374) of whom 371 were Black African 
and 343 were Indian. Subjects were recruited via the caregivers of the Birth to Twenty 
cohort. The first step was a descriptive analysis of 25(OH)D as well as its predictors 
including whole body fat, visceral and subcutaneous adiposity. This was followed by 
examining the associations of 25(OH)D and parathyroid hormone with cardiovascular risk 
factors that comprise the metabolic syndrome. Final analysis was description of bone 
mineral density according to ethnicity and gender and the contribution of lean mass, sub-
total fat mass, visceral and subcutaneous adiposity to bone mineral density in each ethnic 
group. 
Results: Vitamin D deficiency was very prevalent in Indians, 28.6% in comparison to 
5.1% in the Black African group (p<0.0001). In both groups season of collection was a 
positive predictor and PTH was negatively associated with 25(OH)D. Neither whole body 
fat nor visceral or subcutaneous adiposity was predictive of 25(OH)D in either group. 
Using the harmonized definition of the metabolic syndrome (Met S), was diagnosed in 
29% of the Black African and 46% of the Indian subjects (p<0.0001). Subjects with Met S 
had higher PTH than those without (p<0.0001), whilst 25(OH)D levels were not 
significantly different (p=0.50). Logistic regression analysis showed that Indian ethnicity 
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(OR 2.24; 95% CIs 1.57, 3.18; p<0.0001) and raised PTH (OR 2.48; 95% CIs 1.01, 6.08; 
p=0.04) adjusted for 25(OH)D) produced an increased risk of Met S but 25(OH)D did not 
(OR 1.25; 95% CIs 0.67, 2.24; p=0.48). Whole body, hip, femoral neck and lumbar spine 
bone mineral density were significantly higher in Black African than Indian subjects 
(p<0.001 for all). Whole body lean mass positively associated with bone mineral density at 
all sites in both ethnic groups (p<0.001 for all), and partially explained the higher bone 
mineral density in Black African females compared to Indian females. Whole body fat 
mass correlated positively with lumbar bone mineral density in Black African (p=0.001) 
and inversely with sub-total bone mineral density in Indian subjects (p<0.0001). Visceral 
adiposity correlated inversely with sub-total bone mineral density in the Black African 
subjects (p=0.037) and with lumbar bone mineral density in the Indian group (p=0.005).  
No association was found between serum 25(OH)D and bone mineral density. PTH was 
inversely associated with hip bone mineral density in the Black African group (p=0.01) and 
with sub-total (p=0.002), hip (p=0.001) and femoral bone mineral density (p<0.0001) in the 
Indian group. 
Conclusions: This study highlighted the high prevalence of vitamin D deficiency in the 
Indian population and the fact that local conditions such as sunshine exposure and 
season of collection of blood are important determinants of 25(OH)D levels. It also 
showed that Indian ethnicity and PTH are risk factors for the Met S, but differences in risk 
between both ethnic groups are not due to differences in 25(OH)D levels. The thesis also 
showed that there are significant differences in bone mineral density across ethnicity, with 
lean mass an important contributor to bone mineral density across race and gender.  
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PREFACE 
The idea for this study came as a result of the introduction of a high performance liquid 
chromatography (HPLC) method, in our laboratory, for the measurement of 25-hydroxy 
vitamin D (25(OH)D) which is the main metabolite of vitamin D . Volunteers were required 
for a method comparison study. Three Indian pathologists including myself donated five 
ml of blood for the comparison study and all of us were noted to be vitamin D deficient. 
 
Obesity has reached global epidemic proportions in both adults and children and is 
associated with several comorbidities including type 2 diabetes mellitus (T2DM), 
hypertension, dyslipidaemia and major cardiovascular disease. Inverse relationships have 
been demonstrated between circulating levels of 25(OH)D and obesity as well as with the 
metabolic syndrome (Met S) or the metabolic abnormalities associated with it, namely, 
elevated fasting glucose and insulin resistance (IR)/diabetes. Osteoporosis also of major 
public health importance and it shares a number of risk factors with cardiovascular 
disease namely lack of exercise, smoking and possibly low vitamin D status. While there 
is some data on the prevalence of the metabolic syndrome in various populations here, 
there is very little data on vitamin D status of the various ethnic groups in South Africa. I 
was intrigued to investigate if there were differences in vitamin D status of local 
populations living in Johannesburg, an area that receives at least eight hours of sunshine 
per day throughout the year, and if these differences contributed to differences in 
cardiometabolic risk factors. 
 
I was fortunate to have access to the caregivers of the Birth to Twenty cohort which 
allowed me to recruit healthy male and female adults from two population groups. The 
infrastructure at Birth to Twenty also allowed me to perform Dual-energy X-ray 
Absorptiometry scans, ultrasound measurements of adiposity and dietary intake of all 
subjects assessed by a seven day food frequency questionnaire. Thus the findings of this 
thesis fill in a gap not only on knowledge of the relationship between 25(OH)D and risk of 
the Met S but also on body composition of African men in particular.  
 
This PhD thesis is presented as 6 chapters: 
 Chapters 1 and 2 are the literature review and methods chapters, respectively. 
 Chapters 3 to 5 contain the results of the studies undertaken for this PhD, with each 
chapter written in the format of a research publication. Chapter 4 has been published 
as a paper, whilst the other 2 chapters have been submitted and are currently under 
review by the respective journals. 
 Chapter 6 comprises of the conclusions and recommendations for further work.  
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CHAPTER 1 
1. LITERATURE REVIEW 
 
1.1  INTRODUCTION 
Up to the middle of the previous century, infectious diseases were the main 
causes of death worldwide. Then with strides in medicine such as vaccinations 
and antibiotics as well as with improved socio-economic conditions, non-
communicable diseases (NCD) became increasingly important as a cause of 
morbidity and mortality in the industrialised world. The dawn of the third millennium 
saw NCDs becoming common throughout the world with an increasing trend in 
developing countries. The leading causes of disease burden in 1990 were 
pneumonia, diarrhoeal diseases and complications of pregnancy and childbirth but 
by 2020 it is estimated that NCDs will account for 80 percent of the global burden 
of disease, causing seven out of ten deaths (1, 2). A World Health Organization 
report of 2011 noted that ischaemic heart disease was responsible for seven 
million deaths worldwide (Figure 1.1) (3).  
.  
Figure 1.1: The 10 Leading Causes of Death in the World (taken from  
reference number(3)) 
 
Deaths from NCD account for three out of every ten deaths worldwide and this is 
set to increase (4). The International Diabetes Federation (IDF) estimates that the 
number of people living with diabetes will increases from 366 million in 2011 to 552 
million by 2030 (5). Eighty percent of these will be from low and middle-income 
2 
 
countries. The projected increase will contribute to increased mortality as well as 
disability adjusted life years (DALY) and sum of years lived with disability (YLD). In 
developing countries, those most frequently affected are between the ages of 35 
and 64. Although the numbers of premature deaths from diabetes are similar to 
that of HIV/AIDS, the problem is largely unrecognized.  
 
South Africa, a low to middle-income country (LMIC), is in the midst of a health 
transition characterized by the simultaneous occurrence of epidemic infectious 
diseases, a rise in NCDs such as diabetes, heart disease, chronic pulmonary and 
mental diseases. The World Health Organization (WHO) estimates that the burden 
of disease in South Africa arising from NCDs is two to three times higher than in 
developed countries, and that NCDs are increasing in prevalence and 
disproportionately affect poor people living in urban areas (6). There are several 
reasons for this rise including an increased number of people over the age of 60, 
and risk behaviour such as smoking and lifestyle factors which lead to obesity (7). 
As illustrated in Figure 1.2, from 1999 to 2006 there have been sustained 
increases in diabetes and hypertensive heart disease in South Africa (Figure 1.2). 
 
 
Figure 1.2: The Burden of Non-Communicable Diseases in South Africa 
from 1999-2006 (taken from reference (6) and used with 
permission) 
 
Interrelationships between risk behaviour, risk factors and disease outcome are 
illustrated in Figure 1.3. 
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Figure 1.3: Interrelationships between Risk Factors and Non-
Communicable Diseases (taken from reference (8) and used with 
permission) 
Obesity, previously thought to be a disease of affluence, has reached epidemic 
proportions with prevalence rates of up to 30% in African women (9). Overall, it 
appears that overweight and obesity may already be more prevalent than 
underweight and under nutrition in many developing countries (10). Vitamin D 
deficiency shares several risk factors and risk behaviours with those traditionally 
linked to NCDs particularly cardiovascular disease (Figure 1.4) and has become 
pandemic (11-13). 
 
Both cardiovascular disease and vitamin D deficiency are strongly linked to 
obesity. 
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Figure 1.4: Possible Interrelationships between Vitamin D Deficiency, 
Traditional Risk Factors and Non-Communicable Diseases 
 
There is a lack of data on the vitamin D status of South African populations and 
any possible association of vitamin D with cardiovascular risk factors. It is 
important that we understand the drivers of NCDs and define the role played by 
non-traditional risk factors like vitamin D deficiency in the aetiology of obesity-
related disorders.  
 
The next section gives an overview on the definition and epidemiology of the 
metabolic syndrome (section 1.2), whilst Section 1.3 covers the history, physiology 
and the measurement of vitamin D. Section 1.4 includes information on the 
prevalence of vitamin D deficiency, and section 1.5 is a review of studies on the 
association of vitamin D with components of the metabolic syndrome. 
 
1.2  THE METABOLIC SYNDROME 
The prevalence of obesity is reportedly quite different among the four major South 
African population groups. Thus, it is highest in African women at 31-34%, 20-22% 
in Indian women, 8% in African men and 3-9% in Indian men (9). The drivers of 
this obesity epidemic include rural to urban migration, sedentary lifestyle and 
adoption of high calorie western diets (14). The particularly high prevalence of 
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obesity seen in Black African women is similar to that seen in African-American 
women in the United States (6, 15). In addition to total body fat, the pattern of body 
fat distribution is as an important risk factor for dysglycaemia, hyperlipidaemia and 
hypertension in patients with and without T2DM.  Factors involved in the control of 
body fat distribution include gender, age and ethnicity. Women have more total 
body fat than men even when matched for BMI (16), because women have a 
larger subcutaneous adipose tissue depot than men, but less visceral fat (17). This 
gender difference is apparent prenatally and from the first year of life (18). 
Abdominal obesity, represented by waist circumference or waist-hip ratio is 
considered particularly atherogenic because it causes dysregulation of a number 
of metabolic processes including those controlling glucose, lipids and blood 
pressure. Thus begins a clustering of metabolic and cardiovascular conditions: 
dysglycaemia, dyslipidaemia, hypertension and a procoagulant state which are 
collectively known as the metabolic syndrome (Met S) (6, 19). 
 
The first formalized definition of the Met S was proposed in 1998 (20). This 
definition emphasized insulin resistance as the major risk factor and required 
evidence of insulin resistance for diagnosis. Since then there have been several 
definitions using different criteria (21-23), leading to widely different prevalence 
estimates (22). The two major sets of criteria that have been used are those of the 
National Cholesterol Education Program Third Adult Treatment Panel (ATP III) (21, 
24, 25) and the International Diabetes Federation (IDF) (23). The ATP criteria 
placed more emphasis on cardiovascular risk and required three of any five 
components: central obesity, raised blood pressure, raised triglycerides, low HDL 
cholesterol and fasting hyperglycaemia. The IDF placed central obesity as 
essential to the diagnosis of the metabolic syndrome and suggested ethnic specific 
cut off points for waist circumference. In 2009, an additional definition was 
proposed, as a joint interim statement (JIS) by several organizations. This was an 
attempt to harmonize the definition of the Met S (22). They determined that there 
should not be an obligatory component, three out of five components would be 
used and ethnic specific cut off points be used for waist circumference. The 
available information based on the ATP III and the IDF criteria suggests that the 
Met S is pandemic but that prevalence varies widely depending on the ethnic 
groups studied and the criteria applied (26).  
 
The Met S can be explained by viewing abdominal adipose tissue as an endocrine 
organ that secretes a number of bioactive compounds into the circulation. Many of 
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these molecules have inflammatory effects (adipokines) but also modulate insulin 
sensitivity, blood pressure, lipid levels and a number of other cardiovascular and 
metabolic pathways, all of which are involved in the aetiology of obesity-related 
diseases (27). 
 
With the rising prevalence of obesity, the Met S is also increasing in developing 
countries. The prevalence of the Met S is high in Black Africans from urban and 
rural parts of South Africa. (28, 29). A cross sectional diabetes epidemiological 
study in rural South Africans  found the prevalence to be 26.5% using the 
harmonized definition (28) and in in urban Black Africans with coronary artery 
disease (CAD) it was shown to be much higher at 60% (29). Indians have an 
unusually high tendency to develop T2DM and CV (30). There are no data on the 
prevalence of the Met S in Indian living in South Africa, however data from India 
indicate a prevalence of between 11-41% depending on the area and the criteria 
used to define it (31). 
 
The Met S gives a 2 to 3 fold increased risk for coronary artery disease (CAD), a 
similar risk for ischaemic stroke (32) and a much greater risk for future diabetes 
(33, 34). The more features of the Met S an individual has, the greater the risk of 
metabolic disease (35). 
 
It has been suggested that the Met S may be a risk factor for osteoporosis as they 
share a number of common risk factors including a sedentary lifestyle, smoking, 
sex-hormone deficiency and oxidative stress (36-38). Increased body weight is 
inversely associated with bone mineral density, however studies analysing the 
association of abdominal obesity with BMD have contradictory findings (39). 
Studies from various parts of the world suggest that vitamin D deficiency may 
increase the risk of the Met S (40, 41) and that vitamin D repletion might prove 
protective against Met S and its sequelae, T2DM and cardiovascular disease (42). 
In addition, vitamin D deficiency leads to secondary hyperparathyroidism that can 
precipitate and exacerbate osteopaenia and osteoporosis in adults (43). 
 
There is limited data from Africa on the prevalence of vitamin D deficiency and its 
possible association with components of the Met S or BMD.  
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1.3  THE DISCOVERY OF VITAMIN D 
The discovery of vitamin D (44) followed by the virtual elimination of rickets ranks 
as one of the greatest and most fascinating medical achievements. In the 
nineteenth century, with the onset of the industrial revolution, people in Europe 
moved from rural farming areas to smoggy urban areas and rickets became 
widespread. Sir Edward Mellanby reasoned that rickets might be caused by a 
nutritional deficiency. He reasoned that he could produce rickets in dogs by 
feeding them oatmeal, the staple diet of the Scottish. What he did not realise was 
that he also deprived the dogs of sunlight. He then demonstrated that these dogs 
were cured of their rickets when fed cod liver oil (45) and attributed this effect to 
vitamin A. Earlier on, vitamin A had been discovered by McCollum and Davis, who 
showed that it prevented xerophthalmia (46). When McCollum heated cod liver oil, 
which destroyed vitamin A, he showed that the cod liver oil still cured rickets. He 
concluded that there was another vitamin in cod liver oil with anti-rachitic 
properties and as vitamins A, B and C had already been discovered he named it 
vitamin D (47). At the same time that Mellanby was experimenting on dogs, 
Huldshinsky and Chick working independently, showed that rickets in children 
could be cured either by exposing them to sunlight or artificially produced 
ultraviolet light (48). Steenbock and Hart, who were working on the calcium 
balance of lactating goats, showed that irradiation of the animals or their diets 
could cure rickets. Steenbock traced this property to the nonsaponifiable fraction of 
fat in food. He found that ultra violet (UV) light activated a substance that then 
showed anti-rachitic properties. This discovery, led to the widespread use of 
irradiation of food to increase the vitamin D content, and culminated in the virtual 
elimination of rickets. A British group led by Askew determined the structure of 
vitamin D2. Windaus and Bock confirmed the structure of vitamin D2 and 
furthermore isolated 7-dehydrocholesterol, the precursor of vitamin D3 and then 
produced D3 from its precursor (48). 
 
1.3.1 Physiology of Vitamin D 
Terminology  
Various molecules may be non-specifically referred to as vitamin D and it is 
important to define the relationships and functions of these molecules. The 
nomenclature is derived from the historical sequence of identification of 
substances found to have anti-rachitic activity. Vitamin D3 is a prohormone 
produced by ultraviolet irradiation (UVB) of 7-dehydrocholesterol in skin (Figure 
1.1). Due to individual variability in sun exposure there are considerable 
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differences in the amounts of vitamin D produced by this route (49). Diet and 
dietary supplements are also sources that provide either vitamin D2 (ergocalciferol) 
or D3 (cholecalciferol). Either way, they must be activated by metabolism to 25-
hydroxyvitamin D [25(OH)D] in the liver and then to 1α,25 hydroxyvitamin D in the 
kidney [1,25(OH)2D]. 1,25(OH)2D acting via its nuclear receptor carries out both 
skeletal and extra skeletal functions. Ultimately, vitamin D metabolites are 
excreted by further hydroxylation to 24,25(OH)2D, which increase their water 
solubility and the metabolites are excreted in bile.  
 
Vitamin D Binding Protein 
The generation of vitamin D3 occurs in the plasma membrane from where it then 
moves to the extracellular fluid and is bound to vitamin D binding protein (DBP) 
(50). Vitamin D binding protein, a member of the albumin and alpha-fetoprotein 
gene family, is a serum transport protein for all vitamin D metabolites. It is 
synthesized in the liver and serum concentrations range between 4-8µmol/L (51, 
52) and has a half-life of 30 to 72 hours. Levels are raised in pregnancy and are 
lowered in liver disease, nephrotic syndrome and malnutrition but are not affected 
by levels of 25(OH)D or any of the metabolites (53). DBP serves as a reservoir for 
circulating 25(OH)D and 1, 25(OH)2D. In addition it binds several other proteins 
and is crucial in the clearing of actin filaments from the microcirculation (54). 
 
Vitamin D Hydroxylases 
Both vitamins D2 and D3 have no known biological function and are active only 
after conversion to 1,25(OH)2D in the kidney. This occurs via a series of reactions: 
the first of which is a hydroxylation step in the liver. There are two enzymes in the 
liver capable of hydroxylating vitamin D, a microsomal hydroxylase (CYP2R1) and 
a mitochondrial hydroxylase (CYP27A1). 
 
CYP2R1 is primarily expressed in the liver and the testis (55) and is believed to be 
the main enzyme involved in hydroxylation. Genetic loss of CYP2R1 leads to 
deficient 25-hydroxylation of D3 demonstrating its physiological importance (56). 
Recent genome wide association studies (57) have implicated CYP2R1 as one of 
the four major determinants of 25(OH)D, the others being DBP, CYP24A1 and 7-
dehydrocholesterol reductase (DHR7). Further evidence that strengthens the case 
for CYP2R1 being  the functional 25 hydroxylase is the presence of a mutation 
Leu99Pro, which results in vitamin D dependent rickets type 1 (58). Biological and 
clinical evidence argue against CYP27A1 being a physiologically relevant 25-
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hydroxylase. Firstly, the null mouse phenotype does not include any bone lesions 
(59). Secondly, human mutations result in a bile-acid related disorder known as 
cerebrotendinous xanthomatosis rather than rickets (60) and finally, the genome 
wide association study of the determinants of serum 25(OH)D concentrations 
concluded that variants at the locus for CYP2R1 but not CYP27A1 are associated 
with serum 25(OH)D concentrations (57). CYP2R1 does not appear to be subject 
to feedback regulation. 25(OH)D is biologically inactive and must be converted by 
CYP27B1 to the biologically active form 1,25(OH)2D. This occurs in the kidney as 
well as in extra renal tissue such as placenta, skin, colon, macrophages, prostate 
and breast (61, 62). Extra renal CYP27 B1 is not subject to regulation by 
1,25(OH)2D, PTH, calcium or phosphate while the main influences on 1,25(OH)2D 
production in the kidney are by 1,25(OH)2D itself, parathyroid hormone as a signal 
of calcium status, and fibroblast growth factor 23 (FGF23) as a signal of phosphate 
homeostasis. 
 
25(OH)D and 1,25(OH)2D are inactivated by CYP24A1. This multi-catalytic 
enzyme inactivates 25(OH)D to 24,25(OH)D and other metabolites. It also 
converts 1,25(OH)2D to water-soluble calcitroic acid.  
 
Mode of Action of 1,25(OH)2D 
1,25(OH)2D, like many other steroid hormones mediates its actions by the 
regulation of the expression of specific genes and by rapidly activating signal 
transduction pathways. Genomic responses to 1,25(OH)2D result from its 
interaction with the vitamin D nuclear receptor (VDR) (63). This receptor does not 
bind vitamin D3, binds 25(OH)D weakly and binds 1,25(OH)2D with high affinity. It 
is similar to other nuclear receptors in that it has six functional domains: the 
variable regions (A and B domains), the DNA binding domain (C domain), the 
hinge region (D domain), the ligand binding region (E domain) and the 
transcriptional activation domain i.e. the F domain. Binding of 1,25(OH)2D to its 
nuclear receptor causes a tight association of VDR with its heterodimeric partner 
the retinoic X receptor (RXR) (64). The VDR-RXR complex is able to recognize 
vitamin D response elements in vitamin D regulated genes. 1,25(OH)2D also binds 
to VDR in caveolae of plasma membranes and generates rapid non-genomic 
responses via activation of second messenger systems (65). 1,25(OH)2D down 
regulates its own production (66) and it is thought that this is mediated by 
interaction of the steroid hormone with its nuclear receptor. 
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Macrophages and dendritic cells express VDR, which suggests that vitamin D 
plays an important role in modulating the immune response. In both macrophages 
and dendritic cells CYP27B1 is regulated by cytokines e.g. interferon -γ (IFN-γ) 
and other inflammatory mediators such as lipopolysaccharides (LPS) (67). One of 
the most important cytokines released by macrophages is tumour necrosis factor 
alpha (TNF-α) (68). 1,25(OH)2D has been shown to inhibit  the expression of a 
number of pro-inflammatory cytokines including C-reactive protein, interleukin-1β, 
interleukin-6 and TNF-α and up regulate the anti-inflammatory cytokine, 
interleukin-10 (69). These actions therefore have the potential to dampen the pro-
inflammatory cascade associated with CVD.  
 
The clinical evidence demonstrating the importance of the VDR for normal calcium 
absorption is from patients with type II vitamin D dependent rickets who have an 
inactivating mutation in the VDR gene (70). Laboratory evidence is from VDR 
knockout mice where deletion of the receptor leads to a 70% or greater reduction 
in calcium absorption as well as poor growth, low serum calcium and high 
parathyroid hormone (PTH) along with osteomalacia (71). 
 
1,25(OH)2D Regulation of Serum Calcium 
1,25(OH)2D acts directly to increase calcium absorption from the gut (Figure 1.5) 
via multiple mechanisms including facilitated diffusion, transport mechanisms 
utilizing calbindin and passive transport mechanisms (72). 
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Figure 1.5:  Synthesis and Metabolism of Vitamin D in the Regulation of 
calcium, Phosphorus and Bone Metabolism  (taken from 
reference (73) and used with permission) 
 
Additionally, 1,25(OH)2D regulates serum calcium via its effects on PTH. PTH is 
involved in maintaining normal serum levels of calcium and phosphate and is itself 
regulated through 1,25(OH)2D and serum calcium. PTH activates CYP27B1 in the 
proximal tubule and thus increases 1,25(OH)2D. Vitamin D receptor mRNA has 
been localized to the parathyroid glands and cell culture studies have shown that 
the addition of 1,25(OH)2D led to a marked decrease in PTH mRNA, followed by a 
decrease in PTH secretion (74). In addition to its direct effects on PTH mRNA 
expression, 1,25(OH)2D may also act on PTH secretion by modulating the activity 
of the calcium sensing receptor (CaSR). This is a G-protein coupled receptor 
(GPCR) predominantly expressed in kidney and parathyroid glands where it allows 
regulation of PTH secretion and renal tubular calcium absorption in response to 
the prevailing calcium concentration. High plasma Ca2+ concentrations suppress 
PTH secretion, gene expression, PTH cellular proliferation and PTH degradation 
(75). The CaSR is also expressed in other tissues including the thyroid, intestine, 
bone, brain, heart and lung where its function is unknown (76). Parathyroid 
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hormone acts via a number of organs to regulate serum calcium. This is 
summarised in Table 1.1 below. 
 
Table 1.1: Effects of Parathyroid Hormone in the Regulation of Serum  
Calcium 
Organ Effect 
Kidney: distal 
tubule 
Increased tubular reabsorption of calcium(50) 
Proximal tubule 
Increased phosphate excretion due to decreased phosphate 
transporter protein(77) 
Proximal tubule Activates CYP27B1 and thus increases 1,25(OH)2D
(50) 
Bone 
Osteoblasts; increased proliferation, differentiation, 
activity(78) 
 
Up regulates Receptor Activator of Nuclear Factor κ β ligand 
(RANKL) and inhibits osteoprotegerin (OPG) and thus 
increases osteoclastogenesis(79) 
 
The decrease in PTH gene transcription effected by 1,25(OH)2D is used in the 
management of patients with chronic kidney disease (CKD). Such patients are 
treated with 1,25(OH)2D or a prodrug to reduce the secondary 
hyperparathyroidism seen in CKD.  
 
Phosphate regulates PTH gene expression indirectly by reducing calcium levels, 
via Fibroblast Growth Factor 23 (FGF23) which suppresses the production of 
1,25(OH)2D, and by direct effects on the parathyroid gland. FGF-23 is a circulating 
hormone produced by osteocytes, osteoblasts and endothelial cells.  FGF-23 acts 
as a vitamin D counter regulatory hormone. It reduces 1,25(OH)2D via down 
regulation of CYP27B1 and up regulation of CYP24 to decrease production of and 
increase catabolism of 1,25(OH)2D (80). FGF-23 along with other factors promotes 
the urinary excretion of phosphate (81, 82). FGF23 signals through its receptors 
FGFRs bound by a transmembrane protein Klotho (83) and acts on the parathyroid 
gland to decrease serum PTH.  
 
Both calcium and phosphate are filtered, reabsorbed and excreted by the kidney to 
varying degrees, generally in amounts that reflect the endogenous requirements of 
both substances. The kidney is the major site of production of 1,25(OH)2D as 
discussed in section 1.3.1 and the vitamin D endocrine system plays an important 
role in controlling the renal excretion of both calcium and phosphorus. The kidney 
expresses the enzymes involved in metabolism of 1,25(OH)2D, as well as the VDR 
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and several of the proteins involved in calcium transport, including the plasma 
membrane calcium pump (84, 85), the epithelial calcium channel (86), the sodium 
calcium exchanger (87) and calbindin (84). 
 
1.3.2  Dietary Sources of Vitamin D 
The main dietary sources are summarized in Table 1.2 
Table 1.2: Dietary and Supplemental Sources of Vitamin D2 and Vitamin 
D3 
Source Vitamin D Content (approximate) 
Fish: 
Salmon Fresh, wild  
              Fresh, farmed 
              Canned 
Sardines, canned 
Mackerel, canned 
Tuna, canned 
 
 
600-1000IU of vitamin D3 
100-250IU of vitamin D2 or D3 
300 to 600 IU of vitamin D3 
300IU of vitamin D3 
250 IU of vitamin D3 
230IU of vitamin D3 
Cod liver oil 400 to 1000IU of vitamin D3 
Egg yolk 20 IU of vitamin D2 or D3 
Cereals Variable 
Supplements: 
Ergocalciferol 
Vitamin D3 
Multivitamin 
 
50 000IU supplements 
400, 800, 1000 and 2000IU 
400 IU vitamin D, D2 or D3 
 
Modified from(73) 
 
1.3.3 Cutaneous Production of 25(OH)D 
The amount of 25(OH)D produced in the skin is dependent on the amount of 
substrate, namely 7-dehydrocholesterol, which is affected by increasing age (88) 
and also by exposure of the skin to UVB, which is in turn affected by geographical, 
physical and cultural conditions. Geographical conditions that influence 25(OH)D 
status include season (89) as well as time of day. Some of these studies are 
summarized in Table 1.3 below.    
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Table 1.3: Seasonal Variation in 25(OH)D Levels  
Location Population 
Winter 
25(OH)D 
nmol/L 
Summer 
25(OH)D 
nmol/L 
Reference 
United States, 
Massachusetts 
Healthy subjects , male and female 62 77 (90) 
New South Wales 
Australia 
Males and females 
retrospective patient samples  
47 63 (91) 
Cape Town 
South Africa 
Healthy, HIV positive and negative with 
and without TB 
31 57 (92)
a
 
Brazil Students and staff at university 55 85 (93) 
 
a) Winter to early spring and late summer to autumn 
 
It was thought that distance from the equator modified 25(OH)D levels. 
Theoretically regions closer to the equator should have higher levels of 25(OH)D, 
due to longer periods of sunlight and this appeared to be confirmed by studies 
from North America years ago (89, 94). However this has been questioned after 
Hagenau et al conducted a meta-analysis of cross–sectional studies on serum 
25(OH)D globally and suggested that after adjusting for age and gender there was 
no trend of changing 25(OH)D levels with latitude (95). Observed differences were 
attributed to differences in lifestyle, supplementation, fortification policy etc. The 
data on seasonal variation are more convincing, with studies from across the globe 
reporting a seasonal variation in 25(OH)D levels for all age groups. While levels 
are often lower in winter (89, 91, 92, 96) in some very hot countries 25(OH)D 
levels have been shown to be lower in summer as people avoid the sun by staying 
indoors (97). Individual factors that impair 25(OH)D production include dark skin 
which  requires longer exposure to sunlight to produce 25(OH)D in equal amounts 
as light skin (98), cultural practices such as veiled clothing (99) and possibly the 
use of sunscreens. These are used to protect the skin from ultraviolet A and B 
(UVA and UVB) exposure; the same UVB exposure is needed for vitamin D 
synthesis. Experimental studies suggest that the use of sunscreens can decrease 
vitamin synthesis in the skin (100) however recent studies suggest that while 
sunscreens are effective at blocking UVB, they are often applied improperly and 
therefore may not actually diminish vitamin D synthesis (101). Limiting outdoor 
activities can further reduce the amount of sun exposure and thus cutaneous 
exposure. The elderly, hospitalised or institutionalised individuals are at increased 
risk of lower 25(OH)D levels compared to healthy adults (102, 103). Toxicity does 
not occur with prolonged exposure to sunlight because 25(OH)D3 can also 
undergo thermal isomerisation to inactive products, such as lumisterol and 
tachysterol.  
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1.4  OTHER FACTORS THAT AFFECT VITAMIN D SUPPLY AND METABOLISM 
Parathyroid Hormone 
Parathyroid hormone reduces the half-life of 25(OH)D and anything that causes 
secondary hyperparathyroidism may result in depletion of 25(OH)D levels. Cases 
of calcium deficiency induced rickets have been reported from several countries 
(104-106). The mechanism is via the resulting elevation in PTH and 1,25(OH)2D 
levels and a decrease in 25(OH)D half-life (107). 
 
Renal Function 
As illustrated in Figure 1.1, 25(OH)D is converted to its active metabolite in the 
kidney. Poor renal function acts in number of ways to reduce 25(OH)D 
metabolism. For example, impaired renal function may reduce the conversion of 
25(OH)D to 1,25(OH)2D. In addition, the resulting secondary hyperparathyroidism 
reduces the half-life of 25(OH)D and thus its concentration in circulation (108). 
Cultural Practices 
Cultural practices such as clothing are important contributors to differences in 
25(OH)D concentrations. The religious practice of the veil, which often involves 
total covering of the body except for the eyes, is an independent risk factor for 
hypovitaminosis D in the Middle East and Africa (109, 110). Dietary practices also 
affect 25(OH)D concentrations. Studies from the polar regions of Canada have 
shown that consumption of fatty fish is associated with higher plasma levels of 
25(OH)D (111). Ethnic differences in the consumption of dairy products, in 
countries such as the US, where fortification is policy, are reported among Asian 
and African immigrants and may be a contributing factor to differences in 25(OH)D 
levels (13). 
 
1.5  GENETICS 
The hereditability of vitamin D status appears to be considerable. A genome wide 
association study of people of European ancestry showed that variations in GC 
(which encodes the DBP), the NADSYN1/DHCR7 locus and CYP2R1 which 
encode enzymes in the vitamin D metabolic pathway are associated with 
circulating 25(OH)D levels (112).  Similar findings have been noted by a number of 
other studies (113, 114) and have been replicated in African-Americans (115). In 
Gujurati-Asians, the Gc phenotype was shown to be associated with an increased 
prevalence of tuberculosis but not with lower 25(OH)D levels (116). It is important 
to note that these are associations, but direct cause has not been proven. 
However, if future studies identify significant associations between polymorphisms 
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and 25(OH)D levels, it will allow for potential identification of at risk individuals and 
early supplementation if required. 
 
The effects of body fat mass and distribution on vitamin D levels will be discussed 
in detail in section 1.9.6. 
 
1.6  MEASUREMENT OF 25(OH)D 
The results of cross-sectional studies showing an association between vitamin D 
deficiency and diseases such as osteoporosis, T2DM and the Met S, have driven a 
rapid increase in 25(OH)D testing. Both immunoassays and chemical methods 
such as high performance liquid chromatography (HPLC) and liquid 
chromatography mass spectrometry (LC/MS) are used by laboratories. 
 
The first assays for the measurement of 25(OH)D were described in the 1970s and 
were based on competitive binding after solvent extraction. In 1985, the first 
radioimmunoassay (RIA) for the measurement of 25(OH)D was developed and this 
used a specific 25(OH)D antibody. Since then immunoassays employing either 
enzymes or chemiluminescent substrates have largely replaced RIAs. Later on, 
methods based on high performance liquid chromatography were developed. With 
the increasing use of tandem mass spectrometry for small molecule work, such 
methods are also increasingly being used. 
 
25(OH)D is measured as a reflection of body stores of vitamin D because  it has a 
longer half-life than vitamin D2  and vitamin D3 (t1/2 of three weeks compared to 24 
hours) and the 25 hydroxylase enzyme is not subject to significant regulation. 
Laboratory testing of 1,25(OH)2D is also available but this is not used in the 
assessment of vitamin D deficiency as it has a t1/2 of about four hours, 
concentrations are highly regulated and it is raised in cases of secondary 
hyperparathyroidism (117). 
 
The very lipophilic nature of the compound, the high concentrations of DBP and 
the cross-reactivity of metabolites complicate analysis of 25 (OH) D. DBP binds 
with equal high affinity to 25(OH)D2 and 25(OH)D3 and less than 1% of the 
hormone is found in the free form. The US Food and Drug Administration require 
that assays measure both 25(OH)D2 and 25(OH)D3. Normally 25(OH)D3 comprises 
95% of total circulating 25(OH)D unless the patient is on supplements (118, 119) 
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Isotope dilution mass spectrometry is considered the gold standard for the 
measurement of small molecules, however, until recently there was no reference 
method available for 25(OH)D. More recently, two candidate reference methods 
were produced, one from the US and one from Europe in 2010 and 2011 
respectively (120, 121). In addition and importantly, the first standard reference 
material was introduced in 2009 (SRM 972) and these measures are expected to 
improve the analytical performance of methods and allow for harmonization across 
platforms. 
 
Chemical methods for the measurement of 25(OH)D include HPLC and LC/MS. 
Prior to chromatographic extraction an initial purification step is performed. Various 
deproteinization and extraction steps are performed prior to analysis by HPLC or 
LC/MS (122-124). The simplest is a liquid-liquid extraction. Extraction and 
chromatographic separation inevitably leads to some loss of analyte that can be 
corrected for by the inclusion of an internal standard. 
 
Studies that have compared HPLC with other methods have shown that 
agreement of HPLC with LC/MS is close (125). Lensmeyer et al compared the 
correlation between HPLC and LC/MS as well as to a competitive binding assay 
on the Nichols Advantage system and an RIA from Diasorin. For HPLC, the 
correlation coefficient with LC/MS was 0.99. The Nichols Advantage overestimated 
25(OH)D by 58% when 25(OH)D3 was the predominant form and underestimated it 
by 27% when 25(OH)D2 was the predominant form (126). The advantages of 
HPLC are its utility in resource-constrained settings, as the equipment is 
considerably cheaper than LC/MS, and it requires less expertise. The 
disadvantages of HPLC include the requirements for relatively large sample 
volumes, often a minimum of 500 ul and the long throughput times.  
 
Immunoassays are commonly used to measure 25(OH)D. The advantages of 
immunoassays are that they are automated and can easily be incorporated into 
routine clinical chemistry practice. The immunoassay technique requires that 
25(OH)D is first released  from DBP, upon which the DBP is inactivated or 
precipitated. Immunoassays reportedly use a small volume (50ul or less) of 
sample; however, the dead volume required within the auto analyser is often 
considerably higher. 
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There are a number of issues pertinent to 25(OH)D assays that will be discussed 
in some detail, in below. 
 
Assay Performance and Standardization 
A publication by Binkley et al (2004) (127) was the first to highlight the variation in 
results obtained between the different methods used for the measurement of 
25(OH)D. This publication emphasized the need for a reference standard material 
and the National Institute of Standards and Technology (NIST) working together 
with a number of other institutions then developed a standard, SRM 972, which 
encompasses four levels of standard. Level one is made from human serum, level 
two was diluted with horse serum to achieve lower levels of 25(OH)D2, level three 
was spiked with 25(OH)D2 and level four was spiked with 3-epi-25(OH)D3. The 
hope was that this would improve inter-assay comparability, however, in a later 
study that compared  automated immunoassays with LC/MS the bias for 
automated assays was shown to range from 0.5nmol/L to 11.4 nmol/L (128). 
Clinically this means that results can vary from 29 nmol/L, in the deficient range, to 
40nmol/L, which is within the normal range. The classification of a patient as 
vitamin D sufficient or insufficient may therefore depend purely on the 
methodology used.  
 
Benefits of the introduction of reference material and commercially available 
calibration material are evident by the considerably improved inter-laboratory 
coefficients of variability (CV) for LC/MS methods (129, 130). Data from DEQAS 
showed that about 10% of all methods for vitamin D testing used LC/MS. LC/MS 
methods had a positive bias of about 11% in comparison to the NIST LC MS/MS 
assay. Carter et al  attributed this high positive bias to the fact that the NIST assay 
can resolve 25(OH)D3 from the 3-epi-2%(OH)D3 which most LC MS/MS methods 
do not (131). 
 
Matrix Effects 
Matrix effects are a problem with immunoassays. The lipophilic nature of 25(OH)D 
makes it particularly vulnerable to the presence of lipids in the serum or plasma. 
These affect the ability of the binding agent to bind 25(OH)D equally in the sample 
and in the standard. Another problem is that 25(OH)D cannot be measured until it 
is removed from DBP. In a study of the effect of varying concentrations of DBP, 
researchers showed that five out of the six immunoassays evaluated showed an 
inverse relation between DBP concentrations and deviation from the gold standard 
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isotope dilution/online solid-phase extraction liquid chromatography/tandem mass 
spectrometry (ID-LC/MS/MS)  methods (132). This has particular significance in 
the assessment of patients such as pregnant women and ICU patients. Pregnant 
women have high levels of DBP, which interfere with the efficacy of several of the 
automated assays. ICU patients on the other hand, have low levels of DBP, which 
may be one of the reasons for the low levels of 25(OH)D reported in ICU studies. 
 
With LC/MS methods, the presence of co-eluting substances may lead to matrix 
effects such as ion suppression, which can in turn affect accuracy and precision. 
Furthermore, protein precipitation, which is used to displace 25(OH)D from its 
binding protein does not eliminate phospholipids or other matrix constituents. 
LC/MS methods vary with some employing only protein precipitation, while others 
use additional liquid-liquid extraction or solid-phase extraction (133). A significant 
advantage of using LC/MS is that the internal standard, needed for the correction 
of extraction losses and for the influence of ion suppression can be chosen so that 
it is chemically almost identical to the analyte of interest, by using stable isotope 
labelled standards.  
 
Assay Cross Reactivity 
More than 40 25(OH)D metabolites have been identified and any one of these may 
cross react in assays (134). In a comparison of LC/MS methods with 
immunoassays, several immunoassays showed variable measurement of 
25(OH)2D (135). Some assays e.g. the Abbot assay underestimates 25(OH)2D2 
while the Siemens assay overestimates 25(OH)2D3 (136). This is problematic when 
vitamin D2 is used for supplementation, as often happens in state hospitals in 
South Africa. Another problem is that some metabolites may circulate in 
concentrations that could interfere with 25(OH)D. Thus, 24,25(OH)2D is found in 
serum in concentrations that are 10-15% of the circulating 25(OH)D levels. 
Furthermore, metabolite identification by immunochemical methods is challenging 
(137), but can be quantitated separately by LC/MS methods (138, 139). 25(OH)D 
is also metabolized through the C3-epimerization pathway (140). While the 
biological relevance of this remains to be determined, the C3 epimer is of interest, 
because it appears to be high in the serum of infants and may make a significant 
contribution to measured 25(OH)D levels in most LC/MS methods (141) but 
reportedly does not interfere with immunoassays.  
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The choice of a suitable method to measure 25(OH)D is challenging given the 
wide range of methodologies available. Even with the introduction of reference 
material and a reference method, standardization of immunoassays is not likely in 
the near future. 
 
Given their cost, convenience and speed, automated immunoassays will likely 
remain the method of choice for African laboratories. Most automated assays 
report a functional sensitivity of 17.5nmol/L and as severe 25(OH)D deficiency is 
defined as levels <30nmol/L, a functional sensitivity at this level would be perfectly 
satisfactory.  
 
1.7  DEFINITION OF VITAMIN D DEFICIENCY 
The diagnosis of vitamin D deficiency based on the plasma concentration of 
25(OH)D and this is used on a public health basis to consider the adequacy of 
vitamin D supply. Investigators have used different cut off levels to define vitamin 
D deficiency and adequacy (142-144). Thresholds to define deficiency and 
insufficiency have sometimes been based on levels at which 25(OH)D maximally 
suppresses PTH. Using this end point, investigators have reported cut off values 
ranging from 18nmol/L to 100nmol/L with a cluster around 80nmol/L (145-148). In 
2010, the Institute of Medicine (IOM) issued a report on dietary reference intakes 
(DRIs) for calcium and vitamin D (131). The IOM stated that people with a serum 
25(OH)D <30nmol/L  are at risk of vitamin D deficiency as defined by skeletal 
disease, persons are potentially at risk at levels from 30nmol/L to 50nmol/L and 
practically all persons are vitamin D sufficient at levels >50nmol/L. The IOM stated 
that 50nmol/L was the estimate of the concentration that covered the needs of 
97.5% of a normal healthy population in relation to bone health. The Endocrine 
Society released guidelines 6 months later, which defined vitamin D deficiency as 
a serum 25(OH)D value of <50nmol/L (149). They based this cut off on three main 
premises: 
 
1) Elevation of PTH levels when 25(OH)D levels drop below 50nmol/L  
2) Reduction in falls among older people on 800IU of vitamin D compared with 
those on 400 IU  
3)   Increased calcium absorption with 25(OH)D levels above 50nmol/L  
 
The use of PTH in defining optimal vitamin D status has limitations, as increases in 
PTH occur with age (150), obesity (151, 152) and declining renal function (153). 
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The use of different cut offs has a huge effect on estimates of deficiency 
prevalence. Thus, data from the National Health and Nutrition Examination Survey 
(NHANES) showed that changing the definition of vitamin D deficiency from 
<27.5nmol/L to <50 nmol/L, increased the prevalence of vitamin D deficiency from 
2% to 14% (154). Furthermore, as discussed previously the variability in the 
results from different methods for measuring blood levels of 25(OH)D causes 
considerable difficulty in the interpretation of results. 
 
1.8  WORLDWIDE VITAMIN D STATUS 
Reports from across the world suggest that vitamin D deficiency is re-emerging as 
a major global public health problem. In the following sections, I have summarized 
the available data; however, it is almost impossible to make direct comparisons 
across studies due to differences in the cut-off levels used to define vitamin D 
deficiency as well as the variation that arises from methodological differences. 
 
North America (US and Canada) 
In the United States, serum 25(OH)D levels have been assessed in participants in 
the NHANES over the periods 1988-1994 and 2002-2004(12). This is a national 
survey of the US population randomly selected from households in 81 counties 
across the United States. Comparisons of prevalence across regions are 
confounded by the fact that data collection and sampling occurred during the 
winter months in the lower latitudes and during the summer months in higher 
latitudes. Serum 25(OH)D was assayed in a central laboratory by 
radioimmunoassay after extraction with acetonitrile. 
 
Vitamin D deficiency was defined as serum 25(OH)D of less than 25nmol/L and 
inadequacy as levels less than 30 to less than 62.5nmol/L. About one quarter of 
the population was at risk of inadequacy and 5% at risk of deficiency. The season-
adjusted prevalence differed by sex and age and ranged from1- 8% in males to 1-
12% in females. 
 
In males as well as in females the prevalence of deficiency was lowest in those 
aged 1-8 years and increased until the age of 30 years in males and 18 years in 
females. Prevalence of those at risk of deficiency also varied by ethnicity and was 
greatest in non-Hispanic blacks (32%) followed by Hispanics (9%) and was lowest 
in non-Hispanic whites (3%). Initially it was reported that mean serum 25(OH)D 
decreased from 75nmol/L (95% CI, 72.5-75nmol/L) for the 1988-1994 collection to 
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60nmol/L (95% CI 57.5-62.5 nmol/L) for the 2001 to 2004 collection. However, it 
was later reported that the manufacturer had made some changes to the assay 
that was used for the measurement of serum 25(OH)D levels (155). These 
included the use of a new antibody with improved binding as well as the addition of 
detergents to a buffer to reduce non-specific binding.  After a statistical 
adjustment, so that data from both collections could be compared (156) the age 
and season-adjusted prevalence of deficiency increased between 1988-1994 and 
2001-2002 among males (3% to 8%) and females (7% to 11%). This clearly 
illustrates how assay differences confound the literature. Within NHANES it was 
subsequently recommended that the LC/MS method developed by NIST serve as 
a higher order reference measurement procedure and the need for a 
commutability study for the NIST SRM 972 was noted (156). 
 
To analyse possible reasons for lower vitamin D status in the NHANES cohort in 
2001-2006 relative to 1988-1994 Ganji et al  looked at changes in BMI, milk 
consumption and physical activity in the group (157). They reported that mean BMI 
increased in all the subsets studied, milk consumption increased in non-Hispanic 
blacks only while physical activity increased in non-Hispanic blacks. The increased 
prevalence of vitamin D deficiency was attributed to increased adiposity. 
 
There are less data from Canada compared to the US. The Canada Health 
Measures Survey collected physical measures of health and wellness as well as 
blood and urine samples from over 5000 people at 15 sites spread across five 
regions of Canada (158). The 25(OH)D was measured by the Diasorin 
chemiluminescent assay. Using a cut-off level of 27.5nmol/L, an estimated 4% of 
the population were vitamin D deficient.  Mean 25(OH)D level was 67.7nmol/L and 
with higher levels in females. Overall, the pattern of 25(OH)D levels followed a U 
shaped distribution: highest among children and those above 60 years and lowest 
between the ages of 20-39 years. Higher 25(OH)D levels were associated with 
white racial background, increased milk consumption and blood collection from 
April to October. Some of these findings were reproduced in the Canadian 
Multicentre Osteoporosis Study, (159) which is an on-going longitudinal population 
based cohort study in nine Canadian cities. Data from almost 2000 men and 
women showed that 2.3% of the population had 25(OH)D of less than 27.5nmol/L. 
Women were over-represented in this study and the mean 25(OH)D levels were 
not significantly different to levels observed in males when stratified by age. The 
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strongest predictors of lower 25(OH)D concentrations were winter and spring 
seasons, non-white race, BMI ≥ 30kg/m2 and lower vitamin D supplementation. 
 
South America 
Data on the vitamin D status in Latin American studies are scarce and there are no 
population studies from this region. An international epidemiological investigation 
conducted in postmenopausal women with osteoporosis, found a high prevalence 
of hypovitaminosis in Mexico (67.1%), Brazil (42.4%) and Chile (50.4%) using a 
cut off level of <75nmol/L (43). At a cut-off of 37.5nmol/L, the prevalence was still 
considerably high at 8.1% in Mexico, 6.0% in Brazil and 7.8% in Chile. 25(OH)D 
was measured at a central laboratory using the Nichols Advantage competitive 
binding chemiluminescence immunoassay. 
 
Unger et al investigated the vitamin D status of 603 healthy male and female 
volunteers aged between 18 and 80 years in Sao Paulo Brazil (93). Bloods were 
collected after winter and a subset of 209 bloods were collected a second time, 
after summer. Marked seasonal variation in 25(OH)D levels was noted. Median 
winter 25(OH)D levels were 55nmol/L (41.5-72.3) and summer levels were 
85nmol/L (65.5-109). The prevalence of vitamin D deficiency, as defined by 
25(OH)D levels of less than 37.5nmol/L was 13.8% in winter as compared to 3.8% 
in summer. Other predictors of 25(OH)D levels were age and skin colour. 
 
Differences in 25(OH)D levels were attributed to altitude and skin colour in a cross 
sectional study carried out amongst two groups of boys in Argentina (160). The 
prevalence of vitamin D  deficiency (<25nmol/L) in Indian boys with dark skin, 
living in a mountainous region was 51.2% as compared to 0.9% in a group of 
mixed population boys living in Buenos Aires. Another possible contributor to lower 
levels in children from the mountainous area is the use of increased clothing to 
keep warm, although the investigators did not discuss this. A study from Sao 
Paulo, Brazil, in apparently healthy girls revealed mean 25(OH)D levels to be 
similar to the Argentinian study at 53.2 ± 17.0 nmol/L. There was no seasonal 
variation in 25(OH)D levels (161). 
 
Europe 
The vitamin D status within different European countries shows wide variation and, 
as in other regions of the world, varies with season, latitude and skin pigmentation. 
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Both the United Kingdom Low Income Diet and Nutrition Survey and the United 
Kingdom National Diet and Nutrition Survey showed that season, skin colour, 
dietary intake of vitamin D and intake of dietary supplements were significant 
predictors of 25(OH)D (162). Of particular interest was the observation that the 
low-income group had lower 25(OH)D concentrations than the general population. 
In addition to the season and use of supplements, 25(OH)D concentrations were 
lower in northern parts of the United Kingdom compared to the southern parts. 
25(OH)D levels were highest in September. Women had lower levels than men in 
summer and autumn but not in winter. 
 
A Norwegian study showed 25(OH)D levels  to be higher (74.8 ± 23.7nmol/L) in 
those born in Norway compared with people of Pakistani origin living in Oslo (25.0 
± 13.6nmol/L) (163). While the reasons for these differences were not investigated, 
the high levels in indigenous Norwegians were attributed to consumption of oily 
fish and fortification of foods with vitamin D. The levels of 25(OH)D noted for 
Norwegians are in contrast to those from a population-based survey in Finland 
which showed the population mean (± SEM) 25(OH)D level in men to be 45.1 ± 
0.53 nmol/L and this was not significantly different to levels in women(164). Both 
Norway and Finland are at approximately the same latitude, 60oN. It is possible 
that some of these differences are due to differing assay methodology as well as 
season of draw. All bloods were drawn in the winter months of January and 
February for the Finnish study. 
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Table 1.4: European Studies of 25(OH)D Levels 
Country Reference Population and (N) 25(OH)D assay 25(OH)D nmol/L 
Norway (163) Norwegians (869) 
Pakistanis (177) 
Diasorin  
RIA 
74.8 ± 23.7 
25.0 ± 13.6 
Finland 
 
Finland 
(164) 
 
(165) 
Finnish men and women 
aged 62-79 (1604) 
Bangladeshi(34), 
Somali(48) and 
Finnish(61) 
premenopausal women 
RIA 
 
ELISA  
 
45.1 ± 0.53* 
 
Bangladeshi 42.9 ±16.1 
Somali 36.8 ± 11.8 
Finnish 54.1 ± 19.1 
Italy (166) Italian premenopausal 
women(608) 
ELISA  
 
Northern sites 69.0 ± 
27.8 
Central sites 72.3 ± 28.3 
Southern sites 72.0 ± 
28.0  
France (167) 
 
 
(168) 
Premenopausal women 
from several countries 
including France(637) 
Osteoporotic and 
osteopaenic women 
(1292) age 52-94 years 
Diasorin  
RIA 
87 ± 2.20* 
 
 
51.5 ± 26.1 
 
 
Spain 
(169) 
 
(170) 
Male and female adults 
ages 18-84 years(177) 
Male and female 
adolescents (100) 
Chemiluminescen
t assay 
ELISA 
 
Males 61.3 ± 22.9 
Females 59.5 ± 21.9 
63.6 ±18.9 
Germany (171) Men and women(4030) Diasorin 
chemiluminescent 
Men 45.2 (30.5-68.7) 
Women 44.7 (30.7-72.7) 
The 
Netherlands 
(172) Dutch men and women 
Turkish men and women 
Moroccan (613) 
Diasorin  
RIA 
Dutch 67 (50-83) 
Turkish 27 (18-29.5) 
Moroccan 30 (20-45) 
 
 
RIA=radioimmunoassay; ELISA= enzyme linked immunosorbent assay; *values are mean 
± SEM whilst all other values are mean ± SD or median (interquartile range)   
 
What is obvious is that most European countries lack large population studies that 
have investigated the prevalence of vitamin D deficiency. It is interesting to note 
that several studies demonstrate lower levels of 25(OH)D in immigrant 
communities (163, 165, 173, 174). The reason for this observation has not been 
investigated, but may include darker skin colour, and cultural practices such as 
dress style. 
 
Asia  
Apart from Korea, there are no Asian population studies. There are several studies 
from China, but I have selected only studies with very large sample sizes numbers. 
Small studies have been included if they were performed in India. These are 
summarised in table 1.5. 
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Table 1.5: Asian Studies of 25(OH)D Levels 
Country and 
Reference 
Population and (N) 
 
25(OH)D nmol/L   Determinants of lower 
25(OH)D 
Korea 
(KNHANES) 
(175) 
Age >10 years. 
Males and females, 
population 
survey(6925) 
Males 53.0 ±18.8 
Females 45.5 ±17.8 
Winter, spring, urban 
residence and indoor work. 
India (176) Male and female 
young adults ages 
18-35 years(329) 
Summer 132 ± 84.3 
Winter 78.5 ± 53.0 
Season, duration of sun 
exposure in winter , calcium 
intake  
Rural India 
(177)  
Males and females 
(23) 
36.4 ± 22.5 Higher levels in rural 
populations compared with 
literature for urban 
populations 
India (178) Males and females 
rural vs. Urban(1143) 
Males rural 59.3 ± 2.0* 
Males urban 46.3 ± 2.0* 
Females rural 47.5 ± 2.2*  
Females urban 38.8 ± 0.8* 
Higher levels in rural 
populations. 
India (179) Pregnant women and  
Adolescent girls 
(288) 
Pregnant women 37.8 ± 19.8 
Adolescent girls 33.3 ± 16.0 
Female gender associated 
with lower 25(OH)D 
India (96) Pregnant women and 
then women and 
their infants(541) 
Looked at three trimesters as 
well as seasonal effect 
1st trimester summer 23.4 ± 
11.3 
2nd trimester summer 25.7 ± 
15.1 
3rd trimester summer  
27.7 ±9.7 
There was no significant 
change in 25(OH)D levels 
across trimesters but 
25(OH)D levels were lower in 
winter across all trimesters. 
Strong positive correlation of 
maternal 25(OH)D with infant 
25(OH)D 
India (180) Healthy adults aged 
50 years and 
above(1346) 
Divided group into those 50 to 
65 and then above 65 
Aged 50-65  
35.2 (0.77,249) in  
Aged > 65  
34.8 (4.04,230) 
VDD defined as 25(OH)D 
<50nmol/L was present in 
91.2% of all subjects with no 
significant difference in both 
groups. 
Pakistan (181) Males and 
females(300) 
Ages 38-55 years 
47.9 (31.5, 61.5) Use of vitamin D supplements 
Japan (182) Women age >74 
years 
59.9 ±17.9 Fish intake  
China (183) Men and women 
(25988)ages 20-
96years  
52.2 (42.3, 62.5) 
30% males and 46% females 
had 25(OH)D <50nmol/L 
All samples taken during 
winter. Men had significantly 
higher 25(OH)D levels than 
women 
China (184) Pregnant 
women(1695) 
Mean age 28.1 years 
43.9 ± 28.6 
 
69% of subjects had 25(OH)D 
<50nmol/L 
25(OH)D correlated negatively 
with age, body weight and 
BMI 
 
*values are mean ± SEM whilst all other values are mead ± SD or median (interquartile range) 
VDD= Vitamin D deficiency 
 
The results of Asian studies highlight gender differences in 25(OH)D levels. The 
implications of low maternal 25(OH)D levels for infant and child health are 
important to follow up, perhaps particularly so in female infants as girls have 
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significantly lower levels than boys. It is important to note that 25(OH)D levels are 
higher in rural Indian populations than in urban populations and are lower in those 
who work indoors. This is to be expected, particularly where dietary intake of 
vitamin D is low and is especially relevant because of increased rural to urban 
migration. 
 
Australia 
Although Australia has a sunny climate, low mean 25(OH)D levels have been 
reported from certain high-risk groups such as women living in residential care 
(185). Marked seasonal variation was noted from a longitudinal study in an elderly 
population from Tasmania with mean levels in winter of <50nmol/L. Also shown is 
that supplementation with 25(OH)D reduced the winter drop in 25(OH)D 
concentrations (186). A large population based study noted that the prevalence of 
vitamin D deficiency defined as a level of <50nmol/L was 31% with a higher 
prevalence in women (39%) compared to men (22%) (187). Predictors of low 
levels were increased age, non-European origin, living in southern Australia, 
female gender, obesity and physical inactivity. 
 
Africa and the Middle East 
There is a paucity of population-based studies from Africa and the Middle East.  
Lack of sunshine exposure and veiled clothing style are important factors that 
influence hypovitaminosis D (188). A study from Saudi Arabia reported that 79.1% 
of females have 25(OH)D levels of <25nmol/L which is in the deficient range (189). 
A high prevalence of vitamin D deficiency has also been noted in Saudi men, in 
which lower levels of 25(OH)D were noted to be associated with increased age 
and obesity (190). However, adequate 25(OH)D levels have been reported from a 
number of sub-Saharan countries. Pregnant HIV infected women from Tanzania 
were noted to have mean levels of 89.2nmol/L, while a study from Uganda showed 
a high level of vitamin D sufficiency as defined by levels >75nmol/L in HIV infected 
individuals, with and without tuberculosis (191). 
 
There are no population-based studies from South Africa. A study of 10-year old 
children from Johannesburg showed that mean 25(OH)D levels were high and that 
deficiency was rare (192). This study showed that white children had significantly 
higher levels than their black peers had (120-±36 nmol/L vs. 93.3 ± 34nmol/L). 
Winter season, female gender and increased fat mass were all associated with 
lower 25(OH)D levels. Alcohol use was shown to be a determinant of lower 
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25(OH)D levels in adolescents from Tygerberg (193).  Kruger et al (2011) 
investigated risk factors for low bone mineral density (BMD) in rural as well as 
urban African women and noted that  women older than 50 years who lived in an 
urban area had lower 25(OH)D levels compared to their rural peers (194). The 
prevalence of vitamin D deficiency defined as a level less than 37.5nmol/L was 
noted to be 41% in a retrospective analysis of 25(OH)D laboratory results at 
Tygerberg hospital (195). In another Cape Town study, marked seasonal variation 
of 25(OH)D levels was noted, with highest levels observed from January through 
to March (56nmol/L vs. 30.7nmol/L) (92). 
 
In summary, while there is no uniform definition of vitamin D deficiency, the lowest 
levels are noted in immigrant populations in Europe as well as in African-
Americans. Cultural factors such as mode of dress are associated with high 
prevalence of deficiency even in very sunny countries like Saudi Arabia. There are 
very few studies that have looked at levels in South African adults, in particular 
South African men and none that have reported on 25(OH)D levels in the Indian 
population in South Africa, a group noted to be at high risk for deficiency from 
studies across the world. Studies from India and South Africa have highlighted 
differences in 25(OH)D levels of rural populations compared to urban populations 
and this raises concerns for a nation whose population is in transition. 
 
1.9  CONSEQUENCES OF VITAMIN D DEFICIENCY 
The classical effect of vitamin D deficiency is recognized as failure of normal 
mineralization of the bone. This presents as rickets in childhood and as 
osteomalacia in adults. In both these conditions, there is poor mineralization of the 
bone matrix so that bones are soft. The hallmark of severe vitamin D deficiency is 
a low circulating level of 25(OH)D. 
 
 Vitamin D levels of between 50-125nmol/L are found in the majority of studies 
conducted among healthy children in communities where vitamin D deficient 
rickets is uncommon (196, 197). The classical biochemical changes in vitamin D 
deficient individuals are hypocalcaemia, hypophosphataemia, elevated alkaline 
phosphatase and PTH.  Florid rickets manifests  with leg deformities, enlargement 
of the growth plates of the wrists, ankles and costochondral  junctions and rib cage 
deformities (198). X-rays confirmation of the impaired mineralization of the growth 
plate as evident by widening of the growth plate and fraying of the margins of the 
metaphyses is required to make the diagnosis.  
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The clinical manifestations of osteomalacia differ from those of rickets, and often 
include bone pain mainly between the joints as well as proximal muscle weakness 
and gait instability. As the growth plates in adults have already closed, radiological 
features are different. X-rays may reveal pseudo fractures of the pelvis, femurs, 
metatarsals or lateral margins of the scapula (199). In addition to the effects of 
vitamin D on bone, a large number of studies suggest that it has other skeletal and 
non-skeletal benefits. 
 
1.9.1  The Effects of 25(OH)D on Bone Mineral Density  
Bone physiology is dependent on the activities of osteoblasts, osteocytes and 
osteoclasts. Both osteoblasts (which are bone-forming cells) and osteocytes are 
derived from the mesenchymal cell lineage. Conversely, osteoclasts (which are 
bone resorbing cells) are derived from the haemopoetic lineage. Each of these 
three cell types express the VDR and are capable of metabolizing 25(OH)D to 
1,25(OH)2D to exert biological activity(200). Current data indicate that vitamin D 
acts to maintain plasma calcium and phosphate levels and prevent the 
development of rickets or osteomalacia. Calcitriol acts on osteoblasts to maintain 
osteoclastogenesis and bone resorption which are associated with failure of bone 
mineralization. On the other hand there is on-going debate about the association 
between 25(OH)D and BMD.  Common allelic variations in the gene encoding the 
vitamin D receptor have been associated with increased bone density in healthy 
individuals (201). In vitro studies of VDR over expression on mature mouse 
osteoblasts were associated with an inhibition of bone resorption (202). 
Conversely, animal models have shown that 25(OH)D levels are inversely related 
to trabecular bone mineral volume (203). 1,25(OH)2D appears to affect both 
osteoblast and osteoclast function. In vitro experiments with rodent or human 
primary bone cells show that the inclusion of 1,25(OH)2D in the culture media 
inhibits osteoblast proliferation and enhances osteoblast maturation and mineral 
deposition (200, 204). Genes coding for the vitamin D metabolising enzymes 
CYP27B1  and CYP24A1 are expressed in several cell types including osteoblasts 
and osteoclasts (205). Expression of these genes is positively related to each 
other and is unrelated to serum 1,25(OH)2D concentration, suggesting that locally 
produced 1,25(OH)2D may have an autocrine or paracrine effect on bone. In 
support of this concept, expression of bone cell CYP24A1 is not related to serum 
1,25(OH)2D concentrations. 25(OH)D metabolism appears to promote osteoclast 
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differentiation and reduce osteoclast activity (206). Thus, 25(OH)D may act on 
bone by altering the activity of both osteoblasts and osteoclasts. 
 
Cross sectional studies of the relationship between BMD and 25(OH)D  have 
yielded conflicting results with some studies showing BMD to be independent of 
25(OH)D (207-210), while others have shown a positive association between 
25(OH)D and BMD (211, 212). Two systematic reviews concluded that there was 
insufficient evidence of an effect of vitamin D supplementation on BMD (213, 214). 
There are several possible reasons for these conflicting results: small sample 
sizes, different population groups and different covariates used in multiple 
regression analysis. Furthermore, BMD is dependent on several other factors 
including hereditary factors, body weight, medications, age and lifestyle (215-219). 
Few South African studies have reported on 25(OH)D and BMD. Daniels et al 
(1997) showed that there are ethnic differences in BMD between Africans and 
Caucasian females with Africans having greater femoral neck BMD compared to 
Caucasians.  25(OH)D levels were lower in Africans and the greater BMD was 
explained by greater weight bearing in Africans (220). 
 
A consistent finding from observational studies is that vitamin D insufficiency  and  
not necessarily deficiency, increases fracture risk (221). The majority of hip 
fracture patients demonstrate osteoporotic bone histology, meaning that they have 
a reduced ratio of mineral to osteoid (222). Results of some randomised controlled 
trials (RCT) of vitamin D supplementation, particularly when combined with 
calcium supplementation, demonstrate reduced fracture risk (223, 224).These 
findings implicate reduced vitamin D as a cause of osteoporosis.  
 
In a systematic review and meta-analysis  of fracture risk in relation to vitamin D 
supplementation and 25(OH)D levels, Lai et al noted 33% lower 25(OH)D levels in 
cases compared to controls, while the results of seven RCTs showed no difference 
in hip fracture risk in those randomized to supplementation versus placebo (221).  
In addition to the reasons for a lack of association listed above, it is possible that 
the doses of vitamin D used in RCTs were insufficient or that the form of 
supplementation was unsuitable. Results of a meta-analysis by Bischoff-Ferrari et 
al showed that vitamin supplementation at doses of between 700 and 800IU per 
day reduced the relative risk of hip fractures by 26%, versus calcium or placebo, 
while doses of 400IU/day did not show any significant benefit  (225). Different 
inclusion criteria were used for these meta-analyses. Lai et al (221) excluded trials 
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that included combined therapy, while Bischoff-Ferrari included vitamin D 
supplementation and combination therapy (225). Another reason for a lack of 
association may be the form of vitamin D used therapeutically. Cholecalciferol or 
ergocalciferol will not be activated in 25(OH)D replete patients or in those with 
impaired renal function e.g. elderly patients. In contrast, calcitriol or the pro-drug 
alfacalcidiol will act independent of the patient‟s vitamin D status or kidney 
function. An early meta-analysis of trials that included over a 1000 patients 
showed a 22% reduction in falls in subjects receiving vitamin D supplementation 
(226). In depth analysis of this meta-analysis revealed these results were driven by 
two trials that had used calcitriol or alfacalcidiol and these studies supplied up 
more than half the total subject population. 
 
Data from a nested case–control study within the Women‟s Health Initiative (WHI) 
showed that ethnic differences also contribute to disparities in study results. In 
white women 25(OH)D levels greater than 50nmol/L compared to levels lower than 
50nmol/L were associated with lower risk of fractures, while in African–American 
women levels of 25(OH)D of greater than 50nmol/L compared with levels less than 
50nmol/L were associated with greater fracture risk (227). They suggest that this is 
evidence for different 25(OH)D threshold requirements for different ethnicities. 
Other causes for increased fracture risk could be increased secretion of PTH in 
vitamin D deficiency which has been well described and can contribute to bone 
fragility and fractures in the elderly through increased bone turnover and 
decreased bone density (148, 228). The threshold 25(OH)D levels required to 
suppress a rise in PTH levels appears to vary by age, gender, adiposity and race 
(151, 152, 229). 
 
Finally, fracture risk may be due to muscle weakness, which affects gait. Muscle 
weakness and hypotonia are features of rickets and osteomalacia. Adults may 
complain of pain, which may be prominent about the hips and may produce a 
waddling gait. This muscle weakness is multifactorial and includes reduced 
calcium uptake into the sarcoplasmic reticulum (230), impaired muscle contraction 
and muscle atrophy (231). In addition, muscle cells have VDRs and the expression 
of these decreases with advancing age (232). 25(OH)D levels that are often lower 
in the elderly may modulate fracture risk by decreasing falls via effects on muscle.  
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1.9.2  Vitamin D and Cardiovascular Risk Factors 
Epidemiological evidence that has shown that low levels of 25(OH)D are 
associated with increased risk of cardiovascular disease including hypertension 
and myocardial infarction (233, 234). Laboratory evidence confirms this, as the 
VDR appears to be widely distributed in several tissues including the heart and 
blood vessels. VDR deficient mice develop hypertension, cardiac hypertrophy and 
increased thrombogenicity (231). 25(OH)D may influence glucose control as 
pancreatic β cells have both CYP27B1 and the VDR and 25(OH)D is involved in 
both insulin synthesis and release (235). 1,25(OH)2D is thought to affect glucose 
tolerance as it has been shown to be involved in normal insulin secretion and 
reduced concentrations have been associated with β cell dysfunction (41), insulin 
receptor down regulation and insulin resistance (236). In addition, 1,25(OH)2D may 
protect islet cells from cytokine mediated apoptosis (237) and has been shown to 
blunt the impact of advanced glycation end products on endothelial cells (238) 
Furthermore, low levels of 25(OH)D have also been associated with unfavourable 
lipid levels which may lead to increased cardiovascular risk (239). 
 
In the following section I will review some of the studies on associations between 
25(OH)D and dysglycaemia, serum lipids and hypertension. 
 
1.9.3 Vitamin D and Type 2 Diabetes 
There is ample laboratory evidence for a role of vitamin D in insulin secretion such 
as the presence of VDR in pancreatic B cells (240, 241). Vitamin D deficient rats 
have glucose intolerance and altered insulin sensitivity(242). Mechanism may 
involve a rise in intracellular calcium concentrations (243) or insulin exocytosis 
(244). While there is mechanistic evidence for a role of vitamin D on pancreatic B 
cell function the results of clinical studies are not clear-cut and are reviewed below. 
 
 
Results of Cross Sectional Studies 
The initial observation for the relationship between vitamin D and type 2 diabetes 
(T2DM) in humans came from studies showing that both healthy and diabetic 
subjects experienced seasonal variation in glycaemic control (245, 246). Since 
then some studies have shown a similar association between 25(OH) D and T2DM 
or glucose intolerance, while others have failed to show the same relationship. 
Results of some of the large cross sectional studies (N numbers > 1000), that have 
examined associations between 25(OH)D and blood glucose levels, insulin 
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secretory capacity or insulin secretion are summarised in Table 1.6. Smaller 
studies have been included if they included Indian subjects. 
Table 1.6: Studies on the Association between 25(OH)D and Type 2 Diabetes 
Mellitus or Metabolic Syndrome  
 
Study Type 
(Reference) 
(N) 
Ethnicity 
 
Participant Type 
Age Males (%) 
Outcome 
NHANES III- 
cross 
sectional 
(247) 
(6228) 
Mixed 
No Asian 
Americans 
Healthy, excluded 
diabetics 
≥ 20 years (47) 
OR for diabetes varied inversely across quintiles of 
25(OH)D in NHW (OR 0.25 (CI 0.011-0.60)) and MA 
(OR 0.17 (CI 0.08-0.37)), for those in the highest 
quintiles compared with those in the lowest 
(≥81.0nmol/L vs≤43.9 nmol/L). This was not seen in 
NHB. 
HOMA was inversely associated with 25(OH)D in 
NHW (p= 0.058) and MA (p=0.0024). This was not 
seen in NHB. 
Cross 
sectional 
(248) 
(3262) 
Chinese 
Used all 
participants 
50-70 years (44) 
Aim was to evaluate association between 25(OH)D 
and Met S. Showed an inverse association between 
25(OH)D and fasting insulin (β=-0.06, p=0.01), and 
HOMA index only in overweight subjects (β=-0.06, 
p=0.004). 
NHANES 
cross 
sectional 
(249) 
(9773) 
mixed 
All participants 
≥ 18 years 
Aim was to look at the association of 25(OH)D with 
HbA1c. They showed that 25(OH) D was inversely 
associated with HbA1c only in those between 35 and 
74 years (p=0.004) and those who did not report a 
history of diabetes. PTH was also inversely associated 
with HbA1c (p=0.0002) in those aged 35-74 years. 
Cross 
sectional 
(250) 
(5787) 
Korean 
Used all subjects 
≥ 20 years (42 ) 
25(OH)D inversely associated with fasting glucose. 
Compared to individuals with a sufficient serum 
25(OH)D concentration ≥75 nmol/L, the OR (95% CI) 
for diabetes mellitus were 1.73 (1.09–2.74), 1.30 
(0.91–1.84), and 1.40 (0.99–1.98) for serum 25(OH)D 
concentrations <25, 25 to <50, and 50 to <75 nmol/L, 
respectively, after multiple adjustments (P-trend < 
0.0001). 
Case 
control 
(251) 
(210) 
South Asian 
170 subjects with 
diabetes, 40 
without.  
>40 years (50) 
Diabetics recruited from diabetic clinic. 
There was no significant difference in 25(OH)D levels 
between those with T2DM and those without, 
however, vitamin D deficiency was more common in 
those with T2DM (83% vs. 70%, p=0.07) 
Cross 
sectional 
(252) 
(2465) 
Caucasian 
58-71 years (53) 
Self-reported 
diabetes Fasting 
blood sugar or 
OGTT not done 
 Looked at OR for self-reported diabetes in subjects 
with 25(OH)D ≥80 nmol/L  vs. ≤ 37 nmol/L (OR=0.5(CI 
0.1-0.7)) 
Cross 
sectional 
(253) 
(441) 
Asian Indian 
37-53 years (54) 
Randomly selected 
Indian living in India 
Lack of association between 25(OH)D and HOMA-IR 
(β=-0.12; p=0.17), fasting glucose (β=0.26; p=0.79) 
and insulin (β=0.14; p=0.89) 
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Table 1.6 continued   
Cross 
sectional 
(254) 
(1017) 
Caucasian 
30-54 years (32) PTH and not 25(OH)D was associated with the Met S. 
Subjects with PTH in the 2
nd
 to 4
th
 quartiles had the 
highest OR for Met S 2.33 (95% CI 1.40-3.87). PTH 
correlated with blood pressure but not with fasting 
blood glucose or HOMA-IR. 
Cohort 
(255) 
(1070) 
Majority 
Caucasian 
74.5± 9.5years for 
men 
74.6 ± 10.7 years 
for women (38) 
Cohort: these were 
results from a 
follow up study 
No evidence for association of 25(OH)D with Met S, 
Significant trend (p=0.03) for adjusted odds for Met S 
with increasing PTH (OR 2.02 (CI 0.96-4.24)). This 
was only seen in men and was largely due to effects 
on blood glucose and low HDL. 
NHANES 
Cross 
sectional 
data 
(256) 
(3206) 
Mixed 
≥ 20 years (49) 
Excluded physician 
diagnosed diabetes 
After adjusting for BMI, abdominal obesity 
hyperinsulinaemia, HOMA-IR and 2-hour OGTT, risk 
for hyperglycaemia decreased across quintiles of 
25(OH)D. Hyperinsulinaemia was positively 
associated with PTH.  
Korean 
National 
Health and 
Nutrition 
Survey 
(257) 
 
(5559) 
Korean 
≥ 19 years (42) 
Used all subjects 
After adjusting for confounders there was no 
association between 25(OH)D and any of the 
components of the Met S. The association of PTH with 
Met S or its components was not reported. 
 
Key: HbA1c  haemoglobin A1c;  HOMA-IR HOMA Insulin Resistance;  Met S metabolic 
syndrome; OGTT oral glucose tolerance test; PTH parathyroid hormone; OR Odds Ratio;  
NHW Non-Hispanic Whites; NHB Non-Hispanic Blacks; MA Mexican Americans. 
 
Almost all studies used 25(OH)D as a biomarker for vitamin D stores and the 
majority of studies listed in Table 1.6 show an inverse relationship between 
25(OH)D and glycaemia. However, this relationship is not consistent. Possible 
reasons for differences may include failure of some investigators to adjust for BMI. 
Other reasons may reflect ethnic differences or differences in the mean 25(OH)D 
levels of subjects across studies. A number of studies have shown that after 
adjustment for confounders such as BMI, the relationship was no longer significant 
(258, 259). Furthermore, several of the studies failed to adjust for parathyroid 
hormone (PTH), which rises with obesity and is often elevated in vitamin D 
deficient states. Thus, the sequelae of vitamin D deficiency may be mediated by 
increased concentrations of PTH. PTH has been shown to be independently 
associated with hyperglycaemia, HOMA-IR and other components of the metabolic 
syndrome (254, 260) and parathyroidectomy has been shown to improve glucose 
homeostasis (261). 
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Results of Prospective Studies 
The Nurses‟ Health Study followed 83779 women who had no history of cancer, 
diabetes or cardiovascular disease at baseline for the development of T2DM (262). 
They evaluated vitamin D and calcium dietary as well as supplement intake but did 
not measure 25(OH)D concentrations. Over 20 years, 4843 incident cases of 
T2DM were reported. They reported a clear inverse dose-dependent relationship 
between calcium intake and incident diabetes. The relative risk of diabetes was 
0.87 (CI 0.75-1.00) when the highest level of vitamin D supplementation was 
compared with the lowest group (800IU vs. 400 IU). They also showed that women 
who took a combination of calcium plus vitamin D at a higher concentration of > 
1200mg and >800IU respectively had a lower incidence rate of diabetes vs. <600 
mg and <400IU. 
 
A nested case control study of the same cohort (608 diabetics and 559 control 
subjects) looked at the association of baseline 25(OH)D and risk of incident 
diabetes (263). After adjusting for diabetes risk factors the OR for incident T2DM in 
the top  versus the lowest quartile of 25(OH)D was 0.52 (CI 0.33- 0.83). 
 
Another study that supports the inverse association of 25(OH)D with diabetes is 
the Women‟s Health Study (264). This included 10 066 women and assessed the 
impact of dietary and supplemental vitamin D and calcium on diabetes and 
cardiovascular disease. Serum 25(OH)D was not measured. There was a 
significant decrease in the cumulative incidence rate of diabetes from 4.6% in 
those with the lowest total intake of vitamin D vs. 3.4% in those with the highest 
intake of vitamin D (p for trend=0.02). They also showed a decrease in the 
incidence for diabetes from 5.5% for those with the highest intake vs. 2.7% for 
those with the lowest intake (p for trend <0.0001). The prevalence of other 
components of the Met S, hypertension, central obesity, low HDL cholesterol 
decreased significantly in those with the highest vitamin D intake, relative to those 
with the lowest vitamin D intake. After adjusting for age, smoking, total calories, 
alcohol use, multivitamin use and parental history of myocardial infarction, total 
vitamin D intake was no longer significant for the Met S (p=0.13). 
 
The Australian Diabetes, Obesity and Lifestyle (AusDiab) study was designed to 
determine the prevalence (1999-2000) and incidence (2004-2005) of type 2 
diabetes in Australia (265). Within an initial cohort of 11247 individuals who had an 
OGTT at baseline, 6537 returned for an OGTT at follow up. During the five-year 
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follow up, 199 incident cases of diabetes were diagnosed. Those who developed 
diabetes had lower mean serum 25(OH)D than those who did not develop 
diabetes (58 ± 23 vs. 65 ± 25nmol/L, p <0.001) as well as lower calcium intake. 
This was after adjusting for a number of covariates including age, ethnicity, 
physical activity and season. They also noted that higher serum 25(OH)D was 
associated with increased insulin sensitivity. 
 
A Swedish study by Deleskog et al investigated whether serum 25(OH)D predicted 
the development of impaired fasting glucose, impaired glucose tolerance  or T2DM 
in 2288 men and women aged 35-56 years and without diabetes at baseline (266). 
Follow up was for 8 to 10 years. Men but not women in the highest quartile of 
25(OH)D had a decreased OR (0.52 (CI 0.30, 0.90)) for developing T2DM after 
adjusting for confounders including BMI and physical activity. This effect was only 
for individuals with either impaired fasting glucose or impaired glucose tolerance at 
baseline and not for those with a normal OGTT result. They did not report on 
associations between 25(OH)D and insulin resistance or insulin secretion. Mean 
25(OH)D levels in all men and women were greater than 50nmol/L. 
 
The importance of adjusting for BMI is highlighted in the results of the Tromso 
study (267). Over 6000 subjects, without diabetes, aged 25 and older were 
recruited, focussing initially on cardiovascular disease. Subjects were stratified as 
smokers or non-smokers. Subsequently diabetes was diagnosed if self-reported or 
based on HbA1c >6.5% in 247 subjects. Baseline 25(OH)D was inversely 
associated with T2DM, but after adjusting for BMI this association was no longer 
significant. The mean 25(OH)D level was adequate at 52.8 ± 16.8 nmol/L. 
 
The Inter99 study, based in Copenhagen, Denmark, reported on the effects of 
lifestyle intervention for CVD. A random sample of 6405 men and women, aged 
30-65 was used to assess the association between baseline 25(OH)D and the 
development of T2DM after five years follow up (268). Diabetes diagnosis was 
based on results of OGTT, or HbA1c of >6.5%, self-report or use of diabetes 
medication. Incident diabetes was diagnosed as diabetes at follow up among 
those who did not have diabetes at baseline. Median 25(OH)D level was 48nmol/L 
(IQR 12.0-118). Six hundred and seventy seven subjects had diabetes at baseline 
and a further 141 developed diabetes during follow up.  Low 25(OH)D was 
associated with a higher prevalence of diabetes at baseline after adjusting for 
confounders including BMI and physical activity. Low 25(OH)D level was 
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significantly associated with incident diabetes in crude analysis but this became 
insignificant after adjustment for confounders. They also reported that low 
25(OH)D was significantly associated with increased fasting and 2-hour blood 
glucose levels as well as insulin resistance. 
 
Kirii et al examined the relation of calcium and vitamin D intake to T2DM risk in a 
large Japanese cohort (269) and reported that neither calcium nor vitamin D intake 
was independently associated with T2DM, but  may have a joint protective action. 
A weakness of this large study was that they did not measure serum 25(OH)D or 
serum calcium and diabetes was self-reported. 
 
A recent publication reported on the association between 25(OH)D at baseline and 
incident T2DM over a 29 year follow up period (270). They reported adjusted HR 
for type 2 diabetes of 1.35 (CI 1.09-1.66) for the lowest vs. the highest quartile of 
25(OH)D. A major flaw of this study was the method used to diagnose diabetes. 
Diabetes was excluded at baseline if a non-fasting blood glucose was <11mmol/L 
and was diagnosed at end point either if the subject was on medication, self-
reported or non-fasting blood glucose was >11mmol/L. 
 
The only prospective study to date that had the development of diabetes as the 
primary end point was from Korea (271). An increased risk for type 2 diabetes was 
noted in those subjects with 25(OH)D levels of <25nmol/L after adjusting for a 
number of confounders including BMI, waist circumference and insulin resistance. 
One thousand and eighty non-diabetic Koreans with one or more risk factors for 
T2DM were recruited. The mean 25(OH)D level was 49 ± 23 nmol/L. Diabetes was 
diagnosed by HbA1c > 6.5%. They reported an increased risk of T2DM in subjects 
with vitamin D deficiency independent of BMI, HOMA-IR and pancreatic function. 
 
In a meta-analysis of twenty one prospective studies that looked at the association 
between 25(OH)D levels and risk of incident T2DM, Song et al noted that there 
was an inverse association between 25(OH)D levels and risk of T2DM that was 
independent of 25(OH)D assay, sample size, gender or population type (272). 
They reported that this association did not differ by sex, sample size, method used 
to diagnose diabetes or 25 (OH) D assays. Nineteen out of 21 studies included 
predominantly white subjects. 
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A recent case control study from Tehran noted that baseline 25(OH)D levels 
contributed to T2DM rate in a non-linear fashion with a sharp increase in risk for 
25(OH)D values below 25nmol/L (273). 
 
Few studies examined the association of vitamin D with β cell function and 
glycaemia prospectively. Kayaniyil et al prospectively examined the associations of 
baseline 25(OH)D with insulin resistance, β cell function and glucose homeostasis 
in subjects at risk for T2DM (274). This was a mixed ethnic population recruited 
from London and Toronto with a mean age of 50.2 ± 9.7 years. They used a 
number of measures to determine insulin resistance, insulin sensitivity, whole body 
insulin sensitivity and β cell insulin function. Baseline 25(OH)D was 58.0 ± 23.2 
nmol/L and did not show any association with insulin resistance or insulin 
sensitivity but reported a significant association with measures of β cell function 
and area-under-the-curve for glucose. A flaw in this study was that follow up 
25(OH)D was not measured.  
 
The results of most prospective studies therefore suggest that baseline vitamin D 
status may have an impact on future risk of T2DM. There is considerable 
heterogeneity in study design, population groups, mean 25(OH)D levels and 
adjustment for confounders and it is therefore important to consider the results of 
randomized control trials. 
 
Results of Randomized Controlled Trials 
There have been very few randomized controlled trials, and those that do exist 
have small numbers of subjects. George et al conducted a systematic review and 
meta-analysis of the effect of vitamin D supplementation on insulin resistance and 
glycaemic control (275). They included 15 trials in the systematic review. The 
randomized controlled trials used vitamin D vs. placebo, vitamin D and calcium 
supplementation vs. calcium supplementation alone and vitamin D and calcium 
supplementation vs. placebo. Outcomes were changes in fasting blood glucose, 
HbA1c, C-peptide, insulin resistance, development of microvascular complications 
or of macrovascular complications. Results of combining all studies showed that 
patients with impaired glucose tolerance or diabetes demonstrated a small 
reduction in fasting blood glucose (FBG) on treatment with vitamin D. The studies 
were small (276, 277), lasted short periods of time and used varying doses of 
vitamin D. Treatment had no effect on long term glycaemic control as determined 
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by HbA1c in those with diabetes and no effect on any outcomes in subjects with 
normal glucose tolerance (277-279). These studies were probably inappropriate to 
determine long-term glycaemic control as the duration ranged from 8 weeks to 6 
months. 
 
In summary, while data from cross sectional studies and observational studies are 
sometimes conflicting, in general, they suggest an association between low levels 
of 25(OH) D and T2DM, but this has not been confirmed by the results of 
randomized controlled trials. The few randomized controlled trials that were 
conducted have included very few subjects, especially those with abnormal 
glucose tolerance, and may therefore not be powered sufficiently to determine the 
effect of 25(OH) D on glucose control.  
 
1.9.4 25(OH)D and Serum Lipids 
Low serum levels of 25(OH)D have been associated with unfavourable lipid 
profiles that could possibly explain the relationship of 25(OH)D with cardiovascular 
disease.  
 
This may be mediated via PTH or 25(OH)D. PTH has been reported to modify 
adipocyte function by inhibiting adipocyte lipoprotein lipase activity (280). 
Alternatively, 25(OH)D may alter lipid levels via effects on calcium. Zitterman et al 
suggested that 25(OH)D increases serum triglyceride (TG) levels by increasing 
serum calcium which then decreases hepatic TG formation or secretion (281). 
Moreover, high calcium intakes have been shown to increase faecal fat excretion, 
reduce fatty acid synthase mRNA expression and serum TG (282). Furthermore, 
vitamin D may affect insulin secretion and insulin sensitivity and thereby influence 
lipid metabolism.  
 
It is unlikely that any effect seen is due to a single mechanism and as the VDR is 
widely distributed there may be direct effects via interactions between 1,25(OH)2D 
and its receptor. However, the results of animal studies are conflicting, as one 
would expect VDR knock-out mice to have increased serum TG whilst they do not. 
Indeed, they have less body fat, less TG and less total cholesterol (TC) than wild 
type mice even when fed a high fat diet(283, 284). The reasons for this are not 
clear. One hypothesis is that 1,25(OH)2D has a dose dependent effect, with low 
doses being stimulatory and high doses inhibitory (285, 286). 
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Results of Cross Sectional Studies of 25(OH)D and Serum Lipids 
Some of the larger cross sectional studies, with 1000 or more subjects are 
summarised in Table 1.7. Of the studies listed in this table, five report a positive 
relationship between 25(OH)D and HDL-C (239, 248, 287-289). In contrast, the 
studies by Kim et al in Korean adults (257) Skaaby et al in Danish adults (290) 
Gagnon et al in Australian adults (291) and Hypponen et al in British adults 
showed no such association (292). It is possible that gender and ethnic differences 
account for these inconsistencies. The relationship between 25(OH)D and TG was 
consistently negative in the studies listed in Table 1.7. While the results of cross 
sectional studies do not prove causality, the consistently negative association 
between 25(OH)D and serum TG warrants further investigation. 
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Table 1.7: Cross Sectional Studies of 25(OH)D and Serum Lipids 
Subjects 
(reference) 
Age in 
Years 
mean 
±SD 
N 
(% males) 
Lipids 
(direction of 
association 
with 
25(OH)D) 
Adjustment Other 
information 
US adults White 
(234) 
59±9 1739 (45) +TC/HDL No adjustments.  
Compared subjects 25(OH)D 
<37.5 to >37.5 nmol/L; p for 
TC/HDL <0.001. 
Norwegian (239) 55.9±12.9 10105(45.5) 
(smokers 
and non-
smokers) 
+TC 
+HDL 
+LDL 
-TG,  
-LDL /HDL 
Age, gender, BMI.  
Linear trends across quartiles 
of 25(OH)D.  
TG in the lowest quartile 
1.62±0.80 vs. 
1.32±0.81mmol/L in the 
highest quartile 
HDL-C 1.50 ± 0.40 vs. 1.59 ± 
0.36mmol/L 
Chinese adults 
(248) 
50-70  3262 (44.2) Males 
 -TG  
+HDL 
NS Women 
 
Age, gender, date, smoking, 
alcohol use, diabetes, BMI. 
MVR p<0.0001 for both TG 
and HDL-C in men. 
Korean adults 
(257) 
≥ 19 1330 (28) -TG 
NS HDL 
Age, gender, BMI, season, 
PTH, calcium intake and 
serum calcium. 
OR for TG across 25(OH)D 
quintiles 0.34 (0.20,0.56); p for 
trend <0.001 
 
US adults 
NHANES 
Three cycles 
2001-2002 
2003-2004 
2005-2006 (287) 
 
>20  3958 
(48.2) 
 
+HDL 
NS TG 
Results for 2554 subjects. 
Adjusted for age, gender, 
poverty-income ratio, waist 
circumference, smoking, PTH 
and calcium. Quintiles of 
25(OH)D. Reported mean 
difference in z-score per 1 SD 
difference in 25(OH)D. For 
HDL 0.002 (CI 0.048, 0.155) 
European men 
(288)  
60±11 3069 -TG 
+HDL 
Age 
MVR p<0.05 for TG and HDL 
US health care 
professionals 
Predominantly 
white (289) 
63.8±8.6 900 
All male 
-TG 
+HDL 
Age 
Linear trend across 25(OH)D 
quartiles; p for trend TG 0.001, 
for HDL <0.001 
Danish adults 
(290) 
30-60 4330 (48) -TG 
-LDL-C 
5 year follow up study. A 
10mmol/L higher baseline 
25(OH)D was associated with 
a drop in TG by 0.52% 
(p=0.03) and a drop in LDL-C 
by 0.66% (p=0.005). 
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Table 1.7 continued 
Subjects 
(reference) 
Age 
Years 
N 
(% males) 
Lipids 
(direction of 
association 
with 
25(OH)D) 
Adjustment Other 
information 
Australian 
(AusDiab) (291) 
Met S 
52.3±12 
No Met S 
49.5±12.8 
4164 
(42.2) 
-TG 
NS HDL-C 
Age, gender, season, ethnicity, 
latitude, WC + Met S 
component at baseline. 
Prospective study of the 
associations of 25(OH)D with 
components of the Met S over 
5 years P<0.01 for TG 
British (292) 45 (range 
41-46) 
6810 (48) -TG 
NS HDL 
Age, gender, BMI 
Compared highest to lowest 
tertiles of 25(OH)D for risk of 
each Met S component OR for 
high TG 0.48 (CI 0.41-0.57) in 
the unadjusted model. 
Key: NS=not significant; MVR=multivariate regression 
 
1.9.5 25(OH)D and Blood Pressure 
Observational studies have suggested higher blood pressures in winter months 
and at latitudes further from the equator, thus inferring that low 25(OH)D levels 
from reduced cutaneous synthesis is responsible for the observed differences in 
blood pressures (233). It is thought that the effect of 25(OH)D on blood pressure is 
mediated via its effect on the renin-angiotensin system (RAS). Laboratory studies 
have shown that VDR-null mutant mice have elevated levels of renin and 
angiotensin II leading to hypertension, cardiac hypertrophy and increased water 
intake (293). These abnormalities were prevented by treatment with an angiotensin 
converting enzyme (ACE) inhibitor. These findings were supported by the results 
of experiments that showed that 1,25(OH)2D suppresses the expression of renin, 
suggesting that vitamin D may be a negative regulator of RAS (294). 
 
Results of two observational studies are in keeping with the hypothesis that 
25(OH)D exerts an effect on blood pressure (BP) via RAS. The LURIC study of 
3316 subjects showed that in multivariate regression analysis both 25(OH)D and 
1,25(OH)2D were independent predictors of plasma renin and angiotensin (295). In 
a much smaller study, Vaidya et al noted that 25(OH)D was inversely associated 
with plasma renin activity in hypertensive subjects off medication (296). 
 
Table 1.8 summarises the results of larger cross sectional studies on the 
association of 25(OH)D with blood pressure. Small studies have been included if 
they included Asian Indian or African subjects. 
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Table 1.8: Results of Cross Sectional Studies on the Association of 
25(OH)D with Blood Pressure 
Subjects 
(Reference) 
Age  
(years) 
N 
(% males) 
Results 
(direction of 
association 
with 
25(OH)D) 
Adjustments 
Other information 
NHANES  
US adults (297)  
>20  12644 
(48.2) 
- SBP 
 
BMI 
Quintiles of 25(OH) 
Significant inverse association 
between 25(OH)D and SBP. 
British adults 
 (292) 
>45  6810 (48.4) -BP Age, gender and BMI  
Compared highest to lowest 
tertiles of 25(OH)D. OR for 
high BP 0.72 (CI 0.61-0.86) 
BP defined ≥140/90mmHg or 
use of antihypertensive 
medication 
NHANES 
Caucasian and 
black adults 
(298) 
20-49  7699 (47) NS Age 
A statistically significant 
inverse association between 
25(OH)D and SBP was no 
longer significant when 
adjusted for age. 
US adult health 
care workers  
Predominantly 
white (289) 
 
63.8±8.6 900 (all 
male) 
NS Age 
Linear trend across quartiles 
of 25(OH)D. 31% had a 
history of hypertension in the 
lowest quartile compared to 
25.4% in the highest quartile 
of 25(OH)D (p= 0.19). 
US adults 
NHANES 
Three cycles 
(287) 
≥20  3958 (48.2) -SBP Adjusted for several variables 
See Table 1.7 Quintiles of 
25(OH)D. 25(OH)D inversely 
associated with SBP. Mean 
difference in BP per one 
standard deviation of 
25(OH)D -0.032 (-0.062, -
0.001) 
Chinese adults 
(248) 
50-70 3262 (44.2) NS SBP 
-DBP 
Adjusted for several variables 
See table 1.7 
MVR DBP p=0.02 
Korean adults  
 
65.9  1330 (38.0) -SBP 
NS DBP 
Age, gender, BMI, season, 
PTH, calcium intake and 
serum calcium 
OR for SBP across quintiles of 
25(OH)D,  
highest vs. lowest 0.47 (0.27, 
0.82);  p for trend= 0.007 
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Table 1.8 continued 
Subjects 
(Reference) 
Age  
(years) 
N 
(% males) 
Results 
(direction of 
association 
with 
25(OH)D) 
Adjustments 
Other information 
Norwegian 
adults (299) 
55-74  4125 (59.7) -SBP 
-DBP 
Age, gender, physical activity, 
BMI 
This was a cross sectional 
study carried out in 1994. In 
2008 reassessed 25(OH)D 
and BP.  
25(OH)D levels did not predict 
future hypertension. There 
was no significant association 
between change in 25(OH)D 
and change in BP 
 
Australian 
adults 
(AusDiab)(291) 
Met S  
52.3± 12 
No Met S 
49.5 ± 
12.8 
4164 (42.2) NS Adjustments as for Table 1.7 
OR for developing systolic or 
diastolic hypertension at 5 
years per 25nmol decrease in 
baseline 25(OH)D  
1.09 (0.95, 1.25) 
Indian (253) 39.7 ±12.8 441 (53.7) NS No adjustments Sex stratified 
analysis showed no trend for 
increasing quintiles of 
25(OH)D with any 
components of the Met S 
including BP 
Urban South 
African black 
women (300) 
57.6±9 291 -SBP 
NS DBP 
Age, BMI, smoking, alcohol 
US adults (255) 44-96 1070 (38.3) NS Age, season, physical activity, 
Finnish 
smokers (301) 
50-69 2271( all 
males) 
-SBP Negative association at 
baseline. Baseline 25(OH)D 
was not associated with SBP 
at four years. 
Key: SBP=Systolic blood pressure; DBP=Diastolic blood pressure; NS=Not significant 
MVR= multivariate regression 
 
Effects of Intervention Studies on Serum Lipids and Blood Pressure 
Several intervention studies have evaluated the effect of supplementation with 
vitamin D on components of the Met S. Jorde et al investigated the effects of 
supplementation with 25(OH)D over a one year period in Norwegian subjects 
(302). All subjects were either overweight or obese. Mean baseline 25(OH)D levels 
were 58±21.1nmol/L. This was a double blinded placebo controlled trial and 
subjects received either 40 000IU or 20 000IU 25(OH)D per week or placebo. All 
subjects received 500mg of calcium in addition. At end of the study, there were no 
significant differences in either blood glucose (by OGTT) or serum lipids between 
subjects and controls. Subjects who received 20 000IUI of vitamin D per week 
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showed a small but significant increase in systolic blood pressure (SBP) compared 
to the placebo group. The main aim of the study was to investigate the effect of 
vitamin D on weight change and it was therefore not powered to detect changes in 
glucose or lipid metabolism. Another year long  randomized controlled trial of 
vitamin D supplementation (3332 IU/day) on healthy overweight subjects with 
mean 25(OH)D levels of 30 ±17.5nmol/L showed a significant decrease in serum 
TG and an increase in LDL-C compared to controls (281), but no effect on blood 
pressure. The mean age in this study was 48±10 years and baseline 25(OH)D 
levels were much lower than in the study by Jorde et al. On the other hand, in a 
three-year intervention trial in a group of post-menopausal women, vitamin D 
supplementation was shown to reduce HDL-C levels and increase serum LDL-C 
levels but did not change serum TG concentrations. Blood pressure changes were 
not evaluated (303). 
 
The Women‟s Health initiative, designed to evaluate fracture  and cancer risk  in 
women receiving 400IU of vitamin D/day with either calcium or placebo, did not 
show any changes in either blood pressure or incident hypertension after seven 
years follow up (304). 
 
There are very few studies that have been designed to evaluate blood pressure as 
a primary end point (305-307). The relatively small number of subjects and short 
duration of follow-up limit all these studies. Asian men failed to show any benefit 
from 120 000 IU of 25(OH)D supplementation fortnightly with regard to lipid profile, 
insulin sensitivity or blood pressure (308). The follow-up was only six weeks with 
71 subjects. The subjects were all male with central obesity. Another of the few 
studies carried out on 89 Asian women and 84 Asian men who were severely 
25(OH)D deficient, failed to show any change in lipid levels after supplementation 
with 400IU/day. Follow-up was for a year and was randomized and double blinded. 
Effects on blood pressure were not evaluated (309). 
 
In a prospective double blinded trial aimed at determining the effect of various 
doses of supplementation with vitamin D3  Forman et al noted that for each 
2.5nmol/L increase in 25(OH)D there was a 0.2mmHg reduction in systolic blood 
pressure (SMP) (p=0.02) (307). They had 283 black participants from the US and 
the study was conducted over two years.  It is debatable if racial differences 
modify the response to vitamin D therapy. Similar therapy with 4000 IU/daily of 
vitamin D3 did not affect lipid profiles of South Asian women living in New Zealand 
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(310). Median baseline 25(OH)D levels of 25 nmol/L (11, 40) increased to 
80nmol/L (67, 94) at the end of the six month period. Blood pressure changes were 
not assessed. Similarly, a number of meta-analyses have attempted to evaluate 
the effect of vitamin D supplementation on blood pressure but have also come up 
with inconclusive results (311-313). 
 
To summarize, while the results of cross sectional studies suggest there is a 
negative association between 25(OH)D and serum TG, blood glucose and blood 
pressure, these have not been supported by data from RCTs. However, the 
majority of RCTs have been of very short duration and studies are often not 
powered to detect the effect of vitamin D supplementation on any of the 
components of the Met S.  Short-term trials are probably inadequate to assess the 
effects of vitamin D supplementation on any outcomes because the optimal dose 
and duration of therapy is not known. Short-term supplementation does not 
maintain vitamin D sufficiency (177) and is therefore not suitable to detect long-
term benefit or harm. Another reason for the lack of efficacy noted may be due to 
suboptimal dosaging of vitamin D. In his meta-analysis Pittas et al  was able to 
detect a blood pressure lowering effect only if 1000 IU/day  of vitamin D was used 
as opposed to <1000IU (313). Baseline 25(OH)D status influence outcomes, as 
Sugden showed that vitamin D therapy was beneficial  in reducing blood pressure 
in those who were deficient to begin with (278). Finally, there ethnic specific 
differences possibly contribute to inconclusive results.  
 
1.9.6 25(OH)D and Obesity 
It has been suggested that obesity leads to lowered vitamin D status (314). The 
reasons for this are multifactorial, including the possibility that fat tissue acts as a 
reservoir for vitamin D3 (315, 316). Obese individuals may have limited physical 
activity and hence less sun exposure (314, 317). However, the results of studies 
on this association are not always consistent, with some showing an inverse 
association between 25(OH)D and obesity (314, 318), whilst others have failed to 
show such an association (319-321). In a systematic review and meta-analysis of 
vitamin D in relation to BMI, Saneei et al showed a weakly significant inverse 
association between 25(OH)D and BMI in adults from developed countries, as well 
as in male adults in developing countries but not in females from developing 
countries (322). These studies were only three in number, all with small sample 
sizes and all from the Middle East (320, 321, 323). The results of RCTs are also 
conflicting with both beneficial effects of supplementation (318, 324) and lack of 
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benefit (281, 325) noted. Several factors confound these studies, for example the 
study size, use of calcium supplements which have been reported to cause weight 
loss in individuals with very low calcium intake (324), differences in 25(OH)D levels 
as well as  ethnic differences. 
 
Differences in body composition between males and females may potentially 
contribute to differences in 25(OH)D levels and the distribution of body fat differs 
by gender as well as ethnicity. A negative relationship between subcutaneous 
adipose tissue and visceral adipose tissue and serum 25(OH)D concentrations 
have been reported in Caucasians (317), Hispanics and African Americans (326), 
and South Asians (327). The relationship between 25(OH)D and body fat appears 
to be complex and has been shown to vary with age, race and gender (328). This 
has been attributed to the differential accumulation of 25(OH)D in the different 
adipose tissue depots. Again, the data on this is conflicting with some studies 
reporting that subcutaneous adipose tissue accumulates 25(OH)D following 
supplementation (329), while others suggest that visceral adiposity may explain 
ethnic specific differences (327). 
 
1.10  SUMMARY AND RESEARCH GAPS 
Vitamin D deficiency is common in many parts of the world, even in countries with 
abundant sunshine due to limited exposure to the ultraviolet light in the range of 
290-315nm. This may be due to cultural practices around clothing or to limited time 
spent outdoors. Deficiency may also arise following the intake of very low calcium 
diets or conditions such as chronic kidney disease. There is a lack of data on the 
status of vitamin D in the various South African ethnic groups. A number of small 
studies have shown that there is seasonal variation in 25(OH)D levels and that 
levels are lower in urban dwellers compared with rural dwellers (92, 194). 
 
Plasma concentrations of 25(OH)D of <30nmol/L are indicative of severe 
deficiency(330). Methodological differences in assays may contribute to large 
variation in measured levels. The evidence for the extra skeletal benefits of 
increased serum concentrations of 25(OH)D is limited, and we await the results of 
properly conducted large randomized controlled trials. 
South Africa is a country that is undergoing a rapid transition with increasing 
urbanization of people and changing nutritional patterns. This has resulted in an 
epidemic of obesity and consequent increased cardiovascular risk (28, 331). It is 
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important to note that South Africa is an ethnically diverse country and results from 
other countries cannot be extrapolated to our unique population groups.  
 
Vitamin D deficiency has also been reported to be associated with increased 
cardiovascular risk as shown by studies reporting an inverse association with a 
number of components of the Met S, i.e. blood glucose, serum lipids and blood 
pressure. Ethnic differences in body composition may contribute to the observed 
differences in vitamin D status.   
 
BMD may be influenced both by body composition and by the vitamin D status of 
an individual. However, data on these associations is lacking in South African 
populations. In addition, data on the body composition of black South African 
males is lacking.  
 
In addition, in a country that is experiencing an increasing burden of non-
communicable diseases it is important to understand what the vitamin D status of 
our various population groups are, as well as what the predictors of deficiency may 
be and whether vitamin D deficiency is one of the drivers of this epidemic.  
 
Hypothesis 
The hypothesis to be tested in this thesis is that ethnic differences in vitamin D 
status contribute to ethnic differences in cardiovascular risk and BMD. 
 
1.11 AIMS 
The aims of this study are threefold: 
1. Firstly, to determine the prevalence of vitamin D deficiency in a group of urban, 
healthy African and Indian populations resident in Johannesburg and the 
association of body composition with 25(OH)D levels 
 
2. Secondly, to determine if ethnic differences in 25(OH)D contribute to 
differences in the prevalence of metabolic syndrome and its components 
 
3. Thirdly, to compare the body composition of Black Africans and Indians and to 
determine if differences in body composition contribute to differences in vitamin 
D status, or to differences in BMD and whether ethnic differences in BMD are 
mediated by vitamin D levels. 
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CHAPTER 2 
2. STUDY DESIGN AND METHODS 
 
2.1  SUBJECT SELECTION 
The study population consisted of two ethnic groups: Black African and Indian. 
Initial recruitment was done via the caregivers of the Birth to Twenty Cohort (Bt20). 
Bt20 is the largest and longest running longitudinal birth cohort study of child 
health development in Africa (332). Recruitment for the Bt20 study began in 
waves: at antenatal clinics, hospitals and clinics at time of delivery and at „well-
baby‟ services where immunisations were given during the first 18 months of the 
child's life. Enrolment took place between 23 April and 8 June 1990, and included 
singleton births of infants born in the Soweto-Johannesburg metropolis. A 
requirement was that the mothers resided within the metropolis for at least six 
months after the birth, so that  infants who were born and registered onto the 
cohort but then moved out of the study area were later excluded and recorded as 
„lost to follow up‟. The realised sample was 3 273 families. All major South African 
ethnic groups were represented in the study but the majority were Black African, 
with Indian (4%), Whites (6%) and Mixed Ancestry (12%) making up the 
remainder. 
 
A random number generator was used to select Black African and Indian 
caregivers of the cohort who were then contacted and asked if they had any 
members in their family that would be interested in participating in the study. The 
reason for not using the cohort subjects was that this study required subjects with 
an age range of 19-65 years. Subjects were predominantly residents of Soweto 
and Lenasia. Five hundred black families were contacted and all the Indian 
families of the Birth to twenty Cohort i.e. about 240. Additional Indian participants 
were recruited via the initial subjects. Recruitment was by ethnicity, age and 
gender. The aim was to have 60 subjects of each ethnicity and gender in three age 
group categories i.e. 19- <30, 30- <50 and 50-65 years (60 Black African males in 
each age group, and 60 Black African females in each age group and similarly for 
the Indian group). Exclusion criteria were age, (younger than18 years or above 65 
years), pregnant or breast feeding, self-reported renal disease or eGFR <30 
ml/min/1.73m2, not of Black African or Indian ethnicity. The sample size was 
calculated to ensure a statistical power of 90% and a probability of less than 0.05 
for detecting a 15% inter-group difference in 25(OH)D concentrations.Seven 
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hundred and thirty subjects were recruited. Two were excluded because they were 
of mixed ancestry and two others because of chronic kidney disease and liver 
disease respectively.  One of the aims of the study was to determine the predictors 
of serum vitamin D levels which include supplementation with calcium and vitamin 
D. The details of the numbers included in each study are given in the relevant 
chapters. Written informed consent was obtained from each subject (Appendix 4). 
The Human Ethics Committee of the University of Witwatersrand approved the 
study protocol (ethics clearance number M10411- see Appendix 1). 
 
2.2  BLOOD COLLECTION 
Fasting blood samples were collected into plain gel separator vacutainer tubes (for 
serum), potassium fluoride tubes (for glucose) and EDTA tubes (for HbA1c and 
25(OH)D). Samples were allowed to clot for half an hour and then centrifuged at 
3000 rpm for 10 minutes. Serum and plasma was then aliquoted into 5ml plastic 
tubes. Samples were analysed the same day for all analytes except for 25(OH)D. 
The 25(OH)D samples were stored at -700C and analysed in batches of 60. All 
sample investigations were performed according to principles of good laboratory 
practice. All reagents used on the ADVIA 1800 and Centaur were supplied in kit 
form by Siemens Diagnostics. The ADVIA 1800 was used for measuring serum 
creatinine, calcium, phosphate, total cholesterol, HDL cholesterol, triglycerides, 
calcium, phosphate, albumin, plasma glucose, and glycated haemoglobin on 
whole blood, whilst the Centaur was used for measuring serum insulin, parathyroid 
hormone, and thyroid stimulating hormone. 
 
2.3  BIOCHEMICAL METHODS   
   
2.3.1  Determination of Serum Calcium 
           Test principle: 
Calcium ions form a violet complex with 0-cresolpthalein complexone in an alkaline 
medium. The colour reaction is measured at 545/658nm. 
Total coefficient of variation (CV) for the assay was 2.4% to 3.5%.  
Reference Range: 2.15-2.55mol/L 
 
2.3.2  Measurement of Serum Phosphate 
Test principle:  
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Inorganic phosphate reacts with ammonium molybdate in the presence of 
sulphuric acid to form an unreduced phosphomolybdate complex which is 
measured at an endpoint reaction at 340/658nm. 
 
Phosphate + molybdate                           phosphomolybdate complex 
Total CV 1.7% to 2.0%. 
Reference Range:  0.78-1.42mmol/L                         
 
2.3.3  Determination of Plasma Glucose 
  Plasma glucose was analysed using a hexokinase method. 
Test principle: 
Under the action of hexokinase, D-glucose is phosphorylated with ATP to form 
glucose-6-phosphate (G-6-P). Glucose-6-phosphate is converted to 6-
phosphogluoconate by glucose-6-phosphate-dehydrogenase (G-6-PDH) in the 
presence of NADP, which is converted to NADPH. The absorbance of NADPH is 
then measured in the UV region (340nm). 
 
Glucose + ATP                                 G-6-P + ADP 
 
G-6-P + NADP+                                                6-phosphogluconate + 
NADPH + H 
Total CV 4.9- 5.9 % 
Reference Range:  Fasting < 7mmol/L        
 
2.3.4  Determination of Serum Creatinine 
Test principle: 
This is based on the reaction of creatinine with picric acid alkaline medium as 
described in the original reaction by Jaffe. A red coloured picrate-creatinine 
complex is produced. The rate of complex formation is measured at 505/ 571 nm 
and is proportional to the creatinine concentration. Rate blanking is used to 
minimize bilirubin interference. Because non-specific plasma proteins interactions 
give a positive bias of about 26.5µmol/L, 26.5µmol/L is subtracted from each 
result. 
 
Creatinine + picrate Creatinine-picrate 
Total CV 6.1- 9.5% 
      
H+ 
OH- 
Hexokinase 
G-6-PDH 
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Reference Range:  Females 60-80 umol/L . Males 80-100 umol/L                                   
 
2.3.5  Estimated GFR (eGFR) 
Estimated glomerular filtration rate was calculated using the Modification of Diet in 
Renal Disease (MDRD) equation as described by van Deventer et al (333). This 
equation is given below: 
eGFR = 175 x S-Cr (umol/L)/88.4-1.154 x age (years) -0.203 x (0.742 if female)  
Reported as ml/min/1.73m2 
Where S-Cr = serum creatinine CKD staging dependent of eGFR 
 
 
2.3.6  Determination of Glycated Haemoglobin (HbA1c) 
Glycated haemoglobin (HbA1c) is formed by the non-enzymatic glycation of the N-
terminus of the β-chain of hemoglobin A. The level of HbA1c is proportional to the 
level of glucose in the blood and is widely accepted as an indicator of the mean 
daily blood glucose concentration over the preceding two months. Glycated 
haemoglobin is described as a percentage of the total haemoglobin (tHb) content. 
To determine the tHb concentration spectrophotometrically, all different forms of 
hemoglobin must be converted into one single form with a uniform absorption 
spectrum. The concentration of HbA1c and the concentration of tHb are measured 
and the ratio is reported as percentage HbA1c. In a pre-treatment step, the whole 
blood sample is mixed with Haemoglobin Denaturant Reagent ((Siemens 
Diagnostics, Tarrytown, USA (1:41dilution)) and incubated for a minimum of 5 
minutes at room temperature. The red blood cells are lysed and the hemoglobin 
chain is hydrolyzed by the protease present in the reagent. 
 
For the measurement of total hemoglobin, Total Hemoglobin Reagent (Siemens 
Diagnostics, Tarrytown, USA) is used. The method is based on the conversion of 
all hemoglobin derivatives into alkaline hematin in an alkaline solution of a 
nonionic detergent as described in the original procedure of Wolf, Lang, and 
Zander (334). 
 
A latex agglutination inhibition method is used for the measurement of specific 
HbA1c. HbA1c present in the sample competes with the agglutinator (synthetic 
latex containing multiple copies of the immunoreactive portion of HbA1c) for the 
anti-HbA1c antibody; thereby reducing the rate of agglutination. A concentration 
curve is obtained by monitoring the change in scattered light as a change of 
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absorbance. The actual change in absorbance is inversely proportional to the 
concentration of HbA1c in the sample. The percentage HbA1c is calculated using 
the HbA1c and tHb values. 
Total CV 1.8% to 2.0%. 
Good control <7%  
 
2.3.7 Determination of Serum Cholesterol 
Test principle: 
This is an enzymatic colorimetric test. Cholesterol esters are cleaved by the action 
of cholesterol esterase to yield free cholesterol and fatty acids. 
 
 Cholesterol esterase 
Cholesterol esters + H2O                                                 cholesterol + RCOOH 
Cholesterol is converted by oxygen with the aid of cholesterol oxidase to cholest-4-
ene-3-one and hydrogen peroxide. 
 
Cholesterol + O2                                             cholest-4-ene-3-one +H2O2 
 
The hydrogen peroxide created forms a red colour by reacting with 4-
aminophenazone and phenol under the catalytic action of peroxidase. The colour 
intensity is directly proportional to the concentration of cholesterol and the 
absorbance of the complex is measured at an end point reaction at 505/694nm. 
 
  2H2O2 + 4 aminophenazone + phenol                               Quinoneimine dye + 
2H2O 
  Total CV 2.0% to 2.2% 
 Desirable ranges depend on cardiovascular risk factors.  
Category 1 Risk <4.5mol/L 
 
 
2.3.8 Determination of High-Density Lipoprotein Cholesterol (HDL-C) in Serum 
Test principle: 
This method consists of two distinct reaction steps: 
The elimination of chylomicrons, VLDL-cholesterol and LDL cholesterol by 
cholesterol esterase and cholesterol oxidase. The peroxide produced is released 
by catalase. 
  
Cholesterol esterase 
 
Cholesterol oxidase 
Peroxidase 
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Cholesterol Ester                                                  Cholesterol + RCOOH 
                                        
Cholesterol + O2                                                  Cholestenone + H2O2 
This is followed by the measurement of HDL-C after release of HDL-C by 
surfactant. The intensity of the quinoneimine dye produced in the Trinder reaction 
is directly proportional to the HDL-C concentration when measured at 596nm. 
 
Cholesterol Ester                                                   Cholesterol + RCOOH 
 
Cholesterol + O2                                                                                   Cholestenone + H2O2 
 
H2O2 + 4-aminoantipyrine + HDAOS                                Quinoneimine + 4H2O2 
HDAOS=N (2-hydroxy-3-sulfopropyl)-3, 5-dimethoxyaniline 
 
Total CV 2.1% to 2.6%. 
Desirable ranges depend on cardiovascular risk factors.  
Category 1 Risk Males >1.0mmol/L. females >1.2 mmol/L 
2.3.9  Determination of Serum Triglycerides 
Test principle: 
The triglyceride method is based on the Fossati 3 step enzymatic reaction based 
with a Trinder endpoint (335, 336). This method quantitates total triglycerides 
including mono- and diglycerides and the free glycerol fractions. The triglycerides 
are converted to glycerol and free fatty acids by lipase. Glycerol is converted to 
glycerol-3-phosphate by glycerol kinase followed by its conversion by glycerol-3-
phosphate oxidase to hydrogen peroxide. A coloured complex is formed from 
hydrogen peroxide, 4-aminophenazone and 4-chlorophenol under the catalytic 
influence of peroxidase. The absorbance of the complex is measured at an 
endpoint reaction at 505/694nm. 
 
Triglycerides + 3H2O                                   Glycerol + Fatty Acids 
  
ATP + Glycerol                                            Glycerol-3-phosphate + ADP 
 
O2 + Glycerol-3-phosphate                                                2H2O2 + 
Dihydroxyacetone phosphate 
  
Cholesterol oxidase 
 
    Peroxidase 
Lipase 
Glycerol  Kinase 
Glycerol-3-phosphate oxidase 
Peroxidase 
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2H2O2 + 4-Aminophenazone + 4-Chlorophenol                            Quinoneimine dye 
+ H2O 
Total CV 0.9% to 2.4% 
Desirable ranges depends of cardiovascular risk factors .  
Category 1 risk <1.7 mmol/L 
 
2.3.10 Calculation of Low-Density Lipoprotein Cholesterol (LDL-C) 
The conventional method of ultra-centrifugal estimation of cholesterol is time 
consuming and expensive. For this reason LDL-C is most commonly estimated 
from measurements of total cholesterol, HDL-C and plasma triglycerides using the 
Friedewald equation (as below) when all analytes are measured in mmol/L(337). 
LDL-C = (Total cholesterol) - (HDL-C) - (TG/2.2). 
HDL-C=High density lipoprotein cholesterol 
TG=triglycerides 
Importantly, the Friedewald equation should not be used when chylomicrons are 
present, when serum triglycerides exceed 4.5mmol/L, and from patients with 
dysbetalipoproteinemia. 
Desirable range depends on cardiovascular risk factors.  
Category 1 risk <2.5 mmol/L 
 
2.3.11 Determination of Plasma Intact Parathyroid Hormone (PTH) 
Test principle: 
This is a two-site sandwich immunoassay using chemiluminescent technology, 
which uses constant amount of two anti-human PTH antibodies. The first antibody 
is a polyclonal anti-human PTH antibody to the N-terminal (1-34) region labelled 
with acridinium ester. The second antibody is a biotinylated polyclonal goat anti-
human PTH antibody to the 39-84 region. Stretptavidin in the solid phase is 
covalently linked to paramagnetic latex particles. A direct relationship exists 
between the amount of PTH present in the patient sample and the amount of 
relative light units detected by the system. 
Total CV 3.4 -5.2% 
Reference Range:   1.2-8.5 pmol/L 
 
2.3.12 Determination of Serum Insulin 
Test principle: 
This is a two-site sandwich immunoassay that uses a constant amount of two 
antibodies. The first antibody is a monoclonal mouse anti-insulin antibody labelled 
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with acridinium ester. The second antibody is also a monoclonal mouse anti-insulin 
antibody covalently coupled to paramagnetic particles. A direct relationship exists 
between the amount of insulin present in the patient sample and the amount of 
relative light units detected by the system. 
Total CV 6.3% to 7.5%. 
Reference Range: 3-25 mU/L 
 
2.3.13 Determination of Thyroid Stimulating Hormone (TSH) 
            Test principle: 
This is a two-site sandwich immunoassay using chemiluminescent technology 
using constant amounts of two antibodies. The first antibody is a monoclonal 
mouse anti-TSH antibody labelled with acridinium ester and the second is a 
polyclonal sheep anti-TSH antibody. A direct relationship exists between the 
amount of TSH present in the patient sample and the amount of relative light units 
detected by the system. 
Total CV 3.17 to 5.87% 
Reference Range:  0.35-4.5 mIU/L                
 
 
2.3.14 Determination of Plasma 25(OH)D 
Plasma 25(OH)D was measured using the Clin Rep high performance liquid 
chromatography (HPLC) kit (Recipe, Munchen, Germany). In this analytical 
method, 25(OH)D was determined from plasma using HPLC with a photodiode 
array (PDA) detector.  Prior to HPLC analysis a short liquid-liquid extraction was 
performed. The liquid-liquid extraction includes a precipitation step that denatured 
the protein bond and extracted the 25(OH)D out of the lipid layer into a clear upper 
layer. Fifty microliter of the eluant was injected onto the HPLC system where the 
analytes were separated on the appropriate C18 analytical column (Recipe, 
Munchen Germany). The separated 25(OH)D2 and 25(OH)D3 were detected at a 
wavelength of 264nm. The concentration was calculated using a standard curve 
with two sets of controls run every 20 samples.  The standards and controls were 
human based lyophilized samples that are traceable to the NIST 25(OH)D 
standard. The chromatograms were integrated using peak height. Total vitamin D 
(25(OH)D) was taken as the sum of 25(OH)D2 and 25(OH)D3. The intra-assay and 
inter–assay coefficient of variation (CV) for 25(OH)D3 for controls at a mean of 
61.7 nmol/L ranged from 0.36-9.4%, and for controls at a mean of 222 nmol/L 
ranged from 2.1-5.5%. For 25(OH)D2  the CV for the low control (mean 49.2 
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nmol/L) was 6.8-9.7% and for the high control (mean 199 nmol/L) ranged from 1.1-
5.7%. The limit of quantification was 6.5 nmol/L for 25(OH)D3 and 11.0 nmol/L for 
25(OH)D2. Any 25(OH)D2 below the limit if quantification was assigned a nominal 
value of zero. 
Reference Range: <12.5 nmol/L severe vitamin D deficiency               
 
2.4  ANTHROPOMETRIC MEASUREMENTS 
2.4.1  Weight, Height and Waist Circumference 
Weight (digital scale, Dismed, USA) to the nearest 100g, and height (stadiometer, 
Holtaine, UK) to the nearest millimetre were measured with subjects wearing light 
clothing and no shoes. Body mass index (BMI) was calculated as weight in 
kilograms divided by the square of the height in meters (kg/m2). A BMI of 20kg/m2 
to 24.9kg/m2 is defined as normal, 25kg/m2 to 29.9kg/m2 defined as overweight 
and ≥ 30kg/m2 as obese (338).These cut off points were derived primarily in 
European populations to correspond to risk thresholds for a wide range of chronic 
diseases and mortality.  
 
The waist and hip circumferences were measured with the subjects standing, feet 
together and arms at the sides. Waist circumference was measured with a soft 
measuring tape to the nearest 0.5cm at the level of the smallest girth above the 
umbilicus in the standing position and hip circumference was measured at the 
widest part of the buttocks (Appendix 5) 
 
 
2.4.2  Body Composition Analysis 
Dual Energy X-ray Absorptiometry (DXA) 
Body composition of the total body was determined by dual energy X-ray 
absorptiometry (DXA; Hologic, Bedford, MA, USA (computer software version 
12.5:7)) according to standard procedures of the International Society of Clinical 
Densitometry.  Scans were conducted using the automatic scan mode, i.e. „array‟, 
„fast array‟ or „slow array‟, depending on the weight of the subject. Subjects wore 
light clothing having removed metal objects, jewellery, etc. DXA was used to 
measure bone mineral content (BMC, in grams), bone area (BA, in square 
centimetres), and areal bone mineral density (BMD in grams per centimetre) of 
whole body, total hip, femoral neck, and lumbar spine. The coefficients of variation 
(CV %) for repeated measurements of the manufacturers phantom were 0.3, 0.4 
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and 0.2% for BA, BMC and BMD, respectively. The CV for repeated measurement 
by the DXA operator of the lumbar spine and total hip were 0.7 and 1.0% 
respectively. DXA scans for whole body were analysed less head as many women 
wore wigs and hair weaves that could not be removed prior to scanning. This 
artificial hair was of similar density to soft tissue and could cause measurement 
artefact. Total body fat and lean body mass (in grams) were also measured by 
DXA.  
 
           Ultrasound Analysis of Visceral and Subcutaneous Adiposity 
Abdominal visceral (VAT) and subcutaneous adiposity (SCAT) was determined by 
ultrasonography using a LOGIC ultrasound system (USS) (GE Healthcare, 
Piscataway, NJ) with a 2-5MHz 3C-RS curved array transducer. Ultrasound VAT 
thickness was defined as the distance measured in cm from the peritoneum to the 
vertebral bodies. Ultrasound SCAT thickness was defined as the depth measured 
in cm from the skin to the linea alba. The scan depth was set at 15cm for the 
visceral fat measure and 9cm for the subcutaneous fat measure to visualize the 
relevant anatomical structures. Both measurements were obtained at the site 
where the xyphoid line and waist circumference met. A single trained operator took 
all measurements. 
This technique has been validated for the measurement of visceral and 
subcutaneous adiposity (339) 
 
CV <2%. This was calculated after the same operator took duplicate 
measurements on 15 subjects. 
 
2.5  QUESTIONAIRRES 
2.5.1  Food Frequency Questionnaire 
A seven-day recall food frequency questionnaire was used to assess nutrient 
intake (Appendix 2). A trained worker conducted interviews in English. The food 
intake questionnaire used in our study was validated for the South African 
population. Nutrient analyses of calcium intake were calculated only from the 
consumption of dairy products, and for Vitamin D from intake of fish, eggs and 
margarine. Portion sizes were reported in household measures and then 
converted to weights using standard tables (340) . Food intake in grams was 
calculated for seven days to be able to include quantities of less than one gram 
per day in the analysis. Thereafter, the nutrient content was calculated and 
expressed as average nutrients consumed per day for each subject. Nutrient 
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analyses were carried out using the following computer software: Food Finder III 
Nutritional Intervention Research Unit and Research Information Systems Division, 
Medical Research Council, South Africa.  
 
2.5.2  Sunshine Exposure Score 
Sunshine exposure was determined using a questionnaire, which assessed the 
participants‟ recollection of daily sun exposure over the previous week (341). 
There were three options for time spent outdoors every day (0 = ≤ 5minutes, 1 = 5 
- 30minutes and 2 =  30minutes). There were four options for skin exposure while 
outdoors (1 = face and hands only, 2 = face, hands and arms, 3 = face, hands, and 
legs and 4 = bathing suit). A daily sun exposure score (min = 0; max = 8) was 
calculated by taking the product of the amount of time spent outdoors and the 
amount of skin exposed. The seven days‟ sun exposure scores were then 
summed to give the weekly sun exposure score (min = 0; max = 56). 
 
Seasons of the year, for the statistical analysis, were categorized as winter (June 
to August), spring (September to November), summer (December to February) 
and autumn (March to May). 
(Appendix 3) 
 
2.5.3 Smoking Status, Educational Status and Alcohol Intake 
A standardized questionnaire was used to collect information on age, sex, visit 
date, smoking (current, former, never), self-reported diabetes, hypertension, 
dyslipidaemia, coronary heart disease and medication use. Alcohol intake was not 
quantified but was categorized as yes or no. 
 (Appendix 3)  
 
2.5.4 Blood Pressure 
Blood pressure was measured thrice in the right arm, with the subject seated and 
after 5 minutes rest using an automated sphygmomanometer. The final reading 
was used (Appendix 5). 
 
2.5.5.   Statistical Analysis 
Statistical methods are given in the methods section of each chapter.  
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CHAPTER 3 
3. THE EFFECT OF ADIPOSITY, SEASON, DIET AND SUPPLEMENTATION ON 
VITAMIN D STATUS OF HEALTHY URBAN BLACK AFRICAN AND INDIAN 
ADULTS 
 
ABSTRACT 
Vitamin D deficiency has been implicated in the aetiology of infectious diseases 
and metabolic syndrome. These are prevalent in the Black African and Indian 
populations within South Africa; however, there are limited data on 25(OH)D 
concentrations in these populations.  
 
The aim of this study was to assess the vitamin D status and its predictors in 
healthy adults in Johannesburg. 
 
We assessed the vitamin D status of 714 adult Black African and Indian subjects 
resident in Johannesburg. The contributions of sunshine exposure, season, dietary 
intake of calcium and vitamin D  supplements, total body fat and body fat 
distribution to 25-hydroxyvitamin D (25(OH)D) concentrations were assessed. 
25(OH)D was measured by high performance liquid chromatography (HPLC). The 
contribution of 25(OH)D3 to total 25(OH)D was assessed. 
 
The mean age of the population was 42.6 ± 13.1 years (range: 18-65). 28.6% of 
Indians had 25(OH)D concentrations < 30 nmol/L in comparison to 5.1% in the 
Black African group (p<0.0001). Parathyroid hormone (PTH) was negatively 
associated with 25(OH)D while season and sunshine exposure were positive 
predictors explaining 16% of the variance (p<0.0001) in Black Africans. In Indians, 
PTH was negatively associated with 25(OH)D while male gender, season and 
calcium supplementation were positive predictors and explained 17% of the 
variance of 25(OH)D (P<0.0001). In multivariate regression analysis, neither total 
body fat nor body fat distribution was predictive of 25(OH)D in either group. 
 
Local conditions such as sun exposure, use of dietary supplements, and ethnicity 
are important determinants of plasma 25(OH)D concentrations.  
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3.1  INTRODUCTION 
South Africa like the rest of sub-Saharan Africa is plagued by the burden of chronic 
infectious diseases including tuberculosis (TB) and HIV (342) as well as a rising 
burden of non-communicable diseases (343). Recently studies have shown that 
vitamin D deficiency or insufficiency is associated with an increased risk of 
cardiovascular disease (289) diabetes (344), cancers (345, 346), infections (92) 
and autoimmune conditions (347) in addition to its classical effects on bone. 
 
Although its definition remains a concern, several studies on vitamin D deficiency 
across the world suggest that it is a global health problem (13, 348). South African 
studies have been limited to children (192), or women (194), or hospitalized or ill 
subjects only (92) and the reported prevalence of vitamin D deficiency ranges from 
8.0% in Black African children to 62.7% in adult subjects with TB and/or HIV, using 
a cut-off of <50 nmol/L to define deficiency.  
 
In order to understand the health risks associated with vitamin D deficiency it is 
important to know the determinants of 25(OH)D concentrations. The objective of 
our study was to determine the vitamin D status in Black African and Indian groups 
in Johannesburg and to identify the main determinants of 25(OH)D concentrations 
in each ethnic group, including body fat mass and body fat distribution. Factors like 
sunshine exposure, age, fat mass, gender, ethnicity and lifestyle may influence the 
serum concentrations of this vitamin (13, 327, 349, 350) and may be important 
contributors to vitamin D status. The serum level of 25(OH)D has been reported to 
be inversely associated with body mass index (BMI) and with subcutaneous as 
well as visceral adiposity (317, 330). We also determined the contributions of  
25(OH)D3 and 25(OH)D2 to total 25(OH)D using HPLC as several commonly used 
immunoassays preferentially detect 25(OH)D3 (351). 
 
3.2  METHODS 
The methods used in this chapter have been described in detail in chapter two. 
They include the measurement of serum calcium, phosphate, creatinine for 
estimation of GFR, plasma parathyroid hormone and 25(OH)D, measurement of 
weight, height and waist circumference, total body fat by DXA and visceral and 
subcutaneous adiposity by ultrasonography. Intake of calcium and vitamin D was 
determined, supplementation with calcium and vitamin D, educational status and 
smoking status. Seven hundred and fourteen subjects for whom we had complete 
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data were included in this study, 371 Black African and 343 Indian (340 males and 
374 females). 
 
3.2.1  Statistical Analysis 
Analysis was conducted using the Stata software package version 12 (College 
Station, TX, USA). The Shapiro-Wilk‟s test was used to test for normality. The 
results of non-normally distributed data are reported as median and interquartile 
range (IQR) and for normally distributed data as mean and SD. Non-normally 
distributed data was transformed to achieve normality (log transformed or square 
root) before regression analysis. The Mann-Witney U test was used to compare 
differences between the two ethnic groups for non-normally distributed data, the 
Student t-test for normally distributed data and the chi-squared test for categorical 
data. A p value of <0.05 was considered statistically significant. We compared 
differences in 25(OH)D between the different ethnic groups by ANOVA. Pair-wise 
comparisons were used only if the overall ANOVA was statistically significant. 
Bonferroni corrections for multiple comparisons were used.  
 
The main aim of this study was to identify the principal determinants of 25(OH)D 
concentrations in each ethnic group and therefore data for Black Africans and 
Indians were analysed separately. Regression analysis was restricted to total 
25(OH)D, rather than to 25(OH)D2 and 25(OH)D3 individually. We carried out 
univariate Spearman‟s analysis to assess the strength of the relationship of 
25(OH)D with parameters that are thought to influence 25(OH)D status. The 
following were considered as potential predictors based on previous evidence: age 
(88), season (352), body fat (353), sunshine exposure (340) and supplementation 
with vitamin D or calcium (354), renal function, smoking status(169), dietary intake 
of calcium and vitamin D (355) and PTH concentrations. These as well as any 
remaining study variables, mostly anthropometric measures, that gave correlations 
of p<0.2 in univariate analysis were used as independent variables in separate 
multivariable models for Black Africans and Indians in which 25(OH)D was the 
dependent variable. Values were reported as standardized β coefficients. In each 
ethnic group the season with the lowest 25(OH)D concentrations were coded as 1 
and the remainder were grouped together and coded as 2. In the Black African 
subjects, winter was coded as 1 and in the Indian subjects, spring. 
Backward stepwise multiple regression analysis was performed until only variables 
with a p value of <0.05 remained. We adjusted all models for gender and height. 
Due to collinearity, BMI and total body fat were not included in the same model. 
63 
 
We also developed two models, one which included individual fat measures 
together with other variables mentioned above in case of collinearity and then a 
second with all fat measures entered together. We tested for collinearity of models 
that included visceral adiposity, subcutaneous adiposity and total body fat and 
there was no collinearity as evidenced by a variance inflation factor of <10.0. We 
also tested for interaction between ethnicity and body composition variables and 
noted that there was no significant interaction. To facilitate direct comparisons of 
the strengths of the associations, the results of the regression models are reported 
as standardised β values.  
 
3.3  RESULTS 
3.3.1  Demographic Variables 
The demographic and biochemical characteristics of the participants are described 
in Table 3.1. 
 
The mean age of the Black African subjects and Indian subjects were similar, 41.6 
± 13.1 years (range 19-65) and 43.5 ± 13.0 years (range 18-65; p=0.06), 
respectively.  More Indian than Black African subjects had completed high school 
(p<0.0001) and there were more smokers amongst the Black African than among 
the Indian subjects (34% vs. 17%, p<0.0001). None of the participants were on 
anti-epileptic medication, but 12.9% of Indians and 1.4% of Black Africans were on 
statin therapy. HIV status was determined by self-report: 87.7% of Black Africans 
reported their status as negative, 8.5% reported being HIV positive and 3.7% had 
never been tested; 94.5% of Indians reported their status as negative while 5.5% 
had never been tested.  To our knowledge none of the participants suffered from 
metabolic conditions likely to impact vitamin D metabolism.  
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Table 3.1: Descriptive Characteristics of Study Population 
 
Variable 
Black African 
(n=371) 
 Indian 
(n=343) 
P value 
Age (years) 41.6 ± 13.1 43.5 ± 12.9 0.06 
Males (N (%)) 180 (48) 163 (45) 0.65 
Education: high school not complete (N (%)) 209 (57.0) 114 (33.0) <0.0001 
Smoker (N (%)) 124 (33.8) 58.0 (16.6) <0.0001 
BMI (kg/m
2
) 26.2 (21.7, 31.7) 26.7 (23.3, 31.0) 0.38 
Waist circumference (cm) 89.0 (78.0, 102) 95.0 (85, 106) <0.0001 
Visceral adipose thickness (cm) 4.93 (3.72, 6.34) 4.91 (3.31 ,6.46) 0.48 
Subcutaneous adipose thickness (cm) 2.32 (1.59, 3.44) 3.04 (2.24, 3.91) <0.0001 
Total body fat (kg) 21.5 (11.9, 31.6) 24.3 (18.1, 32.6) <0.0001 
eGFR (ml/min/1.73m
2
) 87.9 (77.7,103) 88.1 (75.7,103) 0.90 
25(OH)D3(nmol/L) 
25(OH)D(nmol/L) 
25(OH)D3 females (nmol/L)
#
 
25(OH)D females (nmol/L) 
25(OH)D3 males (nmol/L)
#
 
25(OH)D males (nmol/L) 
62.8 (45.5, 88.5) 
64.9 (46.4, 89.4) 
56.8 (40.4, 80.1)* 
58.3 (42.9, 85.6)* 
72.4 (51.1, 94.1) 
73.2 (51.2, 94.1) 
36.7 (24.7, 53.4) 
41.2 (28.4, 56.8) 
32.4 (19.0, 48.9)* 
35.8 (23.0, 54.5)* 
43.9 (30.6, 58.9) 
45.4 (33.6, 62.7) 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
Ca (mmol/L) 2.27 ± 0.09 2.26 ± 0.11 0.21 
Pi (mmol/L) 1.10 ± 0.17 1.10 ± 0.15 0.30 
PTH (pmol/L)  4.70 (3.30, 6.50) 4.85 (3.61, 6.92) 0.09 
Ca intake diet (mg/day) 223 (98.6, 427) 336 (204, 487) <0.0001 
Vit D intake diet (ug/day) 2.96 (1.50, 5.12) 1.17 (0.55, 2.11) <0.0001 
Vit D deficient (N (%)) 22.0 (5.90) 106 (30.3) <0.0001 
Weekly sunshine score 17.8 ± 10.7 16.0 ± 9.53 0.23 
Ca supplements (N (%) 12.0 (3.24) 77.0 (22.5) <0.0001 
Vit D supplements (N (%) 7.00 (1.89) 51.0 (14.9) <0.0001 
 
Key: Data given as mean ± SD, median (IQR) or N (%). 25(OH)D deficiency defined as <30nmol/L, 
insufficiency as 30.0-49.9 nmol/L. PTH=parathyroid hormone, ALP=alkaline phosphatase, 
eGFR=estimated glomerular filtration rate, Pi =inorganic phosphate. *P<0.0005 for females versus 
males of same ethnic group. 
#
For Black African females $ P <0.0001 for Black African males vs 
Indian males @ p<0.0001 for Black African females vs Indian females n=191, for Indian females 
n=180, for Black African males n=180 and for Indian males n=163 
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3.3.2  Anthropometry 
Median BMI was in the overweight range for both groups. Indian subjects had 
greater waist circumference, greater total body fat and greater percentage body fat 
compared to the Black African group (p<0.0001 for all variables). Visceral adiposity 
was similar between both ethnic groups but Indian subjects had greater 
subcutaneous adiposity than the Black African subjects (Table 3.1) did. 
 
3.3.3  Vitamin D Status 
Using the Shapiro-Wilk‟s test, 25(OH)D was not normally distributed. Black African 
subjects had significantly higher 25(OH)D and 25(OH)D3 when compared to the 
Indian population (see Table 3.1). Gender differences were noted for 25(OH)D as 
well as 25(OH)D3. The prevalence of vitamin D deficiency (25(OH)D level of 
<30nmol/L) was 28.6% in Indians compared to just over 5% in Black Africans 
(Table 3.1) and was highest in Indian women (37.9% in Indian females and 17.9% 
in Indian men, p <0.0001; 6.7% in Black African females and 2.8% in Black African 
males, p=0.08). 
  
Across all groups, 94.5 ± 17.9% of all 25(OH)D measured was 25(OH)D3. Mean 
serum calcium and phosphate concentrations were normal and similar across 
ethnicities. Plasma PTH concentrations were raised above the laboratory 
reference range in 12% of Africans and 14% of Indians.  
 
Seasonal Differences 
As expected, seasonal differences were noted in 25(OH)D concentrations in both 
groups. The plasma 25(OH)D level was 40 to 60% higher in subjects in whom 
blood was collected in autumn compared to those who had samples taken in 
winter/spring (Figure 1). This variation was due to changes in 25(OH)D3 with all 
participants showing maximal 25(OH)D3 concentrations in autumn. As expected, 
no significant seasonal difference was observed for 25(OH)D2 concentrations.  The 
prevalence of 25(OH)D deficiency (<30 nmol/L) per season was as follows: 8% in 
winter, 23% in spring, 13% in summer and less than 1% in autumn. The 
prevalence of insufficiency (25(OH)D < 50 nmol/L) per season was 40% in winter, 
31% in spring, 30% in summer and 4% in autumn. 
 
Sunshine exposure score was not significantly different between the ethnic groups 
but was different by gender: Black African male, 18.80 ± 8.49, Black African 
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female, 16.73 ± 11.33 (p=0.02); Indian male, 18.71 ± 10.19, Indian females, 14.43 
± 8.46 (p=0.0001).  
 
Figure 3.1: Seasonal Variation in 25(OH)D According to Ethnicity  
 
Supplementation and Medication: Indian Population 
Among the Indian population, 22% were on calcium supplementation and 15% 
were on vitamin D supplementation (Table 3.1). The 25(OH)D concentrations were 
higher in those Indian participants on vitamin D supplementation (52.2 (32.7, 73.2) 
nmol/L versus 39.2 (26.9, 55.1) nmol/L; p<0.001) or calcium supplementation (54.2 
(35.8, 80.4) nmol/L versus 37.5 (26.3, 53.8) nmol/L; p<0.0001).  
 
25(OH)D concentrations were not significantly different between Indian males on 
statins (49.3 (30.3, 60.9) nmol/L) compared to those not on statins (45.1 (34.0, 
60.9) nmol/L; p=0.7) but were higher in Indian females on statins (52.2 (30.1, 80.8) 
nmol/L) compared to those not taking statins (34.4 (22.4, 52.9) nmol/L; p=0.04). 
 
Supplementation and Medication: Black African Population 
3% of Black African subjects were on calcium supplementation and 2% on vitamin 
D supplementation (p<0.0001 for both comparisons with Indian group) (Table 3.1). 
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 Dietary Intake of Calcium and Vitamin D 
Dietary calcium intake was significantly lower in Black African (223 (98.6, 427) 
mg/day) compared to Indian subjects (336 (204, 487) mg/day; p<0.0001). Dietary 
vitamin D intake was higher in Black African (2.95 (1.55, 5.12) µg/day) than Indian 
subjects (1.17 (0.50, 2.11) µg/day; p<0.0001). 7.5% Black Africans and 1.2% 
Indians had a dietary intake of vitamin D ≥ 10ug/ day (p=0.008). Similarly, 4.5% of 
Black Africans had daily calcium of ≥ 1000mg/day and 2.6% of Indian had a daily 
calcium intake of ≥ 1000mg/day (p=0.002).  
 
3.3.4  Univariate Analysis for Associations with 25(OH)D 
The correlations of 25(OH)D with other variables are shown in Table 3.2. 
Univariate analyses showed that serum PTH was negatively correlated with 
25(OH)D in both ethnic groups and weekly sunshine score was significantly 
positively associated with 25(OH)D in Black Africans but not in Indians. In terms of 
body composition, visceral and subcutaneous adiposity as well as total body fat 
were negatively associated with 25(OH)D in the Black African group. In the Indian 
population, none of the body composition variables were significantly associated 
with 25(OH)D. There was no significant association of 25(OH)D status with age, 
calcium or vitamin D intake in either group.  
 
 
Table 3.2: Spearman’s Correlation of 25(OH)D with Other Variables 
Variable 
25(OH)D Black 
Africans 
(n=371) 
25(OH)D Indians 
(n=343) 
Age (years) 0.002 (0.96) 0.03 (0.54) 
 PTH(pmol/L) -0.26 (<0.0001) -0.23 (<0.0001) 
Calcium intake (mg/day) 0.03(0.55) 0.08(0.14) 
Vitamin D intake (ug/day) -0.008(0.88) 0.07(0.17) 
 BMI (kg/m2) -0.09 (0.09) -0.02 (0.67) 
Visceral adipose 
thickness (cm) 
-0.18 (0.0007) 0.07 (0.19) 
Subcut adipose thickness 
(cm) 
-0.12 (0.02) -0.07 (0.17) 
Whole body fat (kg) -0.11 (0.04) -0.07 (0.20) 
Weekly sunshine score 0.23 (<0.0001) 0.02 (0.67) 
Values given are spearman‟s coefficient, ρ (p) PTH=parathyroid hormone, BMI=body mass 
index 
68 
 
 
3.3.5 Predictors of 25(OH)D Concentrations 
To assess the predictors of 25(OH)D concentrations in more detail, we performed 
multivariable regression analyses (see Table 3.3).  In Black Africans (see model 
1), season during which the blood sample was taken, PTH, and weekly sunshine 
score explained 16% of the variance for 25(OH)D. Season and weekly sunshine 
score were positive predictors of 25(OH)D concentrations whilst PTH was a 
negatively related to 25(OH)D. 
 
In the Indian subjects‟ season of blood sample collection, PTH, gender and 
supplementation with calcium explained 17% of the variance of 25(OH)D (see 
Table 3.3, model 2). Gender, season of blood sample collection and the use of 
calcium supplements all being positive predictors. 
 
Table 3.3: Multivariable Regression Models for 25(OH)D 
Regression 
Model No. 
Ethnic  
Group 
Dependent  
Variable 
(nmol/) 
Independent Variables with Beta 
Coefficient (p value)  
R
2
 for Full Model  
(P-value) 
1 Black 
African 
(n=371) 
25(OH)D 
nmol/L 
Season 
PTH (pmol/L) 
Weekly sunshine 
0.26 (<0.0001) 
-0.21 (<0.0001)  
0.10 (0.05) 
0.16 (<0.0001) 
2 Asian-
Indian 
(n=343) 
25(OH)D 
nmol/L 
Season 
PTH (pmol/L) 
Calcium supplementation 
Gender 
0.12 (0.02) 
-0.17 (0.001) 
0.30 (<0.0001) 
0.21 (<0.0001) 
0.17 (<0.0001) 
 
Key: R
2
 are unadjusted values. Values given are standardised beta coefficients (p-value). 
The following were log transformed: PTH and 25 (OH) D. Season: Winter was the 
reference season for Africans and spring the reference season for Indian subjects (see the 
Statistical Analysis sub-section of the Methods section for a full description of the coding). 
Female gender was coded as 0 and male as 1 
 
3.4  DISCUSSION 
To our knowledge, this is the first study to examine determinants of 25(OH)D 
concentrations in Black African and Indian subjects living in Africa. As noted by 
Prentice et al., Africa is a heterogeneous continent with differences in latitude, 
climate, food availability, skin pigmentation and cultural practices (356). A 
systematic review of global vitamin D status by Wahl et al (348) noted that there 
were lack of data from many African countries. They noted mean concentrations 
between 25 and 49 nmol/L in a single South African study (357) with higher 
concentrations noted in West and Central Africa (348). Hilger et al (2014) noted 
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similar findings in a more recent systematic review of vitamin D status in 
populations worldwide (358). We have shown that Indians living in Johannesburg 
have a high prevalence of 25(OH)D deficiency (28.6%), while deficiency is rare in 
Africans (5%) when using a cut off <30 nmol/L to define deficiency.  
 
Comparison across studies is complicated by the different cut off levels used to 
define vitamin D deficiency and insufficiency and by variations in assay 
methodology.  However, our findings of increased prevalence of vitamin D 
insufficiency in the Indian population are in keeping with a number of studies (13, 
180, 359). Mithal et al noted that 25(OH)D concentrations below 75 nmol/L are 
prevalent in every region of the world while concentrations < 25 nmol/L are most 
common in South Asians and the Middle East (13).  
Ethnicity has been consistently related to circulating 25(OH)D concentrations in 
adults (360, 361) and a high prevalence of hypovitaminosis D has been reported 
from  Indian studies carried out in India as well (178, 180, 359) as well as from 
Indian subjects in the United Kingdom (362). The differences noted in our study for 
25(OH)D concentrations between the two ethnic groups probably reflect 
differences in diet, clothing, and exposure to sunshine.  
 
Mean 25(OH)D concentrations in our Black African population was higher than 
mean 25(OH)D level from Cape Town (357). This may be because of differences 
in latitude, age of the subjects as well as assays used to measure 25(OH)D. 
Concentrations were also higher than those noted in non-Hispanic blacks and 
Mexican-Americans from the US (297) but much lower than concentrations noted in 
indigenous populations in East Africa (363). It appears that urban Black Africans 
have lower 25(OH)D concentrations compared to rural subjects in the older age 
groups (>50 years) (194). 
 
In spite of the fact that Johannesburg experiences between eight and nine hours of 
sunshine a day throughout the year, we noted clear seasonal variation of 25(OH)D 
in both ethnic groups with season a significant positive predictor in both Indians 
and in Black Africans. The 25(OH)D concentrations were lowest for collections in 
the months of July to September (late winter, spring) indicating that sunshine 
exposure does influence 25(OH)D concentrations in both communities. Clear 
seasonal changes in 25(OH)D status similar to our findings have previously been 
reported in South Africa from several different groups of subjects such as the 
elderly with fractures (352) in HIV positive and negative subjects  from Cape Town 
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(92) as well as in healthy Black African and Caucasian children living in 
Johannesburg(192). The sunshine exposure score was a predictor of 25(OH)D in 
our Black African population but not in the Indian population, amongst whom 
females were mostly veiled. Using univariate regression analysis weekly sunshine 
exposure was a significant predictor of 25(OH)D in the Indian population. 
However, after adjusting for age, and gender and season, weekly sunshine 
exposure, was no longer a significant predictor of 25(OH)D concentrations in the 
Indian population. The sunshine exposure score comprised time spent outdoors as 
well as the extent of clothing coverage. It is possible that time of day, and 
character of time spent outdoors (e.g. physical activity) are also important in 
determining UV exposure and these were not assessed in this study. Combined 
these findings suggest that seasonal variation in 25(OH)D concentrations 
observed in Johannesburg among Black African and Indian subjects is probably a 
result of both the time spent outdoors and the amount of clothing worn. 
 
There was no significant association of 25(OH)D status with age in either group; 
while male gender was a predictor of higher 25(OH)D concentrations in the Indian 
population. This study was not able to determine the reasons for this difference but 
it is likely to be related to cultural practices such as wearing of the veil. 
 
We could find only one other study which has examined the relationship between 
body fat distribution and 25(OH)D in Indians (327) and our findings are in contrast 
to theirs. They showed a negative association between visceral fat and 25(OH). 
When the fat measures were all included together the same model none of the fat 
measures were predictive of 25(OH)D.  The reasons for this difference are not 
known. Because of possible collinearity a second regression model with total body 
fat, visceral and subcutaneous fat included individually was developed and neither 
total body fat nor body fat distribution was predictive of 25(OH)D in either group 
(data not presented). 
 There are major differences between the two studies:  the Indian population in 
Johannesburg are quite a homogenous population all having migrated from India 
whereas the cohort described by Sulistyoningrum et al (327) originated in India, 
Pakistan, Bangladesh, Sri Lanka and Nepal. Visceral adiposity and serum vitamin 
D concentrations were each measured in the two studies by different techniques; 
the sample size in the current study (343 versus 192) was higher. The 
mechanisms by which circulating concentrations of 25(OH)D are influenced by 
adipose tissue mass (or vice versa) are not fully understood. However, it is known 
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that adipose tissue  acts as a large depot for vitamin D (364) which may in turn 
significantly affect 25(OH)D bioavailability (316). Furthermore, obese individuals 
display a reduced response of serum 25(OH)D concentrations to UV-B radiation 
(316) and oral vitamin D supplementation (365) when compared with subjects who 
are not obese.  It is interesting to note that data from the National Health and 
Nutrition Examination Survey III (NHANES III) suggest that the relationship 
between body fat and 25(OH)D is stronger in white than in black subjects (366). 
 
Calcium supplementation was positively predictive of 25(OH)D in Indians, while 
vitamin D supplementation was not. This discrepancy may be because many 
calcium supplements contain vitamin D, but the amount was not specifically 
quantified in our study. Significantly more Indian participants were on calcium and 
vitamin D supplementation than were Black African participants. We postulate that 
this may be due to differences in educational and socio-economic status. Dietary 
intake of vitamin D was low because vitamin D content in most foods is naturally 
low and our estimates of vitamin D intake did not include the contribution from 
supplements. Consequently, the lack of a relationship between dietary vitamin D 
intake and serum 25(OH)D is not surprising and supports sunshine exposure as 
the major determinant of vitamin D status in these populations. In our study, 
dietary calcium intakes were much lower in both ethnic groups than the 1000 
mg/day intake recommended by the National Osteoporosis Foundation of South 
Africa. Low calcium intake could result in poor vitamin D status because of 
increased 25(OH)D metabolism. Despite the low dietary intake of calcium and 
vitamin D, the plasma concentration of 25(OH)D was much higher in the Black 
African compared to the Indian population. This highlights the important 
contribution of sunshine exposure to 25(OH)D concentrations in this part of the 
world.  
 
PTH concentrations were not significantly different between the ethnic groups, 
despite a high proportion of Indian subjects with vitamin D deficiency. Attempts 
have been made to define optimal vitamin D status for bone health based on the 
relationship between PTH and 25(OH)D (367) and this relationship appears to vary 
by race (148, 368). Thus, in African-Americans PTH concentrations are maximally 
suppressed at lower 25(OH)D concentrations compared with whites (148). The 
current study shows that the significantly lower 25(OH)D concentrations in the 
Indian compared to the Black African subjects occurs in the presence of similar 
PTH concentrations. This data further suggests that the relationship between 
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25(OH)D and PTH varies by race and that in terms of bone health optimal 
25(OH)D concentrations may be different in each of these two population groups.  
 
Our model explained between 16-17% of the variance in 25(OH)D concentrations 
which is comparable to data from previous studies (369-371). Thus, McDonnell et 
al analysed data on non-food factors affecting vitamin D status and showed that 
these explained only 13% of the variance in total 25(OH)D concentrations (370). 
Similarly, analysis of potential determinants of 25(OH)D in the US Radiologists 
Technologists Study showed that despite detailed data on UV radiation exposure 
only 25% of the variance in 25(OH)D concentrations was explained (371). Other 
factors that contribute to variance include skin colour (372), physical activity (371) 
and genetic factors (112), none of which were assessed in this study. 
 
Visceral adiposity is strongly associated with cardiometabolic diseases (373). In 
South Africa the mortality from cardiovascular disease and the prevalence of type 
2 diabetes is higher in Indian compared with Black African subjects (374). 
However, the current study demonstrates that the level of visceral adipose tissue 
is similar in these two population groups. This suggests that factors other than 
visceral adiposity are important contributors to cardiovascular risk in the Indian 
population. 
 
The strengths of this study include the large sample size, the method used to 
measure plasma 25(OH)D, the multi-ethnic nature of the study population, the 
determination of total body fat and body fat distribution and the assessment of a 
large number of variables that are thought to influence vitamin D status. There are 
however a number of limitations of this study which include the cross sectional 
nature of the study which allows us to draw inferences as to the determinants but 
does not permit definitive determination of the causative nature of any 
associations. Secondly, we did not quantify supplementation with vitamin D or 
calcium and could therefore not accurately assess the contribution of these 
supplements to 25(OH)D concentrations. Furthermore, dietary intake of calcium 
and vitamin D was limited to their quantification in fish, eggs and dairy products, 
but not meat. We also did not assess physical activity that might influence the 
dermal synthesis of vitamin D and visceral and subcutaneous adiposity were 
determined by ultrasound and not by CT scan, which is the gold standard method. 
However, this method has been validated in this population (339). The 
questionnaire used to assess sunshine exposure has been used in a number of 
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studies (341, 375) but has not been validated against personal UV dosimetry or 
observed exposure. The limit of quantitation for 25(OH)D2 was 11 nmol/L and 
because of this 25(OH)D2 was not quantifiable in 9.2% of participants. 25(OH)D2 
only constitutes a small proportion of total 25(OH)D in South Black African 
populations, thus its lack of detectability in some subjects had little influence on the 
overall vitamin D status of the two ethnic groups. Finally, the number of subjects 
studied in each season was not evenly distributed throughout the year. 
3.5  CONCLUSIONS 
This study clearly demonstrates that any policy on vitamin D supplementation 
should be considered in a local context. Thus, season and by implication 
differences in weather conditions, use of dietary supplements and ethnicity are all 
strong determinants of plasma 25(OH)D concentration and these factors, which 
vary widely across nations, must be considered before deciding on 
supplementation programs. Adequate vitamin D concentrations in different 
population groups also require further study. In our study, almost a third of the 
Indians who participated in this study were vitamin D deficient. It is possible that 
this group will benefit from routine supplementation. In view of the seasonal 
changes noted further consideration should be given to whether year long 
supplementation is required or if supplementation can be restricted to winter and 
early spring.  Studies are required to determine optimal dosages. The use of 
calcium was associated with higher 25(OH)D concentrations in Indians, but the 
benefits and its impact on cardiovascular health have to be assessed (353, 376). 
In conclusion, our study has shown that there are major differences in 25(OH)D 
concentrations in apparently healthy adults living in Johannesburg, with Indians 
showing the highest prevalence of 25(OH)D deficiency. Important positive 
predictors of 25(OH)D in this population are supplementation and season.  
 
As we have shown that there are clear differences in 25(OH)D status between 
Indian and Black African groups the next study aimed to determine if these 
differences contribute to ethnic differences in the prevalence of Met S and its 
individual components. 
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CHAPTER 4 
4. THE ASSOCIATION OF 25 HYDROXYVITAMIN D AND PARATHYROID 
HORMONE WITH METABOLIC SYNDROME IN TWO ETHNIC GROUPS IN 
SOUTH AFRICA 
 
ABSTRACT 
Though inconsistent, a number of studies have shown an association between 
vitamin D (25(OH)D) status, parathyroid hormone (PTH) and metabolic syndrome 
(Met S). These have largely been carried out in Caucasians or black subjects living 
in high income countries. There are no data on the relationship of 25(OH)D and 
PTH status with Met S in populations resident in Africa.  
 
The aims of this study were to evaluate if there was an association of 25(OH)D or 
PTH with Met S in non-Caucasian populations in South Africa, and whether these 
molecules explained ethnic differences in the prevalence of Met S and its 
individual components.   
We measured anthropometry, serum 25(OH)D and PTH levels and the 
components of Met S, plus related metabolic variables, in 374 Black African and 
350 Indian healthy adults from the greater Johannesburg metropolitan area.  
 
Metabolic Syndrome was diagnosed in 29% of the Black African and 46% of the 
Indian subjects (p<0.0001). Subjects with Met S had higher PTH than those 
without Met S, (p<0.0001), whilst 25(OH)D levels were not significantly different 
(p=0.5). In multivariate analysis, 25(OH)D was not associated with any 
components of Met S however, PTH was shown to be positively associated with 
systolic (p=0.018) and diastolic (p=0.005) blood pressures and waist 
circumference (p<0.0001), and negatively associated with Homeostasis Model 
Assessment (p=0.0008) levels. Logistic regression analysis showed that Indian 
ethnicity (OR 2.24; 95% CIs 1.57, 3.18; p<0.0001) and raised PTH (OR 2.48; 95% 
CIs 1.01, 6.08; p=0.04) adjusted for 25(OH)D produced an increased risk of Met S 
but 25(OH)D did not (OR 1.25; 95% CIs 0.67, 2.24; p=0.48). 
 
Plasma PTH but not 25(OH)D is an independent predictor of Met S in Black 
African and Indians in South Africa.
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4.1  INTRODUCTION 
The incidence of obesity is on the rise in many low and middle income countries 
(LMICs) (377) and South Africa is no exception, with a national survey showing 
that 60% of South African women were either overweight or obese (9). Obesity is 
associated with an increased risk of cardiovascular disease (CVD) and additional 
risk factors include hyperglycaemia or type 2 diabetes (T2DM), 
hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), and 
hypertension. These CVD risk factors are commonly found in subjects with 
abdominal obesity and this grouping together of CVD risk factors has been termed 
metabolic syndrome (Met S) (22). 
 
The burden of disease related to CVD is expected to increase substantially in 
LMIC, such as South Africa, over the next decades and it is important to 
understand traditional and non-traditional risk factors that contribute to this disease 
burden. Some populations are more susceptible to CVD because of specific 
factors e.g. familial hypercholesterolaemia in the South African Afrikaner 
population (378) or insulin resistance in the Indian population (379). The 
prevalence of cardiovascular and diabetes risk factors is higher in Indians than in 
Black African population groups in South Africa despite greater obesity in the latter 
population (380). 
 
Several studies in various parts of the world suggest that vitamin D deficiency or 
insufficiency may increase the risk of Met S and its sequelae; T2DM and CVD.(40, 
41) Vitamin D is a hormone precursor which before exerting its metabolic effects 
undergoes two successive hydroxylation steps. The first converts vitamin D to 25 
hydroxyvitamin D (25(OH)D) and the second converts 25(OH)D to the main active 
hormonal form 1,25 dihydroxy vitamin D (1,25(OH)2D). Hypovitaminosis D appears 
to exert its effects via reductions in intracellular calcium and through the effects of 
1,25(OH)2D on the regulation of various target genes e.g. by lack of suppression of 
the renin gene leading to hypertension (381) and reduced insulin secretion through 
reduction in islet β –cell function (41). 
 
Elevated PTH levels have also emerged as a potential risk factor for Met S (288, 
382). Parathyroid Hormone has been shown to be inversely associated with insulin 
sensitivity (260) and directly with blood pressure (383, 384). Both 25(OH)D and 
PTH are calciotrophic hormones and their metabolism is inversely related such 
that a decrease in serum 25(OH)D leads to a rise in PTH (385). It is currently 
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unclear whether the association noted between hypovitaminosis D and 
components of Met S is mediated by 25(OH)D or PTH or by both.  
 
There are no studies from Africa that have investigated any associations between 
25(OH)D, PTH and components of Met S. Therefore, the aims of this study were to 
examine the association of 25(OH)D and PTH with Met S in Black African and 
Indian population groups in South Africa and to determine whether ethnic 
differences in 25(OH)D or PTH levels contribute to differences in the prevalence of 
Met S, its component parts and related metabolic variables within these 
populations. The hypotheses to be tested were that 25(OH)D is lower and PTH is 
higher in Met S patients in both population groups, and that ethnic differences in 
the prevalence of Met S and its component parts are related to ethnic differences 
in the blood level of 25(OH)D.       
 
4.2  METHODS 
Details of subject recruitment, biochemistry and anthropometry are described in 
chapter two. The following were measured: weight, height and waist 
circumference, blood pressure, serum glucose, creatinine, insulin, total cholesterol, 
triglycerides and HDL cholesterol, plasma PTH and 25(OH)D. Seven hundred and 
seventeen subjects were included in this study for whom we had complete data, 
373 Black Africans and 344 Indians (342 males and 375 females). 
 
4.2.1 Diagnosis of Metabolic Syndrome, and Measurement of Insulin Resistance 
and Glomerular Filtration Rate 
 
Met S was determined using the harmonized definition (22) Thus, subjects had to 
have at least three of the following criteria: increased waist circumference (≥94cm 
for Black African males, ≥80cm for Black African or Indian females, ≥90cm for AI 
males); elevated serum triglycerides (≥1.7mmol/L); reduced serum HDL-C 
(<1mmol/L for males and 1.3 mmol/L for females); elevated blood pressure 
(systolic blood pressure ≥130mmHg and /or diastolic pressure ≥85mmHg) and 
elevated fasting blood glucose (≥5.6mmol/L). Insulin resistance was measured 
using the HOMA technique (386) and estimated glomerular filtration rate (eGFR) 
was calculated by The Modified Diet in Renal Disease formula (MDRD) (333). 
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4.2.2 Statistical Methods 
Stata 12 (College Station, TX, USA) was used for all analyses. The distribution of 
variables was assessed by the Shapiro-Wilk‟s W test and by examination of the 
normal probability plot. Logarithmic transformations were applied for all non-
normally distributed variables. In descriptive analysis, normally distributed, 
continuous variables were reported as mean ± Standard Deviation (SD) whilst 
non-normally distributed data were expressed as median (interquartile range 
(IQR)). Categorical data were reported as N (percent).  
 
Pearson‟s correlation was used to assess the association of 25(OH)D and PTH 
with the selected variables. Multivariable regression analyses were conducted to 
assess the association of Met S components with 25(OH)D and PTH  after 
adjusting for potential confounders i.e. age, gender and body mass index (BMI). 
Ethnicity was also included as an independent variable to determine if ethnic 
differences in Met S components were mediated by 25(OH)D or PTH. 
 
In order to determine if the higher risk of Met S in the Indian population was 
mediated by 25(OH)D or PTH, logistic regression analysis was performed with the 
stepwise addition of 25(OH)D and PTH to a model that also included ethnicity, 
age, gender and BMI as independent variables. The attenuation of the p-value 
(from significant to non-significant) for the ethnicity odds ratio was used as the 
indicator of any effect.  
 
PTH was found to increase the risk of Met S and therefore we analysed which of 
the individual components of Met S were influenced by PTH by separately adding 
each individual component to a logistic regression model for Met S risk which 
included PTH, age, gender, ethnicity, BMI and 25(OH)D as independent variables. 
As described above, the attenuation of the p-value, in this case for the PTH odds 
ratio, was used as the effect indicator.   
 
In all regression models, Africans were coded as 0 and Indians as 1; whilst 
females were coded as 0 and males as 1. 
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4.3  RESULTS 
4.3.1  Ethnic Differences 
Six participants were excluded from the analyses due to incomplete data collection 
and seven participants with serum calcium above the normal reference range 
(2.15-2. mmol/L) were also excluded. Characteristics of the participants (n=717) 
are shown in Table 4.1. Both ethnic groups had similar (p>0.05) age, BMI, HDL-C, 
eGFR, calcium and PTH levels. Indian subjects had significantly higher fasting 
glucose, triglycerides and total cholesterol (p<0.0001 for each of the 3 
comparisons) compared to the Black African population. They also had a greater 
waist circumference (p=0.0001) and were more insulin resistant (p<0.0001). Black 
African subjects had higher 25(OH)D levels and systolic and diastolic blood 
pressures (p<0.0001 for all three comparisons).  
 
When these differences were analysed by gender Indian males had significantly 
higher cholesterol, triglycerides, fasting glucose and waist circumference 
compared to Black African males (p<0.0001 for all) whilst Black African males had  
higher systolic blood pressures (p<0.0001) HDL-C (p <0.005) and eGFR (p<0.05). 
 
Indian females also had significantly higher cholesterol, triglycerides, fasting 
glucose (<p<0.0001) and eGFR (p<0.005) compared with Black African females. 
Both Indian males and Indian females were more insulin resistant than their Black 
African counterparts (p<0.0001)
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Table 4.1: Characteristics of Subjects According to Ethnicity and Gender 
Variable 
Black 
African 
Indian p-values 
Black 
African 
 Males 
Black 
African 
Females 
p-values 
Indian 
Males 
Indian 
Females 
p-values 
N 373 344 - 181 192 - 161 183 - 
Age (years) 41.6 ± 13.1 43.5 ± 12.9 0.06 42.0 ± 13.2 42.0 ± 13.1 0.9 42.0 ± 13.2 46.0 ± 12.7 0.5 
Glucose (mmol/L) 
4.90 
(4.60, 5.00) 
5.21 
(4.80, 5.70) 
<0.0001 
4.90# 
(4.60, 5.40) 
4.90 * 
(4.60, 5.30) 
0.5 
5.20 
(4.91, 5.80) 
5.10 
(4.80, 5.63) 
0.03 
Triglycerides (mmol/L) 
0.85 
(0.62, 1.27) 
1.26 
(0.83, 1.85) 
<0.000.1 
0.93# 
(0.67, 1.42) 
0.82* 
(0.57, 1.17) 
0.03 
1.37 
(1.00, 2.08) 
1.10 
(0.77, 1.60) 
<0.0001 
HDL-C (mmol/L) 
1.28 
(1.08, 1.53) 
1.26 
(1.07, 1.53) 
0.81 
1.20## 
(1.01, 1.43) 
1.33** 
(1.17, 1.59) 
<0.0001 
1.12 
(1.00, 1.26) 
1.45 
(1.24, 1.73) 
<0.0001 
Systolic blood pressure 
(mmHg) 
131 
(120, 146) 
123 
(113, 134) 
<0.0001. 
133# 
(121, 148) 
129* 
(119, 143) 
0.16 
125 
(118, 135) 
118 
(108, 132) 
0.0003 
Diastolic blood pressure 
(mmHg) 
83.0 
(76.0, 93.0) 
80.0 
(73.1, 87.0) 
<0.0001 
82.0 
(74.0, 93.0) 
83.0* 
(77.3, 93.2) 
0.40 
82.0 
(75.3, 89.1) 
78.2 
(72.0, 85.2) 
0.006 
Waist (cm) 
89.0 
(78.0, 102) 
95.0 
(85.0, 106) 
0.0001 
85.0# 
(75.0, 99.0) 
95.0 
(82.0, 105) 
<0.0001 
98.0 
(90.5, 108) 
93.0 
(82.0, 103) 
0.0006 
eGFR (ml/min/1.73m
2
) 
87.9 
(77.7,103) 
88.1 
(75.7,103) 
0.9 
88.7### 
(74.5,103) 
87.4** 
(77.4,103) 
0.92 
84.2(72.7,9
6.3) 
92.8 
(81.6,108) 
<0.0001 
Calcium (mmol/L) 2.27 ± 0.09 2.26 ± 0.11 0.21 2.28 ± 0.08 2.27 ± 0.10 0.32 2.26 ± 0.1 2.26 ± 0.1 0.63 
Cholesterol (mmol/L) 4.22 ± 1.04 4.97 ± 1.10 <0.0001 
3.93# ± 
0.99 
4.24*± 1.07 0.002 4.72 ± 1.17 4.97 ± 1.04 0.16 
BMI (kg/m
2
) 
26.2 
(21.7, 31.7) 
26.7 
(23.3, 31.0) 
0.38 
23.3 
(20.2, 27.3) 
29.9 
(24.3, 35.3) 
<0.0001.0
0 
26.2 
(23.7, 30.4) 
27.1 
(23.0, 32.8) 
0.36 
HOMA 
1.83 
(1.10, 2.90) 
3.23 
(2.13, 5.01) 
<0.0001.00 
1.43 
(0.80, 2.69) 
2.16 
(1.31, 2.92) 
0.0001 
3.45 
(2.15, 5.50) 
3.15 
(2.05, 4.60) 
0.12 
PTH (pmol/L) 
4.70 
(3.30, 6.50) 
4.85 
(3.61, 6.92) 
0.09 
4.30 
(3.00, 5.60) 
5.30*** 
(3.80, 5.90) 
0.0002 
4.60 
(3.60, 6.40) 
5.00 
(3.70, 7.20) 
0.09 
25(OH)D (nmol/L) 
70.9 
(51.5, 95.1) 
41.8 
(28.6, 56.8) 
<0.0001 
72.7 
(51.1, 94.1) 
58.3 
(42.9, 85.6) 
0.0008 
46.8 
(33.6, 62.7) 
35.7 
(23.0, 54.5) 
0.0002 
Data given as mean ± SD for normally distributed data and median (IQR) for non-normally distributed data. Black African Males vs Indian males, # 
p<0.0001, ## p<0.005, ###p<0.05, Black African females vs Indian females *p<0.0001, ** p<0.005, ***P, 0.05. PTH=parathyroid hormone, HOMA= 
homeostatic model of assessment, BMI=body mass index, eGFR= estimated GFR
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The month of the year during which blood samples were drawn for 25(OH)D 
measurement may be a confounding variable since 25(OH)D levels are known to 
vary across the seasons (352). However, ethnic differences in plasma 25(OH)D 
levels were still observed irrespective of the season during which the blood sample 
was obtained. Vitamin D levels were highest for both ethnic groups during the 
autumn months (data not shown).    
 
4.3.2  Gender Differences 
In both ethnic groups females had lower 25(OH)D levels compared to their male 
counterparts (p=0.0008 in Black Africans and p=0.0002 in Indians) and this was 
also observed for triglyceride levels (p=0.03 in Black Africans and p<0.0001 in 
Indians) (Table 4.1). The PTH levels were higher in Black African females than in 
males (p=0.0002), and although the same pattern was observed in Indians, the 
gender effect was not significant (p=0.09). No gender differences were observed 
for age or calcium levels in either ethnic group. In Black African females, 
cholesterol (p=0.002), BMI (p<0.0001) and HOMA (p=0.0001) were higher than in 
males, but no gender effect for these variables was seen in the Indian population. 
Indian females had higher eGFR than Indian males (p<0.0001) but no gender 
difference was observed in the Black African cohort. In Indian males, glucose 
(p=0.03) and systolic (p=0.0003) and diastolic (p=0.006) blood pressure were 
higher than in females but no differences were noted between sexes in the Black 
African subjects. Within both ethnic groups, HDL-C levels were higher in females 
than in males (p<0.0001 for both). Waist circumference was significantly higher in 
Black African females than in males (p<0.0001), but in the Indian subjects this 
trend was reversed (p=0.0006).    
 
4.3.3  Met S 
Met S was diagnosed in 38% of the participants, with a prevalence of 29% in the 
Black Africans and 46% in the Indian group (p<0.0001). The data in Table 2 show 
that within each ethnic group the most prevalent Met S component was increased 
waist circumference (94.5% in Black African and 96.9% in Indians; p=0.33) and 
elevated triglyceride was the least common (36.7% in Black Africans and 54.7% in 
Indians; p=0.004). The occurrence of raised fasting glucose levels was more 
common in Indians than in Black African Met S patients (p=0.009), whilst raised 
systolic blood pressure was more common in Black African than in Indian Met S 
subjects (p=0.005). Low HDL-C (p=0.28) and raised diastolic blood pressure 
(p=0.13) were not significantly different in frequency across the two ethnic groups 
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(Table 4.2). HOMA-IR was greater n Indian females compared to Black African 
females (p<0.0001) and in Indian males compared to Black African males 
(p<0.0001) (data not shown). 
 
Table 4.2: Prevalence of Individual Components of Met S in Each Ethnic  
Group 
Variable 
BA with Met S 
(N=109) 
I with Met S 
(N=161) 
p-values 
Raised glucose  48.0 (44.0) 97.0 (60.3) 0.009 
Raised triglycerides  40.0 (36.7) 88.0 (54.7) 0.004 
Reduced HDL-C  74.0 (67.9) 91.0 (61.5) 0.28 
Raised systolic blood pressure  96.0 (88.9) 121 (75.2) 0.005 
Raised diastolic blood pressure  83.0 (76.9) 110 (68.3) 0.13 
Raised waist circumference  103 (94.5) 156 (96.9) 0.33 
Data given as N (%) BA - African  I - Indian 
 
In both ethnic groups, subjects with Met S had higher ages, HBA1c, HOMA, PTH, 
cholesterol and BMI measures than those without Met S, whilst eGFR was lower in 
those with Met S (p<0.05 for all comparisons) (see Table 4.3). Calcium (p=0.80) 
and 25(OH)D levels (p=0.50) were not significantly different across these 2 groups 
(Table 4.3). 
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Table 4.3: Comparison of Subjects with and Without Met S within Each  
Ethnic Group  
Data given as mean ± SD for normally distributed data and median (IQR) for non-normally 
distributed data BA=African AI=Indian. BMI=body mass index, eGFR= estimated GFR, PTH= 
parathyroid hormone 
  
 BA without  
Met S 
BA with  
Met S 
p-values AI without 
Met S 
AI with  
Met S 
p-values 
N 260 109 - 186 158 - 
Age (years) 39.1 ± 12.9 47.7 ± 11.3 <0.0001 38.4 ± 12.7 49.4 ± 10.5 <0.0001 
HBA1c (%) 
5.31  
(5.06, 5.32) 
5.64  
(5.35, 6.36) 
<0.0001 
5.33  
(5.04, 5.56) 
5.76  
(5.41, 6.13) 
<0.0001 
HOMA 
1.44  
(0.87, 2.35) 
2.85  
(2.00, 4.00) 
<0.0001 
2.43  
(1.72, 3.58) 
4.56  
(2.99, 6.77) 
<0.0001 
PTH (pmol/L) 
4.50  
(3.25, 5.95) 
5.41  
(3.92, 7.60) 
0.0002 
4.40  
(3.50, 6.20) 
5.40  
(4.13, 7.62) 
0.0001 
25(OH)D (nmol/L) 
72.3  
(52.6, 95.4) 
67.4  
(49.9, 94.8) 
0.45 
48.3  
(34.8, 66.0) 
50.5  
(34.7, 70.1) 
0.50 
eGFR ml/min/1.73m
2
 91.3 ± 23.0 84.2 ± 19.3 <0.0001 93.1 ± 20.2 87.2 ± 19.1 0.003 
Calcium (mmol/L) 2.27 ± 0.09 2.28 ± 0.09 0.30 2.26 ± 1.11 2.27 ± 0.10 0.80 
Cholesterol (mmol/L) 4.02 ± 0.95 4.48 ± 1.05 0.001 4.86 ± 1.03 5.11 ± 1.17 0.04 
BMI (kg/m
2
) 
24.0  
(20.0, 29.0) 
30.9  
(27.4, 35.1) 
<0.0001 
24.9  
(21.1, 29.6) 
28.8  
(25.3, 32.6) 
<0.0001 
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4.3.4  Univariate Analysis 
In a univariate analysis there was a significant negative correlation between PTH 
and 25(OH) D (p<0.0001, see Table 4.4) and a significant trend for PTH to be 
higher in Indian subjects (p=0.04) and in females (p=0.0002).  
 
Table 4.4: Pearson’s Correlations for PTH and 25(OH)D for all Subjects 
Variable Log PTH Log 25(OH)D 
Age 0.26 (<0.0001) -0.02 (0.52) 
Log BMI  
(kg/m2) 
0.22 (0.0001) -0.03 (0.38) 
eGFR  
(ml/min/1.73m2) 
-0.07 (0.05) -0.11 (0.003) 
Log Glucose  
(mmol/L) 
0.09 (0.02) -0.06 (0.09) 
Cholesterol 
(mmol/l) 
0.11 (0.005) -0.17 (<0.0001) 
Log Triglyceride  
(mmol/L) 
0.14 (<0.0001) -0.08 (0.02) 
HDL-C 
(mmol/L)  
0.009 (0.81) -0.06 (0.08) 
Log Systolic blood pressure 
(mmHg)  
0.15 (0.0001) 0.12 (0.001) 
Log Diastolic blood pressure 
(mmHg)  
0.19 (0.0001) 0.08 (0.02) 
Log HOMA  0.09 (0.02) -0.02 (0.67) 
Log PTH  
(pmol/L) 
- -0.19 (<0.0001) 
Log 25(OH)D 
(nmol/L)  
-0.24 (<0.0001) - 
Log Waist 
(cm)  
0.25 (<0.0001) 0.0002 (0.99) 
Data given as r (p-value) eGFR =estimated GFR,  
 
We observed significant (p<0.05) positive associations of PTH with age, BMI, 
glucose, HOMA, triglyceride, cholesterol, waist circumference and systolic and 
diastolic blood pressures. The 25(OH)D levels correlated negatively with BMI, and 
GFR and positively with systolic and diastolic blood pressure (p<0.05 for all 
associations). There were significant trends for 25(OH)D to be higher in Black 
African and in male subjects (p<0.001 for all comparisons).  
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4.3.5  Multivariable Regression Analysis 
Multivariate associations of 25(OH)D and PTH with components of Met S are 
presented in Table 4.5, with age, gender and BMI included as independent 
variables in all models.  
 
Table 4.5: Multiple Regression Models for Determining the Effects of Ethnicity, 
PTH and 25(OH)D on Components of Met S 
Dependent 
Variable 
MODEL NUMBERS AND INDEPENDENT VARIABLES 
MODEL 1 MODEL 2 MODEL 3 
Ethnicity Ethnicity 25(OH)D (log) Ethnicity 25(OH)D (log) PTH (log) 
Log Glucose 
(mmol/L) 
0.02  
(0.013) 
0.02  
(0.015) 
-0.003  
(0.47) 
0.02  
(0.015) 
-0.003  
(0.44) 
-0.01  
(0.43) 
Log 
Triglycerides 
(mmol/l) 
0.13  
(<0.0001) 
0.13  
(<0.0001) 
-0.001  
(0.89) 
0.13  
(<0.0001) 
0.0007  
(0.94) 
0.04  
(0.32) 
Log HDL-C 
(mmol/L)  
0.0002  
(0.99) 
-0.0007  
(0.93) 
-0.007  
(0.11) 
-0.0009  
(0.93) 
-0.006  
(0.175) 
-0.005  
(0.78) 
Log Systolic 
blood pressure 
(mmHg)  
-0.04  
(<0.0001) 
-0.04  
(<0.0001) 
0.002  
(0.34) 
-0.04  
(<0.0001) 
0.002  
(0.28) 
0.02  
(0.018) 
Log Diastolic 
blood pressure 
(mmHg)  
-0.02  
(<0.0001) 
-0.02  
(<0.0001) 
0.003  
(0.14) 
-0.02  
(<0.0001) 
0.004  
(0.11) 
0.03  
(0.005) 
Log Waist 
(m)  
0.02  
(0.002) 
0.02  
(0.001) 
0.003  
(0.37) 
0.02  
(0.005) 
0.004  
(0.19) 
0.09  
(<0.0001) 
Log HOMA  
0.23  
(<0.0001) 
0.23  
(<0.0001) 
0.0009  
(0.93) 
0.23  
(<0.0001) 
-0.0003  
(0.97) 
-0.13  
(0.008) 
Data given as beta coefficient (p-value); all models adjusted for age, gender and BMI. 
Ethnicity, 25(OH) D and PTH were added in a forward, stepwise manner. 
 
Addition of ethnicity to all the models demonstrated that Indian ethnicity was a 
positive determinant of glucose, triglyceride and HOMA levels but a negative 
determinant of diastolic and systolic blood pressure. Addition of 25(OH)D to these 
models had minimal effect on the beta values for ethnicity and in none of the 
models was 25(OH)D shown to be a determinant of any of the components of Met 
S, or HOMA. When PTH was added to each of the models, neither the ethnicity or 
25(OH)D beta values were affected, however PTH was shown to be positively and 
significantly associated with systolic (p=0.018) and diastolic (p=0.005) blood 
pressures and waist circumference (p<0.0001) and negatively associated with  
HOMA (p=0.008) levels. Addition of PTH/25(OH)D ratio did not change results. 
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Logistic regression was used to determine whether the higher prevalence of Met S 
in the Indian population was related to PTH or 25(OH)D levels. The data in Table 
4.6 show that after adjusting for age, gender and BMI, Indian ethnicity carries a 
2.24 (95% CIs 1.57, 3.18; p<0.0001) increased risk of Met S compared to Black 
African  subjects (see Table 4.6, model 1).  
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Table 4.6: Multivariate Logistic Regression Analysis for Determining the 
Effect of Ethnicity, PTH and 25(OH)D on Risk of Met S 
Model 
Numbers 
Independent Variables 
Odds 
Ratios 
95% CIs p-values 
1 Ethnicity 2.24 1.57, 3.18 <0.0001 
2 Ethnicity Log 25(OH)D  
2.29 
1.15 
1.60, 3.28 
0.78, 1.70 
<0.0001 
0.47 
3 Ethnicity Log 25(OH)D Log PTH  
2.27 
1.25 
2.48 
1.56, 3.30 
0.67, 2.24 
1.01, 6.08 
<0.0001 
0.48 
0.04 
All models adjusted for age, gender and BMI, with Met S as the dependent variable. 
Ethnicity, 25(OH)D(mmol/L) and PTH(pmol/L) were added in a forward, stepwise manner. 
 
Additional adjustment for 25(OH)D had no effect on the p-value (or odds ratio 
(OR)) for ethnicity and had no significant effect itself (see Table 4.6, model 2). The 
final addition of PTH to the logistic regression model (see Table 4.6, model 3) had 
no effect on the p-value or OR for ethnicity or 25(OH)D, but did have a significant 
effect itself (OR=2.48; 95% CIs 1.01, 6.08; p=0.04).    
 
In order to determine which individual components of Met S are influenced by PTH 
to increase the risk of Met S, logistic regression analysis was performed. The 
results in Table 4.7 show that the increased risk for Met S conferred by PTH arises 
principally through its effect on systolic blood pressure and its positive association 
with waist circumference. This is demonstrated by the fact that adding these 
variables individually to the logistic regression model attenuates the p-value of the 
OR for PTH (see Table 4.7, models 6 and 7).  
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Table 4.7: Risk of Metabolic Syndrome due to PTH and the Effects of 
Adjusting for Individual Components of the Metabolic 
Syndrome on PTH Odds Ratios in a Logistic Regression 
Analysis  
Model  
number 
Independent variables 
Odds  
ratios 
95% CIs p-values 
1 Log PTH  2.48 1.01, 6.08 0.04 
2 
Log PTH  
Triglyceride ≥ 1.7 mmol/L 
2.91 
11.9 
1.08, 7.83 
7.19, 19.6 
0.03 
<0.0001 
3 
Log PTH  
HDL-C < 1.3 mmol/l (females) or < 1.0 mmol/L 
(males) 
3.08 
13.3 
1.09, 8.76 
8.41, 21.0 
0.03 
<0.0001 
4 
Log PTH  
Glucose ≥ 5.6 mmol/L 
2.28 
9.58 
0.87, 5.97 
5.90, 15.6  
0.09 
<0.0001 
5 
Log PTH  
Diastolic bp ≥ 85 mm/Hg 
2.76 
5.85 
1.05, 7.24 
3.92, 8.73 
0.04 
<0.0001 
6 
Log PTH  
Systolic bp ≥ 130 mm/Hg 
1.76 
8.32 
0.66, 4.65 
5.28, 13.1 
0.25 
<0.0001 
7 
Log PTH  
Waist ≥ 94 or ≥ 90 cm for BA or Indian males or ≥ 
80 cm for females 
2.03 
9.69 
0.82, 5.06 
4.55, 20.6 
0.13 
<0.0001 
8 
Log PTH 
Systolic bp ≥ 130 mm/Hg 
Waist ≥ 94 or ≥ 90 cm for BA or Indian males or ≥ 
80 cm for females 
1.43 
8.46 
10.3 
0.53, 3.85 
5.32, 13.5 
4.66, 22.7 
0.48 
<0.0001 
<0.0001 
All models adjusted for age, gender, ethnicity, BMI and 25(OH)D with metabolic syndrome 
as dependent variable. 
PTH pmol/L, HDL-C mmol/L, Glucose mmol/L, Blood pressure mmHg, Waist cm 
 
Adding both these variables to the regression model at the same time attenuates 
the p-value for the PTH OR to a greater extent than adding each variable on its 
own (see Table 4.7, model 8). This suggests that the effects of each variable are 
additive and independent.  Addition of the other metabolic syndrome components 
to the logistic regression model does not attenuate the p-value/OR for PTH and in 
some cases increases it. The exception is glucose, which does have a weak effect 
on the p-value for PTH, increasing it from 0.04 to 0.09 (see Table 4.7, model 4). 
 
4.4  DISCUSSION 
There are no previous studies from sub-Saharan Africa that have examined the 
relationship between 25(OH)D, PTH and Met S. In this study we investigated 
whether 25(OH)D or PTH is associated with Met S or its components. Our results 
show a significant association of PTH, but not 25(OH)D, with Met S. Higher PTH 
levels were associated with increased systolic and diastolic blood pressure and 
reduced insulin resistance as assessed by the HOMA index and an increased 
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odds ratio for Met S. Furthermore our results suggest that neither 25(OH)D nor 
PTH contribute to ethnic differences in the prevalence of Met S between Black 
African and Indian subjects.  
Our observations of a lack of association of 25(OH)D with Met S are in line with 
those of Scragg et al who observed no association between 25(OH)D status and 
type 2 diabetes in non-Hispanic black subjects, but did observe a negative 
associations between 25(OH)D and risk of diabetes in Mexican Americans and 
non-Hispanic white populations (247). Similarly, in a single study from India, 
Majumdar et al showed that although 25(OH)D insufficiency was highly prevalent, 
it was not associated with Met S or insulin resistance (253). 
 
The results of studies on the association of 25(OH)D and PTH with Met S, 
components of Met S or related disorders have been inconsistent. In a population 
based cross sectional study of US men and women over 20 years-of-age 
(NHANES III, 1988-94) the prevalence of Met S and its components fell across 
increasing quartiles of 25(OH)D after adjustment for age, race, sex, income, 
lifestyle factors, calcium and energy intake (387). This study also showed that the 
odds ratio for Met S increased with increasing PTH in older men only.  In a study 
carried out in an aging European population, investigators showed that the risk for 
Met S decreased across increasing quintiles of 25(OH)D but could show no 
association of PTH with Met S (288). Neither of these studies adjusted for BMI.  
However, Reis et al. showed a lack of association between serum 25(OH)D and 
Met S in an adult Caucasian population (255). Our population, particularly the 
Black African subset, was not particularly vitamin D deficient overall (median 
25(OH)D in Black Africans was 71 nmol/L) and 25(OH)D may be more strongly 
associated with Met S in a deficient population. However, this cannot explain the 
lack of association of 25(OH)D with Met S in the Indian group, as serum 25(OH)D 
levels were significantly lower in this population compared to the Black African 
cohort. 
  
A number of other studies have implicated PTH as being associated with Met S 
rather than 25(OH)D (288, 382). Several lines of evidence support a role of PTH in 
increasing the risk of CVD. It has been associated with increased cardiovascular 
mortality in selected population groups (254, 388, 389) and with increased 
coronary heart disease in a younger group (390). This increased risk may be 
mediated via its effects on blood pressure, insulin resistance, hyperglycaemia and 
low HDL-C (255, 387). In multivariate regression models we confirmed a positive 
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relationship between PTH and blood pressure but could not verify any relationship 
between PTH and blood glucose or lipid levels, although significant associations 
were observed in univariate analyses. The negative relationship that we observed 
between PTH and the HOMA index was only observed after adjusting for 
confounding variables within a multivariate regression analysis. In a univariate 
analysis PTH correlated positively with HOMA. Derangements in glucose 
metabolism in primary hyperparathyroidism are well described with increased PTH 
increasing glucose intolerance (261, 387, 391, 392).  A few studies have described 
a positive relationship between PTH and insulin resistance similar to our 
observation in univariate analyses. Some investigators have postulated that this 
relationship may be secondary to hypercalcaemia as it is absent in 
normocalcaemic subjects (393, 394). Frost et al showed a significant negative 
association of PTH with insulin resistance in young men (395). The negative 
relationship we have noted between PTH and HOMA in a multivariate analysis 
may be for a number of reasons: ethnic differences, the fact that our subjects were 
all normocalcaemic or the adjustment for confounders. In addition to its possible 
effect on insulin sensitivity, clinical evidence also supports a role of PTH in 
increasing blood pressure (383) and observational studies have linked elevated 
PTH levels to an increased risk of hypertension, left ventricular hypertrophy, and 
cardiovascular morbidity and mortality (389). It is thought that PTH mediates its 
effect by directly increasing the secretion of aldosterone from the adrenal glands 
and indirectly by activating the renin-angiotensin system (396). 
 
Logistic regression models demonstrated that the increased risk of Met S in 
subjects with higher PTH levels is largely due to the positive and independent 
relationships of systolic blood pressure and waist circumference with PTH. 
Previous studies have also shown a positive association of PTH with obesity (389, 
397). Furthermore, body weight changes correlate positively with changes in 
serum PTH levels (398, 399) suggesting that obesity may be causative for 
hyperparathyroidism. There are no studies in the literature showing that PTH is 
secreted by adipocytes, but there are studies that demonstrate that PTH does 
modify adipocyte function. These effects include the inhibition of adipocyte 
lipoprotein lipase activity (280) and the attenuation of insulin signalling (400). 
However, both these actions of PTH would limit rather than augment triglyceride 
deposition within adipose tissue. It is possible that increased adiposity may lead to 
greater production of PTH by the parathyroid, and it is interesting to note that 
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studies have shown a positive correlation between serum leptin and PTH 
concentrations (397). 
Our data show that Indian ethnicity is associated with increased risk for Met S and 
most of its components. As a group, Indians tend to be insulin resistant and at high 
risk for diabetes and premature coronary heart disease when compared to other 
ethnic groups (401). This was true of this study cohort. This may be partly 
explained by high visceral fat content (402).  In the present study ethnic 
differences in the levels of Met S related metabolic variables and the prevalence of 
Met S were investigated, using multiple regression and logistic regression 
analyses and were found not to be related to ethnic differences in PTH or 25(OH)D 
levels. 
 
This study is limited by the cross-sectional nature of the data so we cannot draw 
any conclusions about causality. Another limitation is that blood samples were 
collected over several months, and vitamin D is known to display seasonal 
variation. Furthermore, study subjects were not selected randomly and this may 
have introduced some level of selection bias.  Finally, 25(OH)D levels were not 
measured using the reference method of liquid chromatography-tandem mass 
spectrometry (LC/MS/MS), however the technique used in this study (HPLC) has 
been shown to correlate well with the LC/MS/MS method (125). 
 
4.5  CONCLUSIONS 
In conclusion, PTH but not 25(OH)D is associated with Met S in our Black African 
and Indian populations. The PTH effect is largely via its impact on blood pressure 
and its relationship with waist circumference. The relationship between PTH and 
insulin resistance needs to be investigated further, as does the mechanism 
responsible for causing serum PTH levels to rise with increased adiposity.  
 
We have shown that although there are clear differences in 25(OH)D 
concentrations between both population groups this does not contribute to ethnic 
differences in the Met S. We also showed in the first study that Indian subjects 
have greater total body fat compared to Black African subjects. The aim of the 
third study was therefore to investigate body composition differences in both ethnic 
groups in more detail and to identify how body composition and 25(OH)D affect 
BMD in both these population groups. 
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CHAPTER 5 
5. THE ASSOCIATION BETWEEN BODY COMPOSITION, 25(OH)D AND PTH, 
AND BONE MINERAL DENSITY IN BLACK AFRICAN AND INDIAN 
POPULATION GROUPS 
 
ABSTRACT  
As there are little data on the contribution of body composition to bone mineral 
density (BMD) in non-Caucasian populations we  investigated the contribution of 
body composition, and possible confounding of 25(OH)D and PTH, to BMD at 
various skeletal sites in both groups of subjects. 
 
BMD, body fat and lean mass were measured using dual x-ray absorptiometry 
(DXA) and abdominal fat distribution by ultrasound in 714 healthy subjects, ages 
18-65 years. 
 
Whole body (subtotal), hip (H), femoral neck (femoral) and lumbar spine (lumbar) 
BMD were significantly higher in Black African than Indian subjects (p<0.001 for 
all). Whole body lean mass positively associated with BMD at all sites in both 
ethnic groups (p<0.001 for all), and partially explained the higher BMD in Black 
African females compared to Indian females. Whole body fat mass correlated 
positively with lumbar BMD in Black African (p=0.001) and inversely with subtotal 
BMD in Indian subjects (p<0.0001). Visceral adiposity correlated inversely with 
subtotal BMD in the Black African (p=0.037) and with lumbar BMD in the Indian 
group (p=0.005).  No association was found between serum 25(OH)D and BMD. 
PTH was inversely associated with hip BMD in the Black African group (p=0.01) 
and with sub total (p=0.002), hip (p=0.001) and femoral BMD (p<0.0001) in the 
Indian group. 
 
Significant differences in whole body and site-specific BMD between Black African 
and Indian groups were observed with lean mass the major contributor to BMD at 
all sites in both groups.  The contribution of other components of body composition 
differed by site and ethnic group.
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5.1  INTRODUCTION 
South Africa, a low to middle income country undergoing an epidemiological 
transition, is characterized by a high rate of infectious diseases, malnutrition and 
an increasing prevalence of non-communicable diseases (6). There are limited 
comparative bone mineral density (BMD) data on non-Caucasian population 
groups living in countries that are part of the epidemiological transition, although it 
is known that osteoporotic fractures are an important cause of disability and 
mortality world-wide (403). Data from the late 1960‟s have reported that fracture 
rates in white, Indian and mixed ancestry South African populations are similar to 
that in Western countries, while fractures of the hip are reportedly less common in 
Black African subjects (404). A recent comparison of fractures in adolescent 
mother-daughter pairs noted that white adolescents and their mothers had more 
fractures compared to black adolescent mother-daughter pairs (405). Ethnic 
differences in BMD have been  reported with black South African females having 
higher BMD at the femoral neck,  than their white counterparts, and similar BMD at 
the lumbar spine and distal radius,(220, 406) while a more recent study has 
reported higher BMD at the femoral and hip, but lower lumbar BMD in Black 
African  than white women (407). It is possible that ethnic differences in BMD 
contribute to differences in fracture rates however to our knowledge similar data 
are not available for Black African men or Indian subjects.  
 
Differences in body composition may contribute to differences in BMD, as positive 
associations between body weight and body mass index, and BMD, as well as an 
increased fracture risk with low BMI, have been demonstrated (408). Significant 
sex and ethnic differences exist in the prevalence of obesity (9) and in adipose 
tissue distribution, with Black African women having lower visceral adiposity than 
Indian women (402) and white South African women (409). Increased weight is 
associated with increased BMD due to the additional mechanical loading on the 
bone which occurs with increased weight bearing, as well as  via muscle-mediated 
effects of physical exercise (212). However the relationship between fat mass and 
BMD is less clear with some studies reporting a positive association (410) and 
other studies demonstrating  a negative effect on BMD (411). Furthermore, 
visceral and subcutaneous adipose tissue  which are distinct in terms of their 
secretion of steroid hormones and adipokines (27) as well as inflammatory 
cytokines (412) may also affect BMD differently (37). 
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Inverse associations between BMD and both visceral adiposity and sub-cutaneous 
adiposity have been demonstrated in several groups including African-Americans 
and Caucasians (413) obese premenopausal women (414) and obese adolescent 
girls (412).  In contrast, others have shown a positive association between sub-
cutaneous adiposity and BMD in young females (412).  A recent South African 
study reported that after adjusting for a number of variables including visceral 
adiposity and sub-cutaneous adiposity, neither visceral adiposity or sub-cutaneous 
adiposity were associated with BMD in white or African women (407). 
 
Obesity is associated with hypovitaminosis D (316, 350) and secondary 
hyperparathyroidism (316), both of which may affect BMD negatively. We have 
previously reported a 28.6% prevalence of vitamin D deficiency in an Indian 
population resident in Johannesburg, compared to 5.1% in African subjects (415). 
In the same study we showed an inverse association between BMI and 25(OH)D 
and a positive relationship between PTH and waist circumference. Whether 
25(OH)D or PTH levels influence BMD in these population groups has not been 
investigated.  
 
The aims of this study were to:  
(i) investigate ethnic and sex differences in BMD, fat mass and lean mass 
between Black African and Indian men and women 
(ii) identify how body composition contributes to BMD at various skeletal sites in 
both ethnic groups; and  
(iii) determine whether the effects of body composition on BMD at various skeletal 
sites are mediated via PTH and/or 25(OH)D 
 
5.2  METHODS 
Please refer to chapter two for a description of the following methods: weight, 
height, and waist circumference, visceral and subcutaneous adiposity, whole body 
fat, bone area and bone mineral density of whole body, lumbar spine, femoral neck 
and hip, serum calcium, phosphate and creatinine as well as plasma PTH and 
25(OH)D determination of smoking status and alcohol use.  
Seven hundred and fourteen subjects for whom we had complete data were 
included in this study, 371 Black African and 343 Indian, of whom 340 were males 
and 374 females. 
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5.2.1  Statistical Analysis 
Data are presented as mean ± SD for normally distributed data and median 
(interquartile range (IQR)) for data that was not normally distributed. The latter 
variables were log transformed before analysis except for subtotal fat which was 
transformed by square root transformation. Exclusion of subjects with TSH above 
the laboratory reference range made no difference to the analyses and therefore 
these were included in all analyses. Only one participant reported the use of 
corticosteroids. Analysis of variance (ANOVA) with Bonferroni correction was used 
to compare BMD and body composition by ethnicity and gender. All bone data 
were compared after adjustment for height, weight, age and bone area. Pearson‟s 
correlations were used to examine the strength of the association of BMD with 
variables that have been shown to affect BMD (412, 416-421). Multivariable 
regression analyses were performed to determine the variables that made a 
significant contribution to sub-total, lumbar, femoral and hip BMD in the two ethnic 
groups. In the regression models, BMDs were used as dependent variables after 
log transformation, except for the lumbar BMD. Backwards stepwise regression 
analysis was performed until only variables with a p<0.05 were left in the model. 
Smoking status was added to regression models for all subjects as it may have 
been a possible confounder. Alcohol consumption was used in the Black African 
model only as only 4.4% of the Indians reported using alcohol. 
To test if the effects of body composition were mediated by PTH, we noted 
whether removal of PTH from the final regression model uncovered significant 
associations of body composition variables with BMD. Since we did not collect 
data on menopausal status, age was used as a categorical variable with those less 
than 50 coded as 1 and those 50 years or more coded as 2. There was no 
collinearity between the various body composition variables, as evidenced by 
variance inflation factors of <10.0. We tested for interaction of both gender and 
ethnicity with body composition and BMD and noted that there was no interaction 
 
Analysis of covariance (ANCOVA) was used to determine if any variables 
modulated the ethnic differences observed in BMD within each gender group. 
Thus, ANCOVA models were set up using ethnicity as the grouping variable and 
BMD as the dependent variable. Covariates were selected based on their ability to 
influence BMD and their observed differences between the 2 ethnic groups. These 
covariates were lean mass in females, sub-cutaneous adiposity and fat mass in 
males, and 25(OH)D in both groups. Each covariate was added individually to 
each model and the effects on the F- and p-values for ethnicity were noted. If more 
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than one covariate was observed to attenuate the F- and p-values in one model 
they were added together in a further ANCOVA. 
 
5.3  RESULTS 
5.3.1  Ethnic Differences in Body Composition and BMD 
Descriptive and body composition characteristics by gender and ethnicity are 
presented in Table 5.1. The mean age of all the subjects was 42.6±13 years, and 
there was no difference in age or height between the ethnic groups. Black African 
females were significantly heavier and had a greater BMI than Indian females, 
whilst Black African males weighed less, had a lower BMI and a lower waist 
circumference than Indian males. Waist-to-hip ratio was significantly higher in the 
Indian compared to the Black African groups, irrespective of sex. In males, fat 
mass was lower in Black African than in Indian subjects but lean mass was not 
different. Lean mass was significantly higher in Black African than Indian females, 
whilst fat mass was not different.  
 
Visceral adiposity was significantly higher in Black African females and Indian 
males compared to their same sex counterparts, and sub-cutaneous adiposity was 
significantly higher in Indian males compared to Black African males. Visceral 
adiposity/sub-cutaneous adiposity ratio was higher in Black African males and 
females compared to Indian groups. 
 
Subtotal and lumbar bone areas were higher in Black African females and males 
compared to their same sex Indian counterparts. All BMD measures were 
significantly higher in Black African males and females compared to their Indian 
counterparts.  These differences remained significant after adjusting for age, 
height, weight and site-specific bone area. 
 
As body weight and BMI were significantly higher in Indian males compared to 
Black African males, we assessed BMD for 100 men of similar BMI: including 44 
Black African men with a mean BMI of 26.1 (25.4, 26.6) and 56 Indian men with a 
mean BMI of 25.6 (25.4, 26.2), p=0.6. The BMD was significantly higher at all sites 
in Black African men (P<0.0001 for subtotal, hip and femoral BMD and P=0.0002 
for lumbar BMD). 
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5.3.2  Gender Differences in Body Composition and BMD 
Males were taller than females within their respective ethnic groups. Black African 
females were heavier, had a greater BMI and larger waist circumference than 
Black African males, whilst Indian females were lighter and had a smaller waist 
circumference than Indian males. Waist-hip ratio and lean mass were higher, and 
fat mass lower, in males compared to females in both ethnic groups. Although 
visceral adiposity was not significantly different between Black African males and 
females, it was higher in Indian males than females. In both ethnic groups, sub-
cutaneous adiposity was higher and visceral adiposity/sub-cutaneous adiposity 
ratio was lower in females than males.  
 
After adjusting for age, height, weight and site-specific bone area, subtotal BMD 
was significantly higher in males compared to females of both ethnic groups.  
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Table 5.1: Descriptive Characteristics of African and Indian Male and  
Female Participants 
 
BA Females 
(n=187) 
Indian Females  
(n=187) 
P-value 
BA Males 
(n=181 ) 
Indian Males 
(n=160) 
P-value 
Age (yrs.) 41.7±13.1 43.8 ± 12.7 0.08 41.7±13.2 43.0±13.2 0.36 
Height (cm) 158 ±6.90 158±5.98 0.6 171±7.32*** 171±6.18
###
 0.99 
Weight (kg) 
75.5 
(60.8,90.1) 
68.4 
(56.6,80.5) 
0.001 
67.7 
(59.7,79.9)* 
77.3 
(66.8,88.4)
###
 
<0.0001 
BMI (kg/m
2
) 
29.9 
(24.3, 35.3) 
27.1 
(23.0, 32.8) 
0.0007 
23.3 
(20.2,27.3)*** 
26.2 
(23.7,30.4) 
0.002 
Waist (cm) 94.4±15.7 92.5±16.9 0.9 87.1±13.9*** 98.5±13.9
##
 <0.0001 
WHR 0.85±0.09 0.87±0.12 0.04 0.89±0.08*** 0.96±0.08
###
 <0.0001 
STLM (kg) 
38.4 
(34.1,42.7) 
34.4 
(30.3,39.3) 
<0.0001 
46.9 
(42.9,52.1)*** 
48.8 
(42.9,54.4)
###
 
0.89 
STFM(kg) 
28.3 
(20.9,30.0) 
28.4 
(20.1,35.1) 
0.38 
11.9 
(7.27,21.1)*** 
20.1 
(15.4,21.3)
###
 
<0.0001 
VAT (cm) 5.13±1.76 4.19±1.73 <0.0001 4.98±1.91 5.84±1.96
###
 0.0001 
SCAT (cm) 
3.20 
(2.26,4.23) 
3.34 
(2.49,4.07) 
0.61 
1.67 
(1.29,2.33)*** 
2.81 
(2.02,3.56)
#
 
<0.0001 
STBMD (g/cm
2
) 
0.966 
(0.953,0.978) 
0.912 
(0.895,0.925) 
<0.0001 
1.052 
(1.039,1.084)*** 
1.005 
(0.997,1.028)
###
 
<0.0001 
ST bone area (cm
2
) 1713± 153 1647±159 <0.0001 1923± 183* 1905±177## <0.0001 
LSBMD (g/cm
2
) 
0.702 
(0.691, 0.713) 
0.648 
(0.636, 0.659) 
<0.0001 
0.695 
(0.683, 0.707) 
0.671 
(0.659, 0.683) 
0.02 
LS bone area 
(cm
2
) 
48.8± 5.58 46.9±5.31 0.007 58.6±7.13*** 54.9±5.90### <0.0001 
HBMD (g/cm
2
) 
0.998 
(0.909,1.088) 
0.887 
(0.803,0.978) 
<0.0001 
1.068 
(0.934,1.162) 
0.964 
(0.882,1.051) 
<0.0001 
H bone area (cm
2
) 32.9± 3.39 33.4± 4.09 0.9 43.1±4.50*** 43.2±4.58### 0.9 
FNBMD (g/cm
2
) 
0.919 
(0.830,0.995) 
0.777 
(0.692,0.859) 
<0.0001 
0.938 
(0.826,1.026) 
0.793 
(0.723,0.873) 
<0.0001 
FN bone area (cm
2
) 4.92±0.359 4.92±0.374 0.9 5.51±0.418*** 5.56±0.398### 0.9 
PTH (pmol/L) 
5.30 
(3.80, 5.90) 
5.00 
(3.70, 7.20) 
0.8 
4.30 
(2.00,5.60)** 
4.60 
(3.60,6.43) 
0.16 
25(OH)D (nmol/L) 
58.3 
(42.9, 85.6) 
35.7 
(23.0, 54.5) 
<0.0001 
72.7 
(51.1,94.1)* 
45.4 
(33.6,62.7)
##
 
<0.0001 
eGFR 
(ml/min/1.73m
2
) 
87.4(77.4,103) 92.8(81.6,108) <0.0001 88.7(74.5,103) 
84.2(72.7,96.3)
### 
0.004 
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Table 5.1 continued 
 
Key: Data presented as mean±SD if normally distributed and median (IQR) if non-normally 
distributed. BA male vs. BA female, *p<0.05, **p<0.001, ***p<0.0001; AI male vs. AI 
female, 
#
p<=0.05, 
##
p<0.001 
###
p <0.0001; all bone area adjusted for height, age and 
weight.  All bone mineral density data adjusted for bone area as well. VAT=Visceral 
adipose tissue thickness, SCAT=subcutaneous adipose tissue thickness, STFM=subtotal 
fat mass, STLM=subtotal lean mass, STBMD=subtotal BMD, LSBMD=lumbar BMD, 
HBMD=hip BMD, FNBMD=femoral neck BMD, PTH=parathyroid hormone, ST=sub-total, 
LS=Lumbar spine, H=Hip, FN=Femoral neck.BA=Black African 
 
5.3.3  Biochemistry  
Mean plasma calcium and phosphate concentrations were within normal reference 
ranges for our laboratory and were not significantly different between ethnic or 
gender groups. Median eGFR was within laboratory reference ranges for both 
genders, but significantly lower in Black African females compared with Indian 
females, and higher in Black African males compared with Indian males. It was not 
significantly different between Black African males and females (p=0.87) but was 
higher in Indian females compared to Indian males (p<0.0001) PTH levels were 
not significantly different between ethnic groups but were significantly lower in 
Black African males than females. 25(OH)D levels were significantly higher in 
Black African males and females compared to their Indian counterparts, and were 
higher in males than females in both ethnic groups. TSH was not significantly 
different between males and females for each ethnic group but was significantly 
higher in Indian females compared to Black African females (p=0.002) and in 
Indian males compared to Black African males. 
 
5.3.4  Smoking Status and Alcohol Use 
There were more smokers amongst the Black African than the Indian subjects 
(33.7% vs. 16.2%, p<0.0001) and among males than females (Black African: 
53.3% vs. 14.9%, p<0.0001 and Indian: 29.5% vs. 5.4%, p<0.0001).  More Black 
African than Indian subjects consumed alcohol (37.3% vs. 4.4%, p<0.0001) and 
 
BA Females 
(n=187) 
Indian Females  
(n=187) 
P-value 
BA Males 
(n=181 ) 
Indian Males 
(n=160) 
P-value 
Ccalcium (mmol/L) 2.27±0.10 2.26±0.11 0.96 2.28±0.08 2.26±0.10 0.06 
Phosphate (mmol/L) 1.09±0.17 1.11±0.15 0.11 1.05±0.18 1.05±0.15 0.79 
TSH (miU/L) 1.96±1.16 2.41±1.62 0.002 1.97±1.09 2.44±1.71 0.002 
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males in each group consumed more alcohol than did their female counterparts 
(Black African: 45.3% vs. 29.6%, p=0.002 and Indian: 8.3% vs. 1.07%, p=0.001).  
 
 
5.3.5  Univariate Correlation Analysis  
Pearson correlations between BMD and all other variables are presented in Table 
5.2. Scatter plots are presented for subtotal BMD vs. all STLM, VAT and 
SCATvariables.  Lean mass was significantly correlated with all bone parameters 
in the two ethnic groups (all p<0.0001). Fat mass was positively associated with 
hip, femoral neck and lumbar BMD in both ethnic groups. Visceral adiposity 
correlated with hip BMD in the Black African group and with all BMD sites except 
lumbar spine in the Indian group was significantly correlated with sub-total, femoral 
neck and lumbar BMD in the Black African group and with BMD at all sites in the 
Indian group. 25(OH)D was significantly correlated with sub-total and hip BMD in 
both groups. PTH was inversely correlated with sub-total BMD in the Black African 
group and was not significantly correlated with any BMD measures in the Indian 
group. 
 
   
Figure 5.1 Scatter plot for Log Subtotal BMD (g/cm2) vs. Log Lean mass(kg).  
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Figure 5.2 Scatter plot for Log Subtotal BMD(g/cm2) vs. Visceral adipose tissue(VAT)(cm).  
 
Figure 5.3 Scatter plot for Log Subtotal BMD(g/cm2) vs. Log Subcutaneous adipose 
tissue(SCAT)(cm).  
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Table 5.2: Pearson Correlations for BMD by Ethnicity 
Variables 
BA (n=371) Indians (n=343) 
STBMD HBMD FNBMD LSBMD STBMD HBMD FNBMD LSBMD 
Age 
 (years) 
-0.004 
(0.94) 
-0.03 
(0.59) 
-0.22 
(0.0001) 
-0.08 
(0.13) 
-0.04 
(0.51) 
-0.02 
(0.71) 
-0.17 
(0.001) 
-0.06 
(0.24) 
Height 
(cm) 
0.47 
(<0.0001) 
0.20 
(<0.0001) 
0.09 
(0.06) 
0.15 
(0.005) 
0.54 
(<0.0001) 
0.27 
(<0.0001) 
0.19 
(0.04) 
0.12 
(0.02) 
25(OH)D 
(nmol/L) 
0.09 
(0.06) 
0.05 
(0.32) 
0.02 
(0.70) 
0.02 
(0.65) 
0.15 
(0.004) 
0.11 
(0.04) 
0.08 
(0.19) 
-0.02 
(0.63) 
Calcium  
(mmol/L) 
0.04 
(0.50) 
0.006 
(0.90) 
-0.01 
(0.81) 
-0.02 
(0.68) 
-0.11 
(0.007) 
-0.06 
(0.23) 
-0.06 
(0.22) 
0.03 
(0.53) 
Phosphate 
(mmol/L) 
-0.13 
(0.01) 
-0.13 
(0.01) 
-0.02 
(0.75) 
-0.08 
(0.12) 
-0.07 
(0.22) 
-0.07 
(0.72) 
-0.06 
(0.25) 
-0.03 
(0.55) 
PTH (pmol/L) 
-0.12 
(0.02) 
-0.08 
(0.12) 
-0.06 
(0.18) 
-0.01 
(0.82) 
-0.06 
(0.24) 
-0.01 
(0.77) 
-0.08 
(0.11) 
0.05 
(0.38) 
eGFR 
(ml/min/1.73m2) 
-0.17 
(0.0080) 
-0.15 
(0.002) 
-0.04 
(0.46) 
-0.09 
(0.08) 
-0.21 
(0.0001) 
-0.13 
(0.01) 
0.02 
(0.71) 
0.002 
(0.97) 
STFM (kg) 
-0.08 
(0.11) 
0.16 
(0.002) 
0.15 
(0.005) 
0.15 
(0.003) 
0.09 
(0.08) 
0.29 
(<0.0001) 
0.26 
(<0.0001) 
0.16 
(0.002) 
STLM (kg) 
0.61 
(<0.0001) 
0.54 
(<0.0001) 
0.36 
(<0.0001) 
0.28 
(<0.0001) 
0.71 
(<0.0001) 
0.55 
(<0.0001) 
0.39 
(<0.0001) 
0.25 
(<0.0001) 
VAT (cm) 
 
0.04 
(0.39) 
0.16 
(0.002) 
0.07 
(0.16) 
0.06 
(0.22) 
0.36 
(<0.0001) 
0.35 
(<0.0001) 
0.20 
(0.0001) 
0.06 
(0.21) 
SCAT (cm) 
-0.12 
(0.02) 
0.08 
(0.14) 
0.15 
(0.005) 
0.09 
(0.07) 
0.16 
(0.002) 
0.29 
(0.002) 
0.28 
(<0.0001) 
0.14 
(0.006) 
Key: BA=Black African Data given as R-values (p-values); STLM=subtotal lean mass, 
STFM=subtotal fat mass, VAT=visceral adiposity, SCAT=subcutaneous adipose tissue. 
STFM was transformed to normality, by taking the square root and the following were log 
transformed 25(OH)D, PTH, STLM, SCAT and all BMD except for L BMD. 
 
 
5.3.6  Multivariable Regression Models for BMD  
In the Black African group, 43% of the variance in sub-total BMD was explained by 
lean mass and visceral adiposity compared to the Indian group where 54% of the 
variance was explained by lean mass and fat mass. At the hip, lean mass and 
PTH explained 32% of the variance in BMD in the Black African group, whilst 39% 
of the variance was explained by the same variables in the Indian group. Age, lean 
mass and fat mass explained 18% of the variance in femoral BMD in the Black 
African group, while 29% of the variance in femoral BMD in the Indian group was 
explained by age, lean mass and PTH. At the lumbar spine 12% of the variance in 
BMD was explained by age, lean mass and fat mass in the Black African group, 
whilst 12% of the variance in BMD was explained by age, lean mass and visceral 
adiposity in the Indian group. We tested for interaction of body composition 
variables with both gender and ethnicity and noted a lack of significant interaction 
in both sets of analyses. The effect of body composition was not mediated by PTH, 
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as removal of PTH from regression models did not alter the β coefficient or p 
values for any body composition variables. 
 
Table 5.3: Multivariable Regression for Africans and Indians 
Ethnic 
group 
Dependent  
variables 
Independent  
variables 
β coefficient 
(95% CIs) 
P-value  
for β 
Unadjusted  
R
2
 (P value) 
Black 
African 
n=371 
STBMD 
 
Gender 
STLM ( 
VAT  
0.04 (0.02, 0.06) 
0.29 (0.24, 0.35)
 
-0.005 (-0.01,-
0.0003) 
0.001 
<0.0001 
0.037 
0.41  
(<0.0001) 
HBMD 
 
STFM 
STLM 
PTH 
0.02 (0.0003, 0.04) 
0.49 (0.41, 0.57) 
-0.11 (-0.12, -0.02) 
0.028 
<0.0001 
0.01 
0.33  
(<0.0001) 
FNBMD 
 
Age 
STFM 
STLM 
-0.05 (-0.08, -0.02) 
0.05 (0.03, 0.07) 
0.38 (0.30, 0.48) 
<0.0001 
<0.0001 
<0.0001 
 
0.18  
(<0.0001) 
LSBMD 
 
Age 
STFM 
STLM 
-0.05 (-0.08, -0.02) 
0.03 (0.01, 0.05) 
0.20 (0.13, 0.28) 
<0.0001 
0.001 
<0.0001 
0.12  
(<0.0001) 
 
Indian 
n=343 
STBMD 
 
Gender 
STLM 
STFM        
PTH       
-0.05 (-0.08,- 0.02) 
0.42 (0.34, -0.48) 
0.03(0.002,0.06) 
 -0.06 (-0.09,-0.02)         
0.002 
<0.0001 
0.032 
0.002 
0.54  
(<0.0001) 
HBMD 
 
Gender 
STLM 
PTH 
-0.11(-0.16,-0.07) 
0.61 (0.52, 0.71) 
-0.12 (-0.19, -0.05) 
0.038 
<0.0001 
0.001 
0.39  
(<0.0001) 
FNBMD 
 
STLM 
PTH 
0.58 (0.48, 0.68) 
-0.16 (-0.25,-0.08) 
<0.0001 
<0.0001 
0.29  
(<0.0001) 
LSBMD 
 
STLM 
VAT 
0.36 (0.26, 0.46) 
-0.013 (-0.02, -
0.003) 
<0.0001 
0.005 
0.12  
(<0.0001) 
Key: STBMD=sub-total BMD; HBMD=hip BMD; FNBMD=femoral neck BMD; 
LSMD=lumbar spine BMD; STFM=sub-total fat mass; STLM=subtotal lean mass; 
VAT=visceral adipose tissue thickness; SCAT=subcutaneous adipose tissue thickness; 
PTH=parathyroid hormone. STFM was transformed to achieve normality by taking the 
square root, the following were log transformed: subtotal, hip, femoral and hip BMD, PTH, 
25(OH)D and STLM. Units:BMD g/cm
2, 
PTH pmol/L, Age years VAT cm, STLM kg, STFM 
kg,  
 
5.3.7  ANCOVA Models for Detecting Variables that may contribute to Ethnic 
Differences in BMD 
 
Results are presented in Table 5.4 for sub-total and hip BMD only since the trends 
observed for femoral and lumbar BMD were very similar to those for hip and sub-
total BMD within each gender. In females, the effect of ethnicity on BMD was 
attenuated by the addition of lean mass into the model at all sites, particularly at 
the lumbar BMD where ethnicity was no longer significant when including lean 
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mass in the model; addition of lean mass reduced F-value for ethnicity from 10.4 
(p=0.001) to 1.80 (p=0.18). It appears that the effect of visceral adiposity on the 
ethnic difference in BMD seen in females is largely due to its correlation with lean 
mass (r=0.56, p<0.0001). Thus, addition of visceral adiposity to all ANCOVA 
models already containing lean mass as a covariate did not substantially attenuate 
the F-value for ethnicity, whilst the F-value for visceral adiposity was lowered and 
became insignificant for all skeletal sites. In males the ethnicity effect was 
attenuated slightly by the addition of 25(OH)D to the ANCOVA model for each 
skeletal site. 
 
Table 5.4: Contribution of Body Composition and 25(OH)D to Ethnic 
Differences in BMD at Selected Skeletal Sites in Males and 
Females as Assessed using ANCOVA  
Skeletal site; Gender 
Model 
Number 
Grouping Variable* 
and Covariates 
F-value; 
P-value 
Sub-total BMD; Female 
1 Ethnicity 42.7; <0.0001 
2 
Ethnicity 
STLM 
11.2; 0.0009 
115; <0.0001 
3 
Ethnicity 
VAT 
26.4; 0.0001 
27.1; <0.0001 
4 
Ethnicity 
STLM 
visceral adiposity 
10.8; 0.001 
141; <0.0001 
1.41; 0.23 
Sub-total BMD; Male 
1 Ethnicity 26.4; <0.0001 
2 
Ethnicity 
25(OH)D 
12.9; 0.0004 
0.65; 0.006 
Hip BMD; Female 1 Ethnicity 42.1; <0.0001 
2 Ethnicity 
STLM 
11.8; 0.0006 
151; <0.0001 
3 Ethnicity 
VAT 
23.3; <0.0001 
48.2; 0.02 
4 Ethnicity 
STLM 
VAT 
10.2; 0.002 
95.1; <0.0001 
1.83; 0.18 
Hip BMD; Male 1 Ethnicity 41.4; <0.0001 
2 Ethnicity 
25(OH)D 
23.5; <0.0001 
6.68 <0.01 
 
*
Within each model the grouping variable is ethnicity; for each skeletal site the first model is 
an ANOVA and subsequent models are ANCOVAs; STLM=subtotal lean mass, 
STFM=subtotal fat mass, VAT=visceral adiposity. STFM was transformed to achieve 
normality by taking the square root, and the following were log transformed 25(OH)D, 
STLM, SCAT and all BMD. BMD g/cm2, VAT cm, SCAT cm, 25(OH)D nmol/L 
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5.4  DISCUSSION 
In this group of apparently healthy adults we have shown that BMD is significantly 
higher at all sites in Black African compared to Indian subjects, and that lean mass 
was a significant contributor to all BMD sites in both ethnic groups. Differences in 
lean mass between Black African and Indian females mediated the difference in 
lumbar BMD between the ethnic groups in female subjects and contributed to 
differences in sub-total, hip and femoral BMD, whilst in males differences 25(OH)D 
contributed to a small degree to ethnic differences in BMD. Compared to the other 
BMD sites we were able to explain very little of the variance in lumbar BMD using 
the variables collected in this study.  
 
Our findings of a positive association between lean mass and BMD are in keeping 
with those of Amarendra et al (416) in their study of Indian men,  Chantler et al in 
African women (407) and others (422). This is the first report of the significant 
contribution of lean mass to BMD in black South African men. The positive 
association between lean mass and BMD remained after adjustment for fat mass, 
suggesting that the effects of lean mass on BMD are not entirely due to 
mechanical loading. Other contributory factors may include the pull of muscle 
contraction on bone and cytokines from muscle that influence muscle-bone cross 
talk (423). 
 
Several investigators have shown that black men and women have greater bone 
mass whilst Indians have lower bone mass than white subjects (407, 424, 425). 
The greater bone density in Black Africans may be protective of fractures given 
that fracture rates are similar in Indian and Caucasian women (426) whilst Black 
African have lower fracture rates compared to other ethnic groups (404). Our study 
showed that the Black African group had greater BMD at all four sites compared to 
the Indian group. In a comparison of BMD across four ethnic groups, Nam et al 
attributed the greater BMD in African American women compared to Asian women 
to differences in weight (427). In our study, body weight was greater in the Black 
African compared to Indian females, largely due to greater lean mass. When 
adjusting for differences in weight between the ethnic groups, BMD at all sites was 
still significantly higher in the Black African females, however the inclusion of lean 
mass together with ethnicity in ANCOVA resulted in an attenuation of the 
contribution of ethnicity to BMD at all sites, particularly at the lumbar spine. In 
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males, lean mass did not explain any of the differences observed in BMD between 
the ethnic groups possibly because lean mass was not different between Black 
African and Indian males. Genetic factors, which have been shown to be 
responsible for 50-80% of the variance at any age or in any population group (428) 
were not investigated in this study. 
 
The association between fat mass and BMD is contentious with some studies 
showing positive associations (429, 430), whilst others have reported negative 
associations (431, 432). This may be related to ethnic, age or gender differences 
between the populations studied. In this study, the effect of fat mass differed by 
ethnic group, being positively associated with hip, neck and lumbar BMD in the 
Black African group, but inversely associated with subtotal BMD in the Indian 
group. Fat may increase BMD by mechanical loading and the well as the 
conversion of androgens to oestrogens in adipose tissue (433) and  reduce  BMD 
via the effect of proinflammatory cytokines such as IL-6 and TNF-, which are 
increased in obesity (37), or through adiponectin levels which fall with increasing 
obesity. Ethnic differences in adipokines levels have been reported (434) and 
further investigation is warranted to determine if this may explain the different 
associations between BMD and fat mass observed in different ethnic groups in the 
current study. 
After adjusting for a number of covariates, visceral adiposity was negatively 
associated with lumbar BMD in the Indian group and subtotal BMD in the Black 
African group, while sub-cutaneous adiposity was not associated with BMD at any 
of the sites. Similar negative relationships between visceral adiposity and bone 
parameters have been reported in young women (435), young men (436) and 
obese men (437).  However despite several studies consistently showing an 
inverse association between visceral adiposity and BMD, the associations 
between sub-cutaneous adiposity and BMD  less consistent, with absent (435, 
438) positive (412) and negative (424) correlations all being reported. These 
inconsistent findings may be due to differences in body fat distribution between 
different populations, or in bone parameters studied. The consistent inverse 
relationship between visceral adiposity and BMD across studies, suggests that it is 
not influenced to the same degree as sub-cutaneous adiposity by various 
confounders (439). 
 
Only 12% of the variance in lumbar BMD in both African and Indian subjects was 
explained by the variables in the multiple regression models.  This is much lower 
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than the variance explained at other skeletal sites. Our results are similar to those 
of Chantler et al, who showed that body composition, socioeconomic factors and 
lifestyle only explained 22% of the variance at the lumbar spine compared to 33-
42% variance at other sites (407). The lumbar spine consists predominantly of 
trabecular bone, which is not influenced as much by mechanical forces as it is by 
the metabolic and hormonal mileau. It is possible that adipokines or hormones play 
a more important role in determining BMD at the lumbar spine than the variables 
that we have measured in this study. 
 
As far as we are aware this is the first study to report on visceral adiposity in Black 
African males, as well as the differences in body composition between Black 
African males and females from this region. The Black African women had more 
visceral adiposity than the Indian women, despite similar levels of total body fat.  A 
previous study has shown the reverse; however that investigation had a much 
lower N than the current study (9). Male Black African subjects had less visceral 
fat than their Indian counterparts due to the much greater level of total body fat in 
the latter group. The association of regional fat distribution with disease outcomes 
in black South African males and females requires further investigation.  
 
This is also the first study to report on subcutaneous adipose tissue differences 
among the two ethnic groups. A number of studies have shown that Indian females 
have greater subcutaneous adiposity compared to Indian males (440) similar to 
our findings. Two compartments of subcutaneous tissue have been described, 
superficial and deep subcutaneous, distinct anatomically and morphologically 
(441, 442). Women shown to have more superficial fat and men greater deep 
subcutaneous fat. These differences merit investigation in Black African 
populations to further our understanding of ethnic and gender disparities in health. 
 
Serum 25(OH)D levels contributed weakly to ethnic differences at all BMD sites in 
males but not in females. This may be a reflection of the relatively high 25(OH)D 
levels in African males (72.7nmol/L (IQR: 51.1, 94.1). Previous reports suggest 
that 25(OH)D  above a threshold of 50nmol/L(418, 443) or 75nmol/L(444) are 
associated with higher BMD, while other studies in which mean 25(O)D 
concentrations were  lower than 75nmol/L have shown no association between 
BMD and 25(OH)D (148, 445, 446). 
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Within the current study the BMD at all skeletal sites, except for the lumbar spine, 
correlated negatively with PTH in the Indian subjects whilst in the Black African 
group PTH correlated negatively with hip BMD only. Previous studies performed in 
Indian subjects have yielded similar results to ours, with 25(OH)D demonstrating 
no correlation to BMD but PTH showing an inverse association with BMD (419, 
447). Adult African-Americans are reported to show skeletal resistance to PTH 
(448) which may explain the lower incidence of osteoporotic fractures in black 
subjects. Whether this is true of the Black African population in South Africa 
remains to be confirmed. 
 
A major strength of this study is the bi-ethnic sample of males and females with 
quantitative measures of BMD using dual energy x-ray absorptiometry. However 
this was a cross sectional study and while linear regression models can be used to 
explore relationships between predictors and outcomes they do not prove a cause-
effect relationship. As we did not have data on the menopausal status of the 
female subjects age was categorized as < 50 years or > 50 years. Data from our 
centre suggests that African females attain menopause at a mean age of close to 
50 years (Jaff et al., unpublished data). We have not measured sex hormones or 
serum adipokines, which are related to fat mass and may have contributed to the 
BMD at the different skeletal sites or on physical activity, which may also 
contribute to BMD. A further limitation of this study is that ultrasound was used to 
measure visceral and subcutaneous adiposity and this method is not the current 
gold standard technique. However previous studies, including one performed in 
black South African subjects (23), have reported ultrasound as being a precise and 
reliable method of measurement (339, 449). 
 
5.5  CONCLUSIONS 
In conclusion, we have shown that whole body and site-specific BMD is 
significantly higher in Black African males and females compared to Indians of a 
similar age which may explain the differential fracture risk between these ethnic 
groups (404). We have shown that lean mass significantly contributed to BMD at 
all sites in both ethnic groups and visceral adiposity contributed negatively and 
differentially to BMD sites in the two ethnic groups. As significantly less of the 
variance in lumbar BMD, in both ethnic groups, could be explained compared to 
the other sites future studies should endeavour to determine what other factors 
contribute to BMD at this site in these population groups. Public health 
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interventions aimed at improving bone health should include efforts to increase 
lean mass and reduce abdominal obesity.
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CHAPTER 6 
6. DISCUSSION AND CONCLUSIONS 
This chapter summarises the results of the study, highlighting key points in table 
6.1. 
 
6.1  SUMMARY OF FINDINGS 
The hypothesis to be tested in this thesis was that ethnic differences in vitamin D 
status contribute to ethnic differences in metabolic syndrome or its components 
and to ethnic differences in BMD. 
 
Table 6.1: Consolidated Findings 
Objectives Chapter Evidence 
1. Describe the 
prevalence of 25(OH)D 
deficiency in Black 
Africans and Indians in 
Johannesburg 
3 Using a cut off of 25(OH)D of <30nmol/L to define 
deficiency the prevalence of deficiency was 28.5% 
in Indians as opposed to 5.1% in Black Africans 
(p<0.0001).  
2. Identify predictors of 
25(OH)D serum levels 
3  Parathyroid hormone (PTH) was negatively 
associated with 25(OH)D while season and 
sunshine exposure were positive predictors 
explaining 16% of the variance (p<0.0001) in Black 
Africans. In Indians, PTH was negatively associated 
with 25(OH)D while male gender, season and 
calcium supplementation were positive predictors 
and explained 17% of the variance of 25(OH)D 
(P<0.0001).  
3. Examine the 
relationship between 
body fat distribution 
and 25(OH)D levels 
3 In multivariate regression analysis, neither total 
body fat nor body fat distribution was predictive of 
25(OH)D in either group. 
 
4. Test the association of  
25(OH)D or PTH with 
Met S in Black Africans 
and Indians in 
Johannesburg 
 
4 Met S was diagnosed in 29% of the Black African 
and 46% of the Indian subjects (p<0.0001). 
Subjects with Met S had higher PTH than those 
without Met S, (p<0.0001), whilst 25(OH)D levels 
were not significantly different (p=0.50). 
Determine if 25(OH)D or 
PTH explained ethnic 
differences in the 
prevalence of Met S and 
its individual 
components.   
4 In multivariate analysis, 25(OH)D was not 
associated with any components of the Met S 
however PTH was shown to be positively 
associated with systolic (p=0.018) and diastolic 
(p=0.005) blood pressures and waist circumference 
(p<0.0001) and negatively associated with  HOMA 
(p=0.0008) levels. Logistic regression analysis 
showed that Indian ethnicity (OR 2.24; 95% CIs 
1.57, 3.18; p<0.0001) and raised PTH (OR 2.48; 
95% CIs 1.01, 6.08; p=0.04; adjusted for 25(OH)D) 
produced an increased risk of Met S but 25(OH)D 
did not (OR 1.25; 95% CI 0.67, 2.24; p=0.48) 
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Table 6.1 continued 
Objectives Chapter Evidence 
5. Compare the body 
composition, including 
BMD, of Black African 
black men and women 
to Indian men and 
women.   
5 Black African females were significantly heavier and 
had a greater BMI than Indian females (p=0.001), 
but waist circumference was not significantly 
different (p=0.9), whilst Black African males 
weighed less (p<0.0001), had a lower BMI 
(p=0.002) and a lower waist circumference than 
Indian males (p<0.0001).  
VAT was significantly higher in Black African 
females and Indian males compared to their same 
sex counterparts, and SCAT was significantly lower 
in Black African males compared to Indian males. 
All BMD measures were significantly higher in Black 
African males and females compared to their Indian 
counterparts.  These differences remained 
significant after adjusting for age, height, weight and 
site-specific bone area. 
 
6. Understand how body 
composition contributes 
to BMD at various 
skeletal sites in both 
ethnic groups, and 
 
5 Whole body lean mass positively associated with 
BMD at all sites in both ethnic groups (p<0.001 for 
all), and partially explained the higher BMD in Black 
African females compared to Indian females. Whole 
body fat mass correlated positively with lumbar 
BMD in Black African (p=0.001) and inversely with 
sub total BMD in Indian subjects (p<0.0001). 
Visceral adiposity correlated inversely with sub total 
BMD in the Black African (p=0.037) and with lumbar 
BMD in the Indian group (p=0.005). 
7. Determine whether the 
effects of body 
composition on BMD at 
various skeletal sites 
are mediated via PTH 
or 25(OH)D.  
 
5 No association was found between serum 25(OH)D 
and BMD. PTH was inversely associated with hip 
BMD in the Black African group (p=0.01) and with 
sub total (p=0.002), hip (p=0.001) and femoral BMD 
(p<0.0001) in the Indian group. 
 
Key: BMD=bone mineral density, STBMD= subtotal BMD, HBMD= hip BMD, LSBMD= 
lumbar spine BMD, VAT=visceral adipose tissue, Met S=metabolic syndrome  
 
 
 
In summary this study has highlighted a number of points: 
1) The high prevalence of 25(OH)D deficiency and insufficiency in the Indian 
population, particularly in women 
2) The association of PTH with Met S in both ethnic groups 
3)  Differences in body composition among ethnic groups 
In view of the unexpected findings of the lack of association of vitamin D with 
the Met S and the contribution of PTH to Met S an alternative hypothesis is that 
PTH increases risk of Met S 
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6.1.1  Vitamin D Deficiency and Insufficiency 
Prevalence 
This is the first large study from South Africa to report on the prevalence of vitamin 
D deficiency in Black African and Indian populations. It highlighted the high 
prevalence of 25(OH)D deficiency in the Indian population, with the Black African 
population being relatively 25(OH)D replete. 25(OH)D levels in South African 
women have been shown to be above 50nmol/L, not only in this study but also by 
Hamill et al (450) in HIV positive women from the Johannesburg area and by 
Kruger et al (300) in urban women from the North West province. There appear to 
be no data on Black African men or on the Indian population resident in this area. 
It is interesting that the prevalence of vitamin D deficiency as defined by a serum 
25(OH)D level below 30nmol/L was 28.6% in Indians vs. 5.1% in Africans. While it 
is difficult to compare data across studies due to differences in cut offs used to 
define vitamin D deficiency, the prevalence of vitamin D deficiency appears to be 
high in Indians across the globe (90, 451), including those who living in sunny 
countries (180, 452). A prospective cohort study from the Greater Manchester area 
in the UK noted that lifestyle differences  including  exposure to sunshine lead to 
lower 25(OH)D concentrations in Indians in comparison to Caucasians (362). 
While this thesis did not determine the reason for the differences observed, it is 
possible that these arose largely as a result of cultural practices.  
 
Seasonal Variation and Sunshine Exposure 
Seasonal variations in 25(OH)D levels were noted in all groups, with the lowest 
levels of 25(OH)D for winter and spring collections. The highest levels were noted 
in summer and early autumn which is consistent with other studies worldwide. 
However, it is not known whether serum levels obtained at a single time point are 
reflective of long term 25(OH)D levels and there are limited data on tracking 
vitamin D levels. Jorde et al tracked serum 25(OH)D over 14 years in a Norwegian 
cohort and noted a correlation of between 0.42 and 0.52 (453), concluding that a 
single measurement was sufficient to predict future outcomes. These studies 
should be repeated to test whether this is true of other populations.  
As discussed in chapter 3, sun exposure scores were similar for both ethnic 
groups, but differed by gender within groups.  
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6.1.2  Metabolic Syndrome, 25(OH)D and PTH 
Prevalence 
We noted a Met S prevalence of 29% in Africans compared with 49% in Indians 
using the harmonized definition of the Met S. While nationally representative data 
are lacking from South Asian countries, a study conducted in Karachi, Pakistan 
showed a prevalence of 34.8-49% according to the International Diabetes 
Federation (IDF) and the National Cholesterol Education Program Treatment 
Panel III (NCEP ATP III) criteria (454), and data from India suggest that up to one 
third of the urban population has the Met S (31, 455). Similarly, there are limited 
data on the prevalence of the Met S in South African populations. Using the 
harmonized definition of the Met S, Crowther et al noted a prevalence of 42.1% in 
urban women (331), while a study conducted in a rural population of men and 
women gave a prevalence of 22.1% (28). The high prevalence of the Met S in our 
study as well as in the study by Crowther et al was due mainly to abdominal 
obesity.  
 
While 25(OH)D has been associated with individual components of the Met S and 
with the Met S itself, this was not true of the group we studied. As described in the 
introduction, the results of observational studies on the association of 25(OH)D 
with the Met S often yield conflicting results, but generally suggest that there is an 
association between 25(OH)D and blood glucose levels. There are several 
possible reasons for these inconsistencies that have been discussed in the 
introduction, including failure to adjust for BMI. However it is possible that there is 
a threshold 25(OH)D level below which metabolic effects are seen. In a single 
longitudinal study of high risk individuals followed up over five years, Lim et al 
noted that the hazards ratio for T2DM was greatest for those with concentrations 
<25nmol/L compared to those above 50nmol/L (271). It is also possible that the 
differences observed may be as a result of low levels of free or bioavailable 
25(OH)D resulting from variation in the affinity of vitamin D binding protein (DBP) 
for 25(OH)D. DBP  is the primary vitamin D carrier protein, binding 85-90% of total 
circulating 25(OH)D (456). Less than 1% of total 25(OH)D is in the free form. DBP 
appears to inhibit some of the actions of vitamin D, because the bound fraction 
may not be bound to target cells (457). Genetic polymorphisms in DBP produce 
variants that differ in their affinity for 25(OH)D and the prevalence of these 
polymorphisms varies across populations (458, 459). All assays that are currently 
in use for diagnostic purposes measure total 25(OH)D without distinguishing free 
or bioavailable 25(OH) from the bound form.  
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PTH and the Met S 
We have shown that PTH is higher in subjects with the Met S. This is in keeping 
with a number of other studies in adults (255, 382). PTH has also been shown to 
be an independent predictor of insulin resistance and inflammation in adolescents 
(460). Even a modest elevation of PTH is associated with increased risk of death 
from cardiovascular causes (461, 462). In addition observational studies link PTH 
to a higher risk of diabetes, hypertension, hyperlipidaemia and cardiovascular 
disease(390, 463, 464). PTH levels are inversely related to 25(OH)D levels, rise in 
chronic renal disease and with increased obesity (148, 465, 466). There are a 
number of possible reasons for the rise in PTH that occurs with obesity, one being 
the inverse relationship of 25(OH)D with obesity. It has been postulated that this is 
due to sequestration of vitamin D in fat (316, 467), reduced physical activity and 
time spent in the sun (468). Another candidate for the positive association between 
fat mass and PTH is leptin, levels of which are increased with obesity. 
Administration of leptin to deficient mice (ob/ob) greatly increases PTH suggesting 
that leptin is a PTH secretagogue (469). Leptin has been shown to be a predictor 
of PTH and FGF 23 (397).The resultant increased PTH may then affect 
cardiovascular function by altered vascular reactivity possibly by interfering with 
endothelial function (470). Secondly, PTH may increase cardiovascular risk by 
increasing blood pressure. A positive association between PTH and blood 
pressure has been reported not just in our study, but by other investigators (471-
473). Supportive clinical evidence comes is shown in studies from patients with 
primary hyperparathyroidism who have enhanced responsiveness to pressor 
agents such as angiotensin II (474). In addition, increased PTH levels stimulate 
renin and aldosterone synthesis, both of which are important mediators in arterial 
hypertension, by increasing intracellular calcium levels (475). A third mechanism 
whereby PTH can increase the risk of cardiovascular disease is via altered insulin 
sensitivity and secretion perhaps via calcium (476). Therefore an alternative 
hypothesis to the 25(OH)D theory is that PTH may not be an innocent bystander 
but may be directly involved in the pathogenesis of cardiovascular disease (see 
figure 6.1). 
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Figure 6.1: The Role of PTH in the Met S 
 
6.1.3 The Role of Body Composition, 25(OH)D and PTH on Bone Mineral Density in 
Black Africans and Indians 
 
Since both PTH and 25(OH)D are important in maintenance of bone health which 
is also affected by lean mass and fat mass the third paper examined differences in 
body composition between Black Africans and Indians as well as the effect of body 
composition, 25(OH)D and PTH on bone mineral density.  
 
Osteoporosis is characterized by compromised bone density that predisposes 
affected individuals to increased fracture risk (477). Extensive epidemiological data 
has shown that high BMI is associated with increased bone mass, and that 
reductions in body weight may cause bone loss (478, 479). However there are 
also data suggesting that obesity may have a detrimental effect on bone. For 
example obesity and osteoporosis co-exist in subjects with T2DM (480). Apart 
from the effect on BMD in older people, it has also been associated with increased 
fracture risk in young adults and children (481, 482). There are limited data from 
Africa on BMD or its predictors. A systematic review of worldwide hip fracture 
incidence and probability of fracture (483) reported South Africa as being a low risk 
area referencing a 1968 study as the reference (404). The table below 
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summarizes the findings of some studies that have compared BMD in Africans or 
Indians to BMD in Caucasians. 
 
Table 6.2: Comparisons of Bone Mineral Density of Africans and Indians  
with Caucasians as the reference 
    
Study population (reference) Bone 
Site  
N Results 
US adults NHANES  
NHB and Mexican Americans 
,(484)  
LS  7912 LS BMD >> in NHB compared to 
Caucasians 
 
#Osteoporosis Fractures in 
men Study(US adults, Afro-
Caribbean, Hong Kong 
Chinese and South Korean 
(485) 
FN 
H 
LS 
4074 
Caucasian, 
627 African 
American, 
 
BMD at all three sites >> in African-
American compared to Caucasians 
South African Black African 
and Caucasian women (407) 
FN 
H 
LS 
 BMD FN and H >> in  Black African 
compared to Caucasians but << at 
LS 
 
Indians males and females 
compared to Caucasian 
database for densitometer 
(425) 
FN 
H 
S 
FT 
IT 
1137 Indians Indians had << BMD at all sites 
## Indian females compared 
to reference values for US 
Caucasian females (486) 
H 
LS 
2034 Indian 
women 
Indians had lower BMD of LS 
compared with US Caucasian 
females 
 
Key: NHB=Non-Hispanic Blacks, LS =Lumbar Spine, FN=Femoral Neck, H=Hip, 
LS=Lumbar Spine, FT=Femoral Trochanter, IT-Intertrochanteric 
# African included US and Tobago African American. 
## Database established from 1472 white women for spine data and 1487 white women for 
femur 
 
There are no published data on BMD in Black African men and as far as we are 
aware our study is the first report on BMD in Black South African males. In chapter 
five we noted that Black African subjects had greater BMD than Indian subjects.  
In both ethnic groups lean mass was the major contributor to BMD. The results of 
this thesis show that there are racial differences in total lean mass for subjects with 
similar BMI. We showed that lean mass was significantly higher in Black African 
women compared with Indian women, while BMI was not significantly different for 
these groups. Although BMI was significantly higher in Indian men compared to 
Black African men, lean mass did not differ. Black women have been shown to 
have greater lean mass than Caucasian women (487, 488) while Chinese and 
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South Asian men and women have been shown to have less lean mass than 
Caucasians (433).  
 
Another observation was that while total fat mass was significantly lower in Black 
African men compared to Black African women, this was largely due to greater 
subcutaneous adiposity in African women as visceral adiposity was not 
significantly different. We reported greater visceral adiposity among African 
women compared to Indian women. This is contrary to a previous study from our 
center by Waisberg et al (402), with the main differences being that in our study 
visceral adiposity was measured by ultrasound which is not the gold standard, 
whereas CT was used in the other study and in Waisberg‟s study the subject 
numbers were small. In spite of greater visceral adiposity in African women, we 
showed that HOMA-IR was greater in Indian subjects compared with African 
subjects (chapter three).   
 
There are data to suggest that factors other than the amount of adipose tissue 
may be involved in disease pathogenesis. Up to 25% of morbidly obese subjects 
are insulin sensitive (489). The non-adipose contributors to insulin sensitivity are 
not well defined but may include differences in inflammatory cytokines, adipokine 
secretion, AMP kinase activity and oxidative stress (490) and amount of lean mass 
(491). Lean mass, which is predominantly skeletal muscle, is a primary target of 
insulin action and increases are associated with improved insulin sensitivity (492). 
While the adverse health effects of excess fat are well established, the impact of 
low lean mass is only beginning to be considered. Reduced lean mass is 
associated with reduced bone mineral density, poorer clinical outcomes (493) and 
with cardiovascular risk (494). Therefore, although much attention has been paid to 
differences in fat mass, variability in lean mass and lean mass distribution may be 
equally important.  
 
PTH was inversely and differentially associated with BMD sites for both ethnic 
groups, while 25(OH)D was not associated with BMD at any site in either group. 
However, in our study it contributed minimally to differences in BMD between 
African and Indian males.  
 
The relationship between serum 25(OH)D and BMD has been shown to differ 
between black and Caucasian races (447, 495-497). Although African-Americans 
have lower levels of 25(OH)D than do Caucasian Americans, they have a lower 
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prevalence of osteoporosis (498). Secondary hyperparathyroidism has been 
proposed as the mechanism whereby hypovitaminosis D causes low BMD.  
 
PTH increases mainly cortical, but also trabecular bone turnover (495, 499). The 
relationship between 25(OH)D, PTH and BMD has been shown to differ by race in 
studies from the United States (148). Whether this is true of other populations in 
southern Africa remains to be determined.  
 
6.2  THEORETICAL, LOCAL AND NATIONAL RELEVANCE 
We have shown a very high prevalence of the Met S in Black Africans and Indians, 
across a wide age spectrum, using the harmonized definition of the Met S. This is 
an indicator of cardiovascular risk and contributes to the already existing body of 
knowledge on the scale of NCDs in South Africa. A recently published South 
African survey noted that the prevalence of NCDs based on self-report was 51.8% 
in people over the age of 50 (500). It can be attributed to a number of factors 
including lifestyle, socio-economic status, ethnicity and urbanization.  
 
Furthermore, while we have shown that the prevalence of vitamin D deficiency was 
high in the Indian population, it did not predict the Met S in either population group. 
PTH was predictive of the Met S in both groups, and as discussed, PTH is 
influenced, possibly directly by fat. More than one in two South African women and 
one in three adult men are either overweight or obese (9). We also noted 
significant differences in body composition between the groups which may 
contribute to disease risk.  
 
In the 1980s Barker proposed that many nutritional events that occur in 
intrauterine life and early in infancy influence the development of adult diseases 
(501). While we did not find an association of 25(OH)D with either the Met S or 
BMD, we do not know how vitamin D deficiency in the intrauterine environment 
contributes to increased cardiovascular disease. Incorporating this hypothesis, the 
interrelationships illustrated in Figure 1.4 (chapter 1) can be modified to give a 
conceptual framework as illustrated in Figure 6.2.  One addition, worth considering 
is the addition of PTH into the model.  
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Figure 6.2: Possible Interrelationships between PTH, Traditional Risk 
Factors and Non-Communicable Diseases 
 
6.3  AREAS OF FUTURE RESEARCH  
As this was a cross sectional study the results presented cannot prove causality, 
and longitudinal studies would be useful to further investigate some of the 
associations noted in the thesis.  
 
The Relationship of PTH to Cardiovascular Risk and Body Fat in Black 
African and Indian Populations 
PTH has been shown to be positively related to BMI and body fat. It is not known if 
both visceral and subcutaneous adiposity are involved in this association or 
whether adipose tissue secretes PTH, or if all secreted PTH arises from the 
parathyroid gland.  
 
It would also be necessary to carry out a longitudinal study to investigate how PTH 
and 25(OH)D change over time and how these changes affect disease risk. The 
PTH/25(OH)D threshold varies with ethnicity and has not been determined for 
Africans or Indians. We would like to determine this threshold in a larger group of 
subjects. 
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The Relationship between DBP, Total 25(OH)D and Free 25(OH)D 
There are several possible reasons for the lack of association of 25(OH)D with the 
Met S. One being that it is inappropriate to define deficiency at levels <30 nmol/L 
of total 25(OH)D in our populations. The free hormone hypothesis postulates that 
only hormones liberated from binding proteins enter the cells and produce 
biological action (502). 25(OH)D and 1,25(OH)D circulate bound to DBP and 
albumin with less than one percent in the free form (503). Recent data from the 
United States has shown that while black subjects had lower total 25(OH)D than 
whites they had similar concentrations of bioavailable 25(OH)D (504). 
Polymorphisms in DBP contribute to variation in free 25(OH)D. At present there 
are no data on DBP concentrations or polymorphisms in Black African or Indian 
populations. It is important to determine what the concentrations of DBP are in 
these populations and how these relate to free 25(OH)D levels and to PTH levels. 
It is also important to determine what the PTH/ bioavailable 25(OH)D threshold is 
in these populations are, which may provide an indication of optimal 25(OH)D 
levels in these groups. Identifying those individuals with a true deficit will allow for 
interventions for those individuals most likely to benefit.  
 
The Effect of Vitamin D Deficiency on Pregnancy and Child Outcomes 
Another area for future research is the effect that low levels of 25(OH)D may have 
on pregnancy and on neonatal and infant outcomes. During pregnancy, maternal 
25(OH)D levels may decrease, particularly during the third trimester (505). At birth, 
cord blood 25(OH)D levels are directly correlated with maternal levels (506). Since 
Indian women are clearly an at-risk population, it would be important to follow up a 
cohort of women to investigate levels seen in the two groups and the effects, if 
any, on pregnancy and neonatal outcomes. A recent systematic review and meta-
analysis of observational studies showed that vitamin D insufficiency was 
associated with an increased risk of gestational diabetes, pre-eclampsia, small for 
gestational age babies and bacterial vaginosis (507). In nested case control 
studies mid-gestation 25(OH)D levels of <50nmol/L were associated with almost 4 
fold odds of severe pre-eclampsia (508) and levels <37.5nmol/L with a 5 fold risk 
of severe pre-eclampsia (509). Risk factors for pre-eclampsia include increased 
BMI, diabetes, chronic renal disease and hypertension as well as multiple 
pregnancies (510). Several of the above are also risk factors for 25(OH)D 
deficiency. Additional concerns are the effects of maternal 25(OH)D deficiency on 
the skeleton of the foetus.  
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6.4  LIMITATIONS  
Subjects were recruited via caregivers of the Birth to Twenty cohort, and though 
the caregivers were randomly selected, there may be bias which would affect the 
generalizability of the findings beyond the study population. Furthermore, the Birth 
to Twenty cohort represents a group of subjects based in Johannesburg. The 
caregivers represent long-standing residents of Johannesburg and do not include 
recent migrants and may not be representative of contemporary Johannesburg.  It 
can be argued that Johannesburg is not representative of Black African and Indian 
populations living in other parts of the country and as such the thesis findings 
represent specific subpopulations within South Africa. Whether these data can be 
generalizable to other areas in the country is speculative. However the research 
highlights the importance of conducting similar studies in different South African 
settings and population groups. 
 
This study was cross-sectional and as such does not prove causality for any of the 
associations described. All biochemical measurements were performed at a single 
time point and may not necessarily be indicative of long-term status. For 
assessment of predictors of 25(OH)D deficiency, it would have been ideal to have 
used a dosimeter to assess sunshine exposure. The sunshine exposure score that 
we used has been used in a number of studies but has not been validated (341). 
We carried out a limited assessment of vitamin D and calcium intake from diet, and 
calcium and vitamin D supplementation was determined as a „yes‟ or „no‟ response 
and was not quantified. We have suggested that wearing of the veil may be the 
cause for the lower vitamin D levels in Indian women however we did not assess 
how many Indian women used the veil. We also did not assess how many were 
vegetarians. Studies report contradictory results on the relationship between a 
strict vegetarian diet and vitamin D deficiency. Low serum vitamin D levels and low 
bone mass have been reported in some vegan groups who do not take vitamin D 
supplements (511). On the other hand Chan et al in a comparison of vegetarians, 
partial vegetarians and non-vegetarians noted that 25(OH)D levels were not 
associated with vegetarian status (512) 
 
HIV-infection was based on self-report. This may not yield reliable results due to 
stigmatization or not being tested. In addition the type of ART that subjects took 
was not recorded. Hamill et al noted that there was no difference in vitamin D or 
BMD between South African women eligible to receive anti-retrovirals, and those 
infected but with preserved CD4 counts as well as with healthy 
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controls(450).There are reports that the use of Tenofovir is associated with 
significant loss of BMD (513)  
 
This study was not primarily designed to look at reasons for differences in BMD. 
Socio- economic status and lifestyle (407) have been shown to contribute to 
variance in BMD. We assessed education as a proxy for socio-economic status 
and it did not correlate with BMD.  It would have been preferable to use a 
questionnaire that determined employment activity, housing density and physical 
activity as these may have provided some data on reasons for differences in BMD 
between the different ethnic groups. Other important contributors to BMD include 
sex steroids and these were not measured. Visceral adiposity and subcutaneous 
adiposity were determined by ultrasound assessment of thickness and not CT 
scan or MRI. However, the ultrasound measurement of body fat depots has been 
validated against a gold standard (339).  
 
 
6.5  CONCLUSIONS 
This thesis set out to determine the prevalence of vitamin D deficiency in Black 
Africans and Indians living in Johannesburg. It also was designed to determine if 
25(OH)D or PTH contributed to cardiovascular disease in both populations. The 
final aim was to determine differences in body composition and the role of 
25(OH)D and PTH in BMD in both populations.  
 
This thesis provided evidence for an association of PTH with the Met S via its 
positive association with blood pressure and waist circumference, and an inverse 
association of PTH with BMD at a number of skeletal sites in both Black Africans 
and Indians. Longitudinal studies are needed to confirm these findings and to 
explore the relationship between fat and PTH.  
 
The data from this thesis do not support the notion that either bone mineral density 
or cardiovascular risk is compromised by 25(OH)D levels. Overall it is important 
that we identify the vitamin D levels associated with best health in our population 
groups. Until we have the results of studies designed to determine the thresholds 
of vitamin D that are associated with optimal health in our populations it is 
inappropriate to define 25(OH)D levels of less than 50nmol/L as insufficient, as this 
implies that supplementation is required and we have no clinical evidence from 
South Africa that this cut-point is appropriate to treat. . 
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Study of Vitamin D and Cardiometabolic risk 
FOOD FREQUENCY QUESTIONNAIRE (FFQ) 2011 
 
  
  
     
 
 
 
 
 
 
FOOD HABITS 
1.  Are you on a special diet that has been prescribed for you e.g. by a doctor or one 
that you have adopted from someone e.g. a TV star/magazine? 
YES 1 
NO 0 
 
2.  If NO, go to question 4. 
  If YES, describe what kind of diet you are on and where you got the diet from?  
  ________________________________________________________________ 
 
3.   How long have you been on that diet? __________ months/years 
 
4.  Do you currently take any vitamin and mineral supplements?    
YES 1 
NO 0 
   
 IF YES, what do you take? 
 
 
 Name of product 
Amount/day 
(or how many tablets) 
Vitamins/vitamins and minerals   
Tonics   
Vitamin D   
Calcium   
Body building preparations   
Dietary fibre supplement   
Other: specify   
 
DATE:  Day     Month  Year     
 
 
BTT ID NUMBER:       
 
DCR ID NUMBER:     
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5.  Which meals do you skip almost on a daily basis? 
 
 
 
 
 
6.   Is salt added to your food while it is being cooked? 
Always 1 
Sometimes 2 
Never 3 
Don‟t know 4 
 
7.   Do you add salt to your food before you eat it? 
YES 1 
NO 0 
 
8.   If yes, how much salt do you add to your food each day? 
¼ teaspoon 1 
½ teaspoon 2 
¾ teaspoon 3 
1 teaspoon 4 
Other  specify: 5 
 
9.  Do you add Aromat to your food before you eat it? 
YES 1 
NO 0 
 
10.  If yes, how much Aromat do you add to your food each day? 
¼ teaspoon 1 
½ teaspoon 2 
¾ teaspoon 3 
1 teaspoon 4 
Other  specify: 5 
Breakfast 1 
Lunch 2 
Evening meal 3 
None 4 
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11. There are some factors which influence the choice of foods we eat.  Which of the  
following statements are true for you?  
 
  
 
 
 
 
 
 
 
 
 
 
12.  Do you ever eat outside the home  e.g. at  fast food shops such as Nandos, KFC 
and Steers?  
 
YES 1 
NO 0 
 
13.  If YES, in an average month how often do you eat at the following places?  
 Frequency of visits 
 Times/week Times/month Rarely/never 
Nandos    
Spur    
Macdonalds    
Steers    
KFC    
Chicken Licken    
Debonaire‟s Pizza    
Romans    
Anat    
Wimpy    
Something fishy    
Fontana    
Chinese takeaway    
Other restaurants/takeaways    
(Quarters from tuck shop)    
 Strongly 
agree 
Agree Disagree Strongly 
Disagree 
I choose to eat certain foods because they 
taste good 
1 2 3 4 
The food I eat depends on whether it is 
expensive  
1 2 3 4 
I choose to eat certain foods because it looks 
good 
1 2 3 4 
The food I choose to eat differs according to 
my mood (i.e. happy/sad) 
1 2 3 4 
My hunger level determines what type of food 
I eat. 
1 2 3 4 
I choose foods which are not time consuming 
to prepare 
1 2 3 4 
I consider whether a food is good for my 
health before eating the food. 
1 2 3 4 
 Generic 
Sketch 
(look 
up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes 
C.  
Item  
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
 DAIRY-BLUE          
 
1.Tea 
Ordinary  4038       
 Herbal  4053       
 Rooibos  4054       
 1. Sugar in tea   3989       
 
2. Milk in tea 
Full cream  2718       
 Low fat 2%  2772       
 Skim fat free  2775       
 Other         
 1. Coffee   4037       
 
2. Milk in coffee  
Full cream  2718       
 Low fat 2%  2772       
  Skim fat free  2775       
  Other         
 2. Sugar in coffee   3989       
 
2. Milk as a drink 
Full cream  2718       
 Low fat 2%  2772       
 Skim fat free  2775       
 
3. Buttermilk/maas 
Buttermilk  2713       
 Maas  2787       
          
 4. Milk drinks, flavoured          
           
           
X 5. Yoghurt Fruit, LF, sweetnd  2732       
  Plain LF  2734       
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Generic 
Sketch 
(look 
up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes 
 
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
 3. Breakfast cereals          
 2. Milk added to cereal          
 1. Sugar added to cereal   3989       
 9. Ice cream Full cream  3519       
  Low fat  4325       
 9. Ice lollies   3982       
 ASK ABOUT TYPE OF BREAD,THICKNESS OF SLICES AND THE SPREAD  
 1. Bread/rolls  White  3210       
  Brown  3211       
  Whole wheat  3212       
  Traditional  3210       
  Roti         
 Spread? Y / N Brand name Do you use spread every day on your bread?    
 1. Brick margarine HM  3484       
 1. Tub margarine PUM  3496       
 1. other tub e.g. floro   3521       
 1. Butter   3479       
 Cheese spread WM  2730       
 Fish paste   3109       
 Honey/syrup   3988       
 Jam   3985       
circle 
Marmite/ 
Bovril 
  
4030/ 
4029 
      
 Sandwich spread   3522       
 Peanut butter   3485       
 Chocolate spread   9999       
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Generic 
Sketch 
(look 
up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes 
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
 Cold meats Ham  2969       
  Polony  2919       
  Salami  2948       
 6. Cottage cheese Low fat  2729       
  Full fat  2759       
X 7. Cheddar    2722       
 7. Gouda   2723       
 7. Other cheese          
 8. Cheese wedges   2728       
 2. Fat cakes   3257       
 Any topping?          
(Red) QUARTER Tick toppings:        
 White bread   3210 ¼ loaf  = 225      
 Fried Chips   3740 1 portion = 90       
 Cheese   2722 ___ slices x 20 =      
 Polony / French    2919 ___ slices x 15=      
 Vienna (Russian)   2936 ___ unit x 40 =      
 Fried egg   2869 ___ medium x 45 =      
 Atchar   3117 ___ Tsp x 40 =      
 Tomato sauce   3169  ___Tsp x 25 =      
Other Roti          
Other           
 Mashed potato   3876   ¼ cup = 62.5       
 Mince meat, regular   2987       
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Generic 
Sketch 
(look 
up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes 
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
           
 4.  Maize porridge stiff     3400       
 4.  Maize porridge soft          
 2. Milk on soft porridge          
 1. Sugar on soft porridge   3989       
 1. Fat on soft porridge          
 4. Mabele/maltabella stiff   3241       
 4. Mabele soft          
 2. Milk on Mabele          
 1. Sugar on Mabele   3989       
 1. Fat on Mabele          
 4. Oats   3239       
 2. Milk on Oats          
 1. Sugar on Oats   3989       
 4. Maize and pumpkin porridge          
 5.  Pasta/Pasta dishes          
 Remember to ask about added cheese! Grated?         
           
           
 6. Spaghetti Bolognaise Regular mince  3260       
           
 6. Macaroni and cheese WH, HM  3301       
 6. Lasagne Regular  3261       
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Generic 
Sketch 
(look up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes 
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
 7. Rice White  3247       
  Brown  3315       
  With fat?         
 Biriyani          
 7. Samp/mealie rice With fat?         
 7. Samp and beans With fat?  3402       
 7. Wheat rice   3249       
X 8. Pizza Vegetable topping         
  Meat topping         
  
Meat and 
vegetables 
        
 8. Savoury tart          
           
X EGGS-YELLOW          
 Boiled/poached   2867       
 Fried  HM  2877       
  PUM  2878       
  Sun oil  2869       
tick Scrambled LFM, PUM  2888       
  LFM, Sun oil  2889       
  WM, HM  2890       
  WM, Sun oil  2873       
  WM  2872       
 
Omelette (tick scrambled and add 
topping here)  
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Generic 
Sketch 
(look up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes 
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
 FRUITS-ORANGE          
X 1. Apples   4222       
X 2. Bananas Fresh  3540       
  Fried  3611       
 3. Berries Fresh         
  Candied         
X 4. Figs/prickly pears and Fresh         
 Coconuts, dates Candied         
 5. Fruit salad Fresh         
  Sugar added?         
  Canned juice  3667       
  Canned syrup  3580       
X 6. Grapes   3550       
X 7. Guavas Fresh  3551       
  Canned juice  3628       
  Canned syrup  3553       
X 8. Mango Fresh  3556       
  Canned syrup  3633       
 8. Pawpaw Fresh         
 8. Kiwi fruit   3660       
 8. Leechies   3632       
 9. Watermelons   3576       
X 9. Sweet melon          
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Generic 
Sketch 
(look up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes 
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
X 10. Naartjies Mineola fresh  4227       
  Naartjie fresh  3558       
  
Naartjie canned in 
syrup 
 3635       
X 11. Oranges Fresh  3560       
 11. Grapefruit Fresh  3546       
X 12. Peaches Fresh  3565       
  Canned juice  3640       
  Canned syrup  3567       
X 12. Nectarines Fresh  4228       
X 13. Pears Fresh  3582       
  Canned juice  3643       
  Canned syrup  3583       
 14. Pineapple Fresh  3581       
  Canned juice  3647       
  Canned syrup  3648       
X 15. Plums Fresh  3570       
 15. Apricots   3534       
 16. Dried fruit          
 16. Dry stewed fruit          
 16. Raisins   3552       
 17. Fruit juice Fresh         
  Sweetened         
  Unsweetened         
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Generic 
Sketch 
(look up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes 
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
 SOUPS, LEGUMES, NUTS         
X 
1. Soups 
 
Powdered made 
with water 
 3165       
  Vegetable  3162       
  Meat, lentil veg  3153       
  
Dried bean, meat, 
veg 
 3145       
  With bones         
 2. Beans and lentils Anything added         
 3. Nuts           
 3. Peanuts          
     Peanuts and raisins          
 FISH and SEAFOOD- BEIGE         
 1. Fried fish          
 1. Fish cakes          
 1. Fish fingers          
 1. Calamari          
Circle 
one 
2. Grilled/smoked/dried fish          
 2. Haddock          
 3. Pilchards and sardines Canned water         
 Canned  Tomato sauce         
  Mayonnaise  3488       
 3. Tuna Brine water         
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Generic 
Sketch 
(look up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes 
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
 3. Tuna In oil         
  Mayonnaise  3488       
 3. Pickled fish          
 MEAT- RED How do you eat meat?      1= with fat            2= fat trimmed  
 1. Roast beef          
 1. Beef chops          
 1. Beef steak (bone)          
 1. Beef steak (no bone)          
 1. Beef stir-fry          
 1. Beef stew / veg   3120       
 1. Beef stew / cabbage   3006       
 2. Beef patties   2984       
 2. Mince Regular  2987       
  With vegetables         
X 2. Meatballs  Egg / no egg         
 2. Cottage pie   3009       
 3. Burgers Bun  3210       
 
please tick, quantify, brand 
names ( McDonalds bigmac) 
Patty: Beef  2984       
 Cheese slice  2722       
 Tomato sauce  3169       
  Mayonnaise  3488       
Meal? Chips (fried) Size?  3740       
 Soft drink  Size?  3981       
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Generic 
Sketch 
(look up) 
A.  
Food items (with FPM numbers) 
B.  
Description of 
food item 
Tick 
for 
yes 
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
 3. Hot dog HD roll         
  Vienna         
  Tomato sauce  3169       
 3. Pita with…           
           
 3. Chicken burger Bun  3210       
 
please tick, quantify, name of 
burger (e.g KFC twister) 
Crumbed, fried  3011       
 Cheese slice  2722       
 Tomato sauce  3169       
  Mayonnaise  3488       
Meal? Chips (fried) Size?  3740       
 Soft drink  Size?  3981       
 3. Chicken nuggets   3018?       
 4. Chicken stew          
 4. Fried chicken pieces With skin         
  Without skin         
 4. Roast chicken With skin         
  Without skin         
 4. Chicken stir-fry          
 4. Chicken other          
 6. Fat cakes and mince          
 7. Meat pies          
 7. Samoosas  Meat  3355       
  Vegetable  3414       
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Generic 
Sketch 
(look up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes 
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
 7. Sausage rolls    2939       
 7. Spring rolls   2918       
 8. Mutton stew no veg          
 8. Mutton stew with veg          
 8. Mutton leg chop          
 8. Mutton loin chop   2927       
 8. Roast mutton   2947       
 9. Spare ribs   3010       
 9. Pork chops    2930       
 9. Bacon   2906       
 9. Roast pork          
 10. Pork sausages   2932       
 10. Viennas   2936       
circle 10. Frankfurters Beef/pork/chicken         
 10. Boerewors   2931       
 11. Traditional / organ meats         
 Chicken livers   2970       
 Chicken giblets   3014       
 Chicken head   2999       
 Chicken feet   2997       
 Liver and fat   2920       
 Sheep intestine / lungs   4342       
 Shank pork/lamb/beef          
 Mopani worms How cooked?         
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Generic 
Sketch 
(look up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes 
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
 12. Vegetarian products          
 13. Dry sausages   2949       
 13. Biltong   2912       
 VEGETABLES – GREEN         
 1. Asparagus Fresh boiled  3695       
  Canned boiled  4094       
 2. Avocado  Fresh  3656       
 3. Baby marrows Fresh boiled  4171       
  Fat added         
  Sauce         
 4. Beetroot Boiled  3698       
 Grated / sliced Salad  3699       
 Chutney, onion,  Salad         
 5. Butternut Boiled  3759       
  Boiled Sugar added  3989       
  Sugar and fat added  4273       
 5.Pumpkin Boiled  4164       
  Sugar and fat added  3893       
 
6. Broccoli,  
Fresh/frozen 
Boiled          
  Fat added  3808       
 6. Cauliflower Boiled  3716       
  Boiled + cheddar  3715       
 Quantify white/cheese sauce Pg 23         
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Generic 
Sketch 
(look up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes 
for 
yes 
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
 7. Cabbage Boiled  3756       
 7.  ..with potato, onion HM  3813       
 7.  ..with potato, onion Sun oil  3815       
 7. coleslaw (mayo)   3705       
 7. Cabbage, fried HM  3810       
 7. Cabbage, fried Sun oil  3812       
 8. Carrots  Raw  3709       
 8. Carrots Boiled  3757       
  Sugar added  3818       
 9. Gem squash Boiled  3760       
  Boiled + sugar  3754       
 10. Green beans Boiled  3696       
 10.. with potato, onion No fat  3933       
 10.. with potato, onion HM  3792       
 10.. with potato, onion Sun oil  3794       
 11. Mealies Whole, boiled  4133       
  
Whole, boiled 
canned 
 4134       
 11. Sweet corn          
 12. Mixed vegetables Canned, boiled  4264       
 carrot, corn, peas, green beans Frozen, boiled  3727       
 caulif‟, carrot, green beans Frozen, boiled  4265       
  Fresh boiled, PUM  3836       
  Fresh boiled, HM  3835       
 13. Mushrooms Fried HM  3893       
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Generic 
Sketch 
(look up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes 
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
 13. Mushrooms Fried in Sun oil  3841       
 14. Peas Frozen boiled  4146       
  Boiled, sugar, HM  3859       
 15. Potatoes, Baked (ate flesh and skin)  3736       
  (ate skin only)  3970       
  
(ate skin, sour 
cream and chives 
 3973       
 Boiled (ate skin and flesh)  4155       
  (ate no skin)  3737       
  HM  3867       
  PUM  3868       
 Croquette/cake   3915       
 Fried/sautéed HM  3871       
  Sun oil  3873       
 Frozen, boiled   4156       
 Mashed  (SM, PUM)  3875       
  (WM, HM)  3876       
 Roasted in.. .. beef fat  3878       
  .. chicken fat  3923       
  .. lamb fat  3735       
  .. pork fat  3956       
  ..Sun oil  3979       
 15. Potato Salad (mayonnaise)  3928       
 Potatoes, whole canned   4159       
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Generic 
Sketch 
(look up) 
A.  
Food items (with FPM 
numbers) 
B.  
Description of food 
item 
Tick 
for 
yes 
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occas
ionall
y  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
 16. Potato chips Fried in Sun oil  3740       
  Oven baked  3945       
  Mayonnaise  3488       
  Tomato sauce  3169       
 If take away where from?          
 And what size?          
 17. Salad vegetables French  3921       
  Greek  4271       
  Mixed green  3927       
 Dressing? See pg 19!          
 17. Raw tomato    3750       
 17. Cucumber   3718       
 17. Peppers raw, green   3733       
 17. Onion, raw   3755       
 17. Onion, fried  HM  3844       
 17. Onion, fried  Sun oil         
 18. Spinach/morogo boiled  3913       
  Boiled + HM         
  Boiled + PUM         
 18.. with potato, onion HM  3901       
 18.. with potato, onion Sun oil         
 19. Sweet potatoes Baked, ate skin only  3748       
  Boiled, no skin  3903       
  Sugar + HM  3749       
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Generic 
Sketch 
(look up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes 
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
 20. Tomatoes, cooked Fried,  onion  3925       
  
Fried, onion, 
peppers 
        
  
Fried, onion, 
peppers, carrots 
        
 Okra          
 Aubergine          
 Karela          
 FATS-TAN ‘prompt’          
 1. Tub margarine Where used         
  Number of spoons         
  Number in family         
 1. Butter          
 1. Brick Margarine          
 2. White margarine (type of fat)          
 
3. Cream and substitutes 
(brand, real dairy/plant fats) 
         
 4. Oils Where used         
  Number of spoons         
  Number in family         
 5. Salad dressings Homemade         
  Shop bought         
 5. Mayonnaise Where used         
  Number of spoons         
  Number in family         
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Generic 
Sketch 
(look up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes  
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
 BISCUITS, CAKE and PUDDING - PURPLE       
 1. Biscuits/cookies Commercial plain  3216       
brand  Commercial, filling  3217       
  Homemade, plain  3341       
 2. Biscuits/savoury Provita  3235 ___ x 6      
  Ry-vita  3236 ___ x 5      
  Cream crackers  3230 ___ x 8      
 High fat (circle which one) Tuc/salticrax/kips  3331       
 Harvest wheat Whole wheat   3391       
 Spread?          
 Topping?          
 
3. Special buns (hot cross, 
Danish, raisin) 
  3409       
 3. Muffins Bran  3407       
  plain  3408       
 3. Scones plain  3237       
 4. Tart          
 4. Cake (circle) Iced/Cream         
  Plain         
 5. Doughnuts Plain   3232       
 5. Doughnuts Jam  3423       
 5. Doughnuts Icing   3422       
 5. éclairs   3268       
 5. Koeksisters   3231       
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Generic 
Sketch 
(look up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes 
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
X 6. Pancakes/crumpets WM/Sun oil  3238       
 Toppings?          
           
 6. Waffles WM/Sun oil  3238       
 Toppings?          
 7. Baked pudding          
 7. Trifle          
 7. Custard          
 7. Instant pudding          
 8. Rusks Commercial  3329       
 9. Special breads Banana loaf  3333       
  Date loaf  3256       
  Raisin bread  3214       
 Spread?          
 SNACKS, SWEETS and COLD DRINKS-PINK        
 
1. Carbonated cold drinks e.g. 
coke 
  3981       
           
 
1. Diet cold drinks e.g. diet 
coke 
  3990       
 2. Mageu   4056       
 2. Cold drinks (powder)          
 2. Energy drinks   4007       
 2. Squashes   3982       
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Generic 
Sketch 
(look up) 
A.  
Food items (with FPM numbers) 
B.  
Description of food 
item 
Tick 
for 
yes  
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
Generic 
Sketch 
(look up) 
      
Times/ 
day 
Times/ 
week 
   
brands 3. Crisps, potato (lays)   3417       
Size 
packets 
3. Crisps Savoury, (nik naks, 
fritos, ghost pops) 
  3418       
           
 3. Popcorn, plain   3332       
 3. Popcorn, sugar coated   3359       
 4. Sweets          
           
           
 Lollipops          
Brands 4. Chocolates          
describe           
sizes           
           
           
           
           
 SAUCES and CONDIMENTS-GREY         
 1. Cheese sauce    LFM, HM, cheese  3126       
  LFM, PUM, cheese  3127       
  SM, PUM, cheese  3128       
  WM, HM, cheese  3125       
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Generic 
Sketch 
(look up) 
A.  
Food items (with FPM 
numbers) 
B.  
Description of food 
item 
Tick 
for 
yes  
C.  
Item 
code 
D.  
Amount usually eaten(g) 
Generic/amount = g 
E.  
Eaten 
every 
day 
F.  
Eaten 
every 
week 
G.  
Eaten  
Occasi
onally  
H. 
Never 
eaten 
 
      
Times/ 
day 
Times/ 
week 
   
 1. White sauce LFM, HM  3143       
  LFM, PUM  3164       
  SM, PUM  3141       
  WM, HM  3142       
 2. Chakalaka          
 2. Atjar   3117       
 2. Tomato sauce and other          
 2. Chutney          
 ALCOHOLIC DRINKS-GREY         
 
1. Beer  
(regular/low alcohol) 
         
 1. Cider          
 Coolers          
 2. Wine          
 2. Champagne          
 
3. Spirits (any carbonated drink 
e.g. coke added) 
         
           
 4. Liqueurs and Fortified wine          
 OTHER          
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APPENDIX 3 
 UV EXPOSURE AND GENERAL HEALTH QUESTIONNAIRE 
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Study of Vitamin D and Cardiometabolic risk 
 
UV exposure and general health questionaire 
 
 
  
  
     
 
 
 
 
                                        
 
 
 
 
DCR  Id:___________________________                                         Barcode 
  DATE:  ____/_____/2011 
 
 
SECTION ONE: PERSONAL DETAILS 
 
Firstly we would like to ask you some questions about your background: 
1.   Gender:                          Male  Female 
2.   What is your age           Age in  years --------------- 
3.   In what country were you born?   __________________________ 
4.   IF YOU WERE NOT BORN IN SOUTH AFRICA 
      In what year did you come to live in South Africa?    ______________    
  
 
DATE:  Day     Month  Year     
 
 
BTT ID NUMBER:       
 
BONE ID NUMBER:     
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5.   We are interested in your parents‟ ETHNIC ORIGIN (that is, the place where most 
of their  ancestors come from) and the COUNTRY THEY WERE BORN IN.    
  Country of Birth Ethnic Origin (Please tick the appropriate box) 
MOTHER  Asian   African 
    Other  Don't know 
FATHER  Asian   African 
  Other  Don't know 
 
6.   What is the highest technical, professional or academic qualification you have 
completed?    
  (Please circle the appropriate school) 
Did not complete primary school 
Primary school 
Did not complete high school 
Matric 
Technicon 
Bachelors degree 
Post graduate 
 
7.   Please circle which best describes your main occupation: 
Mainly indoors 
Half indoors and half out doors 
Mainly outdoors 
 
SECTION TWO : Smoking. Other risk factors 
 
8.   Do you, or have you ever regularly smoked cigarettes, cigars or a pipe (more than 
one a day for more than six months)? 
     No. I have never smoked regularly (Please go to Question 9). 
Yes. I am a current smoker. 
Yes. I am an ex-smoker. 
IF YES… 
 
  
186 
 
 
 
9(a). On average, how many cigarettes, cigars or pipes do you smoke or did you used 
to smoke  each day?               
9(b). At what age did you start smoking?  years 
9(c). At what age did you stop smoking? years 
 
10. Overall how would you rate your GENERAL HEALTH over the PAST MONTH? 
 
      Excellent          Very good          Good            Fair             Poor              Very 
poor 
 
11. Have you ever had surgery to remove all or part of the Yes     No 
 Thyroid gland in your neck? 
        
12.  Have you ever had surgery on your neck?   Yes     No     
 If YES, please 
explain:________________________________________________ 
 
13.  Have you ever had radiation therapy on your neck?  Yes     No     
 (Not an X-Ray) 
 If YES, please 
explain:________________________________________________ 
 
14. Have you suffered from a heart attack before?   Yes     No     
If yes how were you treated for it? 
Surgery 
Medication 
Both 
 
15.  Have any of you immediate family suffered from a heart attack. Yes     No 
If yes how are you related? 
Mother    Father     Brother    Sister 
At what age did this happen 
 
 
Date:  _____/________/_______________ 
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Ask each volunteer the following questions: 
 
Circle time outdoors and skin exposed for each day in last week 
 
 
 
Day Body area Clothing 
Circle  
which 
item  
is worn 
Sunscreen 
used? If Yes 
add √ below 
Skin 
lightening 
agent used? 
If Yes add √ 
below 
Monday Head Nothing 4   
  Beanie/bike helmet 3   
  Baseball cap 2   
  Cowboy hat 1   
 Torso/arms Nothing 47   
  Bikini top/sports bra 42   
  Tank top 18   
  Tee shirt 10   
  Quarter length shirt 3   
  Long sleeves 0   
 Legs Bikini bottom 38   
  Short shorts/ Skirt 24   
  Knee-length shorts/skirt 8   
  Full-length pants 0   
 Feet Nothing 2   
  Sandals 1.5   
 
 
 
Shoes 
 
0 
 
  
Tuesday Head Nothing 4   
  Beanie/bike helmet 3   
  Baseball cap 2   
  Cowboy hat 1   
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 Torso/arms Nothing 47   
  Bikini top/sports bra 42   
  Tank top 18   
  Tee shirt 10   
  Quarter length shirt 3   
  Long sleeves 0   
 Legs Bikini bottom 38   
  Short shorts/ Skirt 24   
  Knee-length shorts/skirt 8   
  Full-length pants 0   
 Feet Nothing 2   
  Sandals 1.5   
 
 
 
Shoes 
 
0 
 
  
Wednesday Head Nothing 4   
  Beanie/bike helmet 3   
  Baseball cap 2   
  Cowboy hat 1   
 Torso/arms Nothing 47   
  Bikini top/sports bra 42   
  Tank top 18   
  Tee shirt 10   
  Quarter length shirt 3   
  Long sleeves 0   
 Legs Bikini bottom 38   
  Short shorts/ Skirt 24   
  Knee-length shorts/skirt 8   
  Full-length pants 0   
 Feet Nothing 2   
  Sandals 1.5   
 
 
 
Shoes 
 
0 
 
  
Thursday Head Nothing 4   
  Beanie/bike helmet 3   
  Baseball cap 2   
  Cowboy hat 1   
 Torso/arms Nothing 47   
  Bikini top/sports bra 42   
  Tank top 18   
  Tee shirt 10   
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  Quarter length shirt 3   
  Long sleeves 0   
 Legs Bikini bottom 38   
  Short shorts/ Skirt 24   
  Knee-length shorts/skirt 8   
  Full-length pants 0   
 Feet Nothing 2   
  Sandals 1.5   
 
 
 
Shoes 
 
0 
 
  
Friday Head Nothing 4   
  Beanie/bike helmet 3   
  Baseball cap 2   
  Cowboy hat 1   
 Torso/arms Nothing 47   
  Bikini top/sports bra 42   
  Tank top 18   
  Tee shirt 10   
  Quarter length shirt 3   
  Long sleeves 0   
 Legs Bikini bottom 38   
  Short shorts/ Skirt 24   
  Knee-length shorts/skirt 8   
  Full-length pants 0   
 Feet Nothing 2   
  Sandals 1.5   
 
 
 
Shoes 
 
0 
 
  
Saturday Head Nothing 4   
  Beanie/bike helmet 3   
  Baseball cap 2   
  Cowboy hat 1   
 Torso/arms Nothing 47   
  Bikini top/sports bra 42   
  Tank top 18   
  Tee shirt 10   
  Quarter length shirt 3   
  Long sleeves 0   
 Legs Bikini bottom 38   
  Short shorts/ Skirt 24   
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  Knee-length shorts/skirt 8   
  Full-length pants 0   
 Feet Nothing 2   
  Sandals 1.5   
 
 
 
Shoes 
 
0 
 
  
Sunday Head Nothing 4   
  Beanie/bike helmet 3   
  Baseball cap 2   
  Cowboy hat 1   
 Torso/arms Nothing 47   
  Bikini top/sports bra 42   
  Tank top 18   
  Tee shirt 10   
  Quarter length shirt 3   
  Long sleeves 0   
 Legs Bikini bottom 38   
  Short shorts/ Skirt 24   
  Knee-length shorts/skirt 8   
  Full-length pants 0   
 Feet Nothing 2   
  Sandals 1.5   
 
 
 
Shoes 
 
0 
 
  
 
Circle which item of clothing worn and use of sunscreen/skin lightener for each day in last 
week. 
Additional information: 
 
 
 
 
 
 
 
Completed by---------------------------------------------------------------------------------------------- 
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APPENDIX 4 
 PATIENT INFORMATION/INFORMED CONSENT 
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PATIENT INFORMATION 
 
INTRODUCTION 
My name is Jaya George and I am a 
doctor working in the Department of 
Chemical pathology. You are invited to 
consider participating in a research study. 
Your participation in this study is entirely 
voluntary. 
 
Before agreeing to participate, it is 
important that you read and understand 
the following explanation of the purpose of 
the study, the study procedures, benefits, 
risks, and precautions as well your right to 
withdraw from the study at any time. 
 
This information leaflet is to help you to 
decide if you would like to participate. You 
should fully understand what is involved 
before you agree to take part in this study. 
 
If you have any questions, do not hesitate 
to ask me. 
 
PURPOSE OF THE STUDY 
The project is aimed at studying the 
vitamin D levels in various ethnic groups in 
this province and to compare these levels 
will internationally recommended levels. 
Vitamin D is important for normal bone 
strength as well as for normal immune 
function. 
 
We will also measure the levels of calcium, 
magnesium, parathyroid hormone, 
creatinine and alkaline phosphate. 
Changes in vitamin D levels will affect the 
levels of these in blood. Some blood will 
also be stored to check for DNA for 
changes in the vitamin D receptor. 
  
LENGTH OF STUDY AND NUMBER OF 
PARTICIPANTS 
 
Approximately 600 participants will be 
recruited to participate in the study. 
 
The total amount of time required for your 
participation will be a maximum of 4 hours 
and you will not be expected return for 
follow up. 
 
PROCEDURES 
If you agree to take part in this study, you 
will first be asked questions and examined 
to see if you qualify for this study. 
 
A few tubes of blood will be collected from 
a vein in your arm. This is equal to about 
two tablespoons (30 mls) of blood. The 
samples will be given a unique number to 
protect your privacy.  
 
Thereafter, you will have your weight, 
height, waist circumference and blood 
pressure measured and recorded. You will 
also have a scan to assess the density of 
your bones and an ultrasound scan for 
fat.This information will be used to assess 
if body mass index has any impact on 
vitamin D levels. 
 
WILL ANY OF THESE STUDY 
PROCEDURES RASULT IN 
DISCOMFORT OR INCONVENIENCE? 
 
Drawing of blood may cause some 
discomfort associated with pain, bruising 
or bleeding at the puncture site. The 
procedure will be performed under sterile 
conditions to ensure your protection. 
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BENEFITS 
Your participation in this study will assist in 
assessing the status of vitamin D in the 
different population groups in this province.  
 
RIGHTS AS A PARTICIPANT IN THIS 
STUDY 
 
Voluntarily 
Your participation in the study is entirely 
voluntary and you may decline to 
participate. 
 
Withdrawal 
You may withdraw at any time and your 
withdrawal will not affect access to other 
medical care. 
 
FINANCIAL ARRANGMENTS 
You will not be required to pay for any of 
the study related procedures. 
 
REIMBURSMENT FOR STUDY 
PARTICIPATION 
 
You will not be paid to participate in the 
study.  
 
ETHICAL APPROVAL 
This study has been approved by the 
Human Ethics Committee of the University 
of the Witwatersrand, the clearance 
number 
 
SOURCES OF ADDITIONAL 
INFORMATION 
If at any time after you feel that you have 
questions regarding the study, please do 
not hesitate to the principal investigator , 
Dr Jaya George, at this number: 
0828820132. 
 
CONFIDENTIALITY 
All information obtained during the course 
of the study including hospital records, 
personal data and research data will be 
kept strictly confidential. Data that may be 
reported in scientific or medical journals 
will not include any information that 
identifies you as a participant in this study. 
 
Any information uncovered regarding your 
test results or state of health as a result of 
your participation in the study will only be 
made known to your treating doctors. You 
will be informed of any findings of 
importance to your health during 
participation in this study.  
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INFORMED CONSENT      DCR ID 
 
I hereby confirm that the researcher, has explained the nature, conduct, benefits and risks of 
this research project. 
 
 I have also received, read and understood the above written information regarding the 
study. 
 
 I am aware that the results of the study, including personal details regarding my age, sex 
and diagnosis will anonymously be processed into a study report. 
 
 In view of the requirements of research, I agree that the data collected during this study 
can be processed in a computerized system by the researcher appearing on the first page 
of this document. 
 
 I may at any stage, without prejudice, withdraw my consent and participation in the study. 
 
 I have had sufficient opportunity to ask questions and (of my own free will) declare myself 
prepared to participate in the study   
 
PARTICIPANT 
 
   
Printed Name Signature / Name or Thumbprint Date  
 
WITNESS (if applicable) 
 
  
Printed Name Signature / Name or Thumbprint Date 
   
 
 
 
Researcher Name                        Signature                                                                         
Date 
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University of the Witwatersrand 
 
ANTHROPOMETRY/MEASUREMENTS 
 
DATE :  Day   Month    Year  
 
Patient number :       
 
                                                           
Medications: 
Have you taken any medication for the following conditions in the past 6 months? 
Diabetes   Yes  No 
High blood pressure  Yes No 
Cholesterol   Yes  No 
 
Have you been on any other medication for the past 6 months? 
If yes: for what conditions(please list) 
 
MEASUREMENTS 
ANTHROPOMETRY 
 STANDING HEIGHT: (mm) 
 
 WEIGHT: (kg) 
 
 WAIST CIRCUMFERENCE: (mm) 
 
 HIP CIRCUMFERENCE: (mm) 
 
 TANITA measured          
(Attach to file) 
 
BLOOD PRESSURE 
 SYSTOLIC BP 
 DIASTOLIC BP 
 
Y N 
   
   
   
197 
 
 
 PULSE 
 
 
 
 
 
Research Assistant name:            Date: 
 
 
Notes:  
 
 
 
 
 
h 
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APPENDIX 6 
 PUBLICATION 
The association of 25 hydroxyvitamin D and parathyroid hormone with metabolic 
syndrome in two ethnic groups in South Africa 
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